

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## 'MTV Shuga': Mass media communication in adolescent girls and young women in South Africa: Can it increase awareness and demand for HIV and sexual health technologies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062804
Article Type:	Original research
Date Submitted by the Author:	28-Mar-2022
Complete List of Authors:	Chimbindi, Natsayi; Africa Health Research Institute; University College London, Mthiyane, Nondumiso; Africa Health Research Institute Chidumwa, Glory ; Africa Health Research Institute Zuma, Thembelihle; Africa Health Research Institute; University College London, Dreyer, Jaco; Africa Health Research Institute Birdthistle, Isolde; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Floyd, Sian; London School of Hygiene & Tropical Medicine, Infectious Disease Epidemiology Kwegombe, Nambusi; London School of Hygiene & Tropical Medicine Grundy, Chris; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Cawood, Cherie; Epicentre Health Research Danaviah, Siva; Africa Health Research Institute Smit, Theresa; Africa Health Research Institute Pillay, Deenan; University College London, Baisley, Kathy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health; Africa Health Research Institute Harling, Guy; Africa Health Research Institute Seeley, Janet; London School of Hygiene and Tropical Medicine, Department of Global Health & Development; Africa Health Research Institute Shahmanesh, Maryam; University College London, Institute for Global Health; Africa Health Research Institute,
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH, PREVENTIVE MEDICINE

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Title page

**'MTV Shuga': Mass media communication in adolescent girls and young women in South Africa: Can it increase awareness and demand for HIV and sexual health technologies**

Authors: Natsayi Chimbindi\*<sup>1,2,3</sup>, Nondumiso Mthiyane\*<sup>2</sup>, Glory Chidumwa<sup>1</sup>, Thembelihle Zuma<sup>1,2,3</sup>, Jaco Dreyer<sup>1</sup>, Isolde Birdthistle<sup>4</sup>, Sian Floyd<sup>4</sup>, Nambusi Kyegombe<sup>4</sup>, Chris Grundy<sup>4</sup>, Cherie Cawood<sup>5</sup>, Siva Danaviah<sup>1</sup>, Theresa Smit<sup>1</sup>, Deenan Pillay<sup>2</sup>, Kathy Baisley<sup>1,3</sup>, Guy Harling<sup>1,2,3,6,7</sup>, Janet Seeley<sup>1,3,4</sup>, Maryam Shahmanesh<sup>§1,2,3</sup>

1. Africa Health Research Institute, KwaZulu-Natal, South Africa
2. University College London, Institute for Global Health, London, UK
3. University of KwaZulu-Natal, KwaZulu-Natal, South Africa
4. London School of Hygiene and Tropical Medicine, London, UK
5. Epicentre, South Africa
6. MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Gauteng, South Africa
7. Department of Epidemiology & Harvard Center for Population and Development Studies, Harvard T.H. Chan School of Public Health, Boston, USA

\*Joint authors

§Corresponding author (full address details): Maryam Shahmanesh, Institute for Global Health, UCL, 3<sup>rd</sup> Floor, Mortimer Market Centre, Capper Street, London WC1E 6JB. [m.shahmanesh@ucl.ac.uk](mailto:m.shahmanesh@ucl.ac.uk). +44 7776 185 572

Key words (6): HIV, Adolescents, mass communication campaigns, Sexual Health, Teenage Pregnancy, South Africa.

## Abstract (word count=300)

**Objectives:** Mass media edu-dramas have potential to increase demand for HIV and sexual and reproductive health(SRH) services among young people. We investigate the effect of exposure to MTV Shuga Down South(DS) during the scale-up of combination HIV-prevention interventions (DREAMS) on awareness and uptake of SRH and HIV-prevention services by adolescent girls and young women(AGYW).

**Design:** One longitudinal and three cross-sectional surveys of representative samples of AGYW

**Setting:** AGYW in four South African districts with high HIV-prevalence (>10%) (May 2017 and September 2019)

**Participants:** 6341 AGYW aged 12-24

**Measures:** Using logistic regression we measured the relationship between exposure to MTV Shuga-DS and awareness of Pre-Exposure Prophylaxis (PrEP), condom-use at last sex, uptake of HIV-testing or contraception, and incident pregnancy or HSV-2 infection.

**Results:** Within the rural cohort 2184 (85.5%) of eligible sampled individuals were enrolled, of whom 92.6% had at least one follow-up visit; the urban cross-sectional surveys enrolled 4157 (22.6%) of eligible sampled individuals. Self-report of watching at least one MTV Shuga-DS episode was 14.1% (cohort) and 35.8% (cross-section), while storyline recall was 5.5% (cohort) and 6.7% (cross-section).

In the cohort, after adjustment (for DREAMS-exposure, age, education, SES), MTV Shuga-DS exposure was associated with increased PrEP awareness (aOR=2.06, 95%CI:1.57-2.70), contraception uptake (aOR=2.08, 95%CI:1.45-2.98) and consistent condom-use (aOR=1.84, 95%CI:1.24-2.93), but not with HIV-testing (aOR=1.02,95%CI: 0.77-1.21) or acquiring HSV-2 (aOR=0.92, 95%CI: 0.61-1.38). In the cross-sections, MTV Shuga-DS was associated with greater PrEP awareness (aOR=1.7, 95%CI: 1.20-2.43), but no other outcome.

**Conclusions:** Among both urban and rural AGYW in South Africa, MTV Shuga-DS exposure was associated with increased PrEP awareness and improved demand for some HIV-prevention and SRH technologies but not sexual health outcomes. However, exposure to MTV Shuga-DS was low. Given these positive indications, supportive programming may be required to raise exposure and allow future evaluation of edu-drama impact in this setting.

### Strengths and limitations of this study

- We use the opportunity of MTV Shuga being broadcast in the context of an impact evaluation of DREAMS roll out (January 2016-September 2019) in a representative, population-based sample of young people to describe the real-world reach of nationally broadcast MTV Shuga-DS.
- We employed a longitudinal cohort (n~2000) and cross-sectional surveys (n~5000) of representative samples of AGYW aged 12-24 in four districts of South Africa with a high burden of HIV to measure the reach of MTV Shuga-DS.
- However, as this is an observational study, we cannot exclude the possibility that those who are exposed to MTV Shuga are systematically different in ways that impact on the outcome of interest, for example more exposed to social media and sexual health promotion and innovative technologies to support sexual health than those who were not.

1  
2  
3 **[word count 4531]**

## 4 **Introduction**

5 HIV remains one of the gravest health problems facing young people living in sub-Saharan  
6 Africa (SSA). There are over 7.6 million people living with HIV in South Africa, with 200,000  
7 new HIV infections annually in those aged 15-49 years (1). The highest incidence is in  
8 adolescent girls and young women (AGYW) (15-24 years) (1, 2). In response to this the South  
9 African government launched the 'She Conquers Campaign', and the US President's  
10 Emergency Fund for AIDS Relief and others are supporting the roll-out of Determined,  
11 Resilient, Empowered, AIDS free, Mentored, and Safe (DREAMS)(3-5). These programmes  
12 provide an evidence-based combination HIV prevention package, including HIV-testing and  
13 counselling for adolescent girls and young women (AGYW) and male partners, alongside  
14 universal test and treat and improved sexual health services (6, 7).

15  
16  
17  
18  
19  
20  
21  
22  
23 However, the key ingredient to success of these multicomponent interventions will be the  
24 extent to which AGYW and their male partners at most risk of HIV will uptake and adhere to  
25 the active components of the intervention. This is challenging: uptake and retention of  
26 contraception and HIV treatment cascade by young people, even within population-wide  
27 Universal Test and Treat trials, has been suboptimal (2, 8, 9). Data from the baseline analysis  
28 for the DREAMS impact evaluation in uMkhanyakude district, rural KwaZulu-Natal (KZN) in  
29 2015 suggest that less than 40% of girls (15-19 years) and boys and young men (15-29 years)  
30 had ever tested for HIV; linkage to HIV treatment was even lower (10). Contraception use  
31 prevalence was 20% in girls (15-19 years) and 50% in young women (20-24 years) and 21%  
32 of 15-19 year old girls had ever been pregnant (2).

33  
34  
35  
36  
37  
38  
39  
40  
41 It is against this backdrop that the fifth series of Shuga: 'MTV Shuga: Down South' (MTV  
42 Shuga-DS), a mass media serial edu-drama designed for SA, was broadcast on free-to-air  
43 South Africa National television. From March 8<sup>th</sup> 2017, MTV Shuga aired one episode per  
44 week for 12 weeks (with repeats). MTV Shuga is a mass media behaviour change campaign  
45 that aims to improve sexual and reproductive health rights (SRHR). At the centre of the  
46 campaign, which includes radio and social media, is a TV-drama that weaves messages about  
47 HIV, family planning, transactional and intergenerational sex, safer and healthy sexual  
48 relationships, into storylines with young characters ([http://www.mtvshuga.com/show/series-5/MTV Shuga-down-south/](http://www.mtvshuga.com/show/series-5/MTV-Shuga-down-south/)).

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000



1  
2  
3 to have an effect (11, 12). MTV Shuga-DS was designed to reduce HIV-related risk behaviour  
4 and improve SRHR outcomes in adolescents and young adults in SA. This was expected to  
5 be achieved through increasing young people's demand for, and uptake of HIV and SRH  
6 prevention and treatment technologies. The show's characters explicitly model how to discuss  
7 issues that are sensitive or taboo. Moreover, in 'melodramas', tensions between good and  
8 evil are played out through 'good' characters who adopt certain behaviours, and 'evil'  
9 characters who reject them. The former are rewarded while the latter punished. A third  
10 category of character, the 'transitional' character, begins as ambivalent but changes into a  
11 positive role model and promote positive behaviour change. This is a deliberate method to  
12 immerse the audience in the action, rather than passively watching or listening (13). Young  
13 people, or at least early adopters, are anticipated to be immersed in the serial, able to classify  
14 and identify with the transitional characters and their outcomes. Pathways to behaviour  
15 change through MTV Shuga, therefore relate to the extent to which the observer, including  
16 early adopters, are immersed and critically engaged with the story. It also depends on a  
17 context which is supportive rather than disruptive (see the conceptual framework Figure 1  
18 below) (14).

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 **Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on**  
30 **AGYW in uMkhanyakude**

31  
32  
33 A cluster randomised controlled trial of community-viewings of MTV Shuga in Nigeria found  
34 that exposure to MTV Shuga significantly improved HIV knowledge and testing in both sexes,  
35 the intervention arm showing 35% more likely to test for HIV than the control arm. There was  
36 also a 60% reduction in genital chlamydia as a marker of recent sexual risk in women, amongst  
37 those exposed to MTV Shuga compared to those who were not (15). There were, however,  
38 fewer changes in social norms, particularly around gender-based violence. Further work  
39 suggested that the impact was greatest in those who were immersed in the narrative. The  
40 importance of immersion (classification of characters and identifying with them and observing  
41 outcomes) coupled with critical participation and an enabling context were also found in a  
42 thematic analysis looking at how storylines in MTV Shuga-DS shaped awareness, knowledge  
43 and opinions of sexual health and personal relationships among young people in SA (14).

44  
45  
46  
47  
48  
49  
50  
51  
52 Whilst the Nigerian and SA studies provide evidence for the efficacy of MTV Shuga impacting  
53 on SRHR and HIV-testing behaviours in exposed individuals, there is little evidence of how  
54 this will translate into a population-level effect when nationally broadcast and in less controlled  
55 environments. In particular, it is not clear how the impact will spill-over to non-viewers and  
56 how innovations will diffuse when shown and watched by adolescents and young adults in a  
57 real-world scale-up. It is also unclear how such impact will differ according to: setting (rural or  
58  
59  
60

1  
2  
3 urban); differential digital literacy and access to social media (geographically and  
4 socioeconomically), and the dose and context of watching (shared viewing with family, friends  
5 or individual experience through social media).  
6  
7  
8

9 We use the opportunity of MTV Shuga being broadcast in the context of an impact evaluation  
10 of DREAMS roll out (January 2016-September 2019) in a representative, population-based  
11 sample of young people (10) to describe the real-world reach of nationally broadcast MTV  
12 Shuga-DS. Further, we explore the hypothesis that exposure to a mass-media serial edu-  
13 drama, like MTV Shuga, will improve SRHR outcomes by increasing demand for, and uptake  
14 of, existing combination individual and community-based SRH and HIV prevention services  
15 for AGYW in four diverse settings including uMkhanyakude, a socioeconomically deprived  
16 rural district with an extremely high burden of HIV: 40% antenatal HIV prevalence and an  
17 annual HIV incidence of 5% in girls (15-19 years) and 8% in young women (20-24 years) (2,  
18 16) and in three high-prevalence urban districts (HIV prevalence of greater than 10%) of City  
19 of Johannesburg, Ekurhuleni, and eThekweni.  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **Methods**

### 30 **Study design**

31 We employed a longitudinal cohort (n~2000) and cross-sectional surveys (n~5000) of  
32 representative samples of AGYW aged 12-24 in four districts of South Africa with a high  
33 burden of HIV to measure the reach of MTV Shuga-DS. Data were collected between May  
34 2017 and September 2019.  
35  
36  
37  
38  
39  
40

41 We use baseline and follow-up data from a nested cohort of ~2000 AGYW aged 13-22 years,  
42 enrolled in 2017 for the DREAMS impact evaluation. The cohort is nested in a large  
43 population-based longitudinal HIV surveillance study, in the uMkhanyakude district of  
44 KwaZulu-Natal (17, 18). A random sample of 3013 AGYW was selected from the surveillance  
45 population, stratified by age (13-17 years and 18-22 years) and geography, and invited to  
46 enrol in the nested cohort. Baseline interviews were conducted between May 2017 and  
47 February 2018 and follow-up interviews April 2018 and September 2019 in the local language  
48 (isiZulu) using a structured quantitative questionnaire programmed in REDCap (10).  
49  
50  
51  
52  
53  
54  
55

56 The cross-sectional survey was conducted on a household-based representative sample of  
57 ~4000 AGYW (between the ages 12-24 years) in three high prevalence (City of Johannesburg,  
58 Ekurhuleni and eThekweni) districts. Between August 2017 and July 2018, a stratified cluster-  
59  
60

1  
2  
3 based sampling was used to select 18500 AGYW aged 12-24 eligible for a cross-sectional  
4 survey of individuals, based on an expected response rate of 80%.  
5  
6

7  
8 The interview included questions on socio-demographics, general health, exposure to  
9 DREAMS and to MTV Shuga, sexual relationships, awareness and uptake of DREAMS and  
10 DREAMS-like services, migration, and gender norms across the four districts. A Dried Blood  
11 Spot (DBS) was taken at baseline and follow-up for Herpes Simplex Virus type 2 (HSV-2)  
12 antibody testing in the uMkhanyakude district. For sexual behaviour questions, participants  
13 were given a tablet computer to complete a self-interview; the fieldworker was available to  
14 provide support as needed.  
15  
16  
17  
18  
19

## 20 21 **Study setting and population**

22  
23 The cohort was nested within the Africa Health Research Institute (AHRI) triannual  
24 demographic surveillance of a population of approximately 150,000 people who are members  
25 of 15,000 geocoded households in an area of 845 km<sup>2</sup> (17). The study area is mostly rural  
26 and poor with high levels of youth unemployment (over 85% of those aged 18-24 are  
27 unemployed) (2, 16). From 2017, AHRI has embedded data collection clerks within the  
28 government clinics in the surveillance area to capture electronically any clinical attendance  
29 and the reason for the visit. Consenting individuals are linked to their surveillance identification  
30 number at the time of the clinic visit. This allows us to link exposure to an intervention with  
31 engagement with primary health care, including attendance for HIV care or use of  
32 contraceptive services.  
33  
34  
35  
36  
37  
38  
39

40 The cross-sectional survey was conducted in three districts which were mostly urban with  
41 more towns and townships compared to AHRI surveillance area. The three study districts (City  
42 of Johannesburg, Ekurhuleni and eThekweni) consist of an estimated 12,073,421 individuals.  
43 The eThekweni district in KZN province is among those with the highest HIV prevalence (16.8%  
44 HIV prevalence in 2016) in South Africa. Over two-thirds (68%) of eThekweni is considered  
45 rural and 32% urban. About 11 963 (3%) AGYW in eThekweni are estimated to be living with  
46 HIV. The Gauteng province (GP), whilst geographically the smallest, is the most populous  
47 province in South Africa. GP has the fifth highest provincial HIV prevalence in the country with  
48 a prevalence of 11.1% among those aged 15 to 49 years old in 2016. The HIV prevalence in  
49 the two districts, City of Johannesburg and Ekurhuleni, is 11.1% and 14.3% among 15- to 49-  
50 year-olds, respectively. Both districts are densely populated and have high levels of  
51 industrialisation. The HIV prevalence amongst AGYW (15 to 24 years old) in the City of  
52 Johannesburg is 3%, and similarly 3% in Ekurhuleni in 2012.  
53  
54  
55  
56  
57  
58  
59  
60

## Variables and Measurement:

### ***Outcomes definitions:***

We measured the effect of exposure to MTV Shuga on awareness and uptake of HIV prevention and SRHR outcomes at the follow-up visit. Our outcomes were: 1) self-reported HIV-testing in the past 12 months; 2) awareness of Pre-Exposure Prophylaxis (PrEP) for HIV prevention; 3) condom use at last sex; 4) use of contraception; 5) any new pregnancy since baseline; and 6) any new teenage pregnancy (restricted to those under the age of 20). AGYW were considered to use contraception if they self-reported using modern/hormonal contraception (modern contraception was defined as current use of any modern contraceptives, i.e., excluding traditional methods), or self-reported consistent condom use (using condoms as a contraceptive method and at last sex). Condomless sex was calculated using 2019 data among participants who reported having had sex with the most recent partner in the past 12 months. Recent pregnancy was calculated as any new pregnancy that occurred between baseline and 2019, while teenage pregnancy was calculated as any new pregnancy that occurred between baseline and 2019 among participants aged below 20 years. We also examined the effect of exposure to MTV Shuga on incident HSV-2 infections, among those who were HSV2 negative at baseline.

### ***Exposure definitions:***

Exposure to MTV Shuga was defined as ever watched MTV Shuga between 2017 and 2018. The level of exposure was measured based on the content of the series MTV Shuga, defined using 15 questions used to assess knowledge of content of MTV Shuga series. A composite score was developed summing-up the correct responses. The scores ranged between 2 and 14, and the median being 4. The median was used as a cut-off to define level of exposure among those who watched the series. Consequently, the level of exposure was categorized into 3 levels: High (watching a MTV Shuga and being able to correctly respond to 5 or more questions on content); Medium (watching programme and being able to correctly respond to less than 5 questions); and None (not watched any MTV Shuga). This was further categorised into 3 levels: High (watching MTV Shuga and being able to recall the content from MTV Shuga); Medium (watching programme, but unable to recall content); and None (not being aware of and not watched any MTV Shuga).

### ***Potential confounding variables:***

We included socio-demographic and sexual behaviour characteristics of AGYW that were measured at baseline and exposure to HIV prevention. The socio-demographic variables included age (as measured at follow-up), household socio-economic status, education broken

1  
2  
3 down by those who are still in school and those who have completed school, geographic area  
4 (rural or peri-urban/urban), and migration in the last 12 months. The socio-economic status  
5 (SES) variable was constructed using Principal Component Analysis (PCA) based on  
6 ownership of household assets and characteristics such as access to piped water, type of  
7 toilet, electricity and type of cooking fuel (19). Further, potential individual-level confounders  
8 measured included exposure to DREAMS (defined either as ever been invited to participate  
9 in any of the DREAMS activities or ever used any of the DREAMS HIV prevention interventions  
10 in the past 12 months or since 2016 and phone ownership at baseline.  
11  
12  
13  
14  
15  
16  
17

### 18 **Laboratory:**

19 The HerpeSelect® 2 ELISA IgG assay (FOCUS Diagnostics, Cypress, California, USA) for the  
20 qualitative detection of human IgG class antibodies to HSV-2 was used on Dried blood Spot  
21 (DBS) samples collected on Whatman 903 filter cards. The HerpeSelect® 2 ELISA IgG assay  
22 uses purified type-specific gG-2 antigen immobilized on polystyrene microwells reducing the  
23 cross-reactivity issues as seen with viral lysate assays(20). The assay is validated for use  
24 with serum samples but was optimised for use with DBS in the AHRI Diagnostic Research  
25 Laboratory following comparative testing with plasma samples. During the initial evaluation  
26 of the HerpeSelect® 2 ELISA IgG a select number of plasma samples were also tested by an  
27 external accredited pathology laboratory. A 6mm diameter punch of a DBS spot was incubated  
28 overnight in 150ul Assay Diluent for no more than 16 hours at 4°C. The assay was performed  
29 with 50ul of the eluent in accordance with the manufacturer's instructions. Following a  
30 disproportionately high number of positive results based on other studies and our experience  
31 we multiplied the mean cut-off calibrator absorbance values by a factor of 1.5 before  
32 determining the index value for each sample (21, 22). The HerpeSelect® 2 ELISA IgG results  
33 are reported as positive (index value >1.10), equivocal (index value of  $\geq 0.90$  but  $\leq 1.10$ ) or  
34 negative (index value <0.90). All initial equivocal results were re-tested and those that re-  
35 tested equivocal are reported as equivocal. An incident HSV-2 was defined as having been  
36 negative at baseline and positive at follow-up. Those who were equivocal at either baseline or  
37 follow-up were not considered as a sero-conversions.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Statistical analyses:**

52 We included only participants who had data available at baseline and follow-up for nested  
53 cohorts. We used Chi-square tests to compare baseline characteristics between AGYW who  
54 did and did not have any exposure to MTV Shuga. We used logistic regression to examine the  
55 effect of MTV Shuga on health outcomes, adjusting for exposure to DREAMS and all other  
56 potential confounders. Potential effect-modification of MTV Shuga by exposure to DREAMS  
57  
58  
59  
60

1  
2  
3 was examined by fitting an interaction term to fully adjusted model: likelihood ratio tests were  
4 used to compare models with and without interaction terms.  
5  
6  
7

8 We calculated the proportion of AGYW who reported an outcome (condomless-sex, recent  
9 pregnant) or tested positive for HSV-2 at 12-month or 24-month follow-up; and estimated  
10 associations between MTV Shuga and each outcome using a logistic regression, adjusting for  
11 potential confounders (age, household and individual socio-demographic characteristics and  
12 sexual behaviour). For HSV-2 incidence, we included participants who tested negative at  
13 baseline and had at least 1 follow-up test result. For DREAMS exposure, we included data  
14 collected at baseline and 12-month follow-up. For health outcomes (consistent condom use,  
15 modern contraception, HIV testing, PrEP awareness), we used data collected at 24-month  
16 follow-up; and for HSV-2 and pregnancy incidence we used data collected at 12 and 24-month  
17 follow-up.  
18  
19  
20  
21  
22  
23

24  
25 Propensity score logistic regression adjustment was used to estimate the causal effect of MTV  
26 Shuga on health outcomes. A propensity or probability of being exposed to MTV Shuga was  
27 measured by fitting a logistic regression with MTV Shuga exposure as an outcome and  
28 potential confounders. A logistic regression models adjusting for propensity scores were then  
29 used to predict the probability of an outcome for all participants and separately by age group,  
30 under two scenario (1) exposed to MTV Shuga and (2) Not exposed to MTV Shuga. The  
31 predicted probabilities were then used to calculate the marginal risk difference, prevalence  
32 ratio and odds ratio. Confidence intervals were generated by using a bootstrap procedure,  
33 repeating the estimation procedure described above in 1000 samples that were drawn with  
34 replacement from the complete dataset and calculating 95% confidence intervals from the  
35 resulting bootstrap distribution using the 2.5% and 97.5% percentiles.  
36  
37  
38  
39  
40  
41  
42

43 All analyses were performed using Stata version 15 (StataCorp LP, College Station, Texas  
44 USA).  
45

## 46 **Reporting**

47  
48 The STROBE reporting guidelines were used to guide synthesis and standardise reporting of  
49 our results(23)  
50

## 51 **Ethics**

52  
53 The DREAMS Partnership impact evaluation protocol was reviewed and approved by the  
54 University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (BFC  
55 339/16), the London School of Hygiene & Tropical Medicine Research Ethics Committee (Ref  
56 11835) and the AHRI Somkhele Community Advisory Board, the Associate Director of Science  
57 of the Center for Global Health (CGH) at the United States Centers for Disease Control and  
58  
59  
60

1  
2  
3 Prevention (CDC) in Atlanta and the Department of Health, Province of KZN and Gauteng.  
4 Approval for the demographic surveillance and data collection in the clinics was granted by  
5 UKZN BREC. All participants provided separate informed consent for the questionnaires and  
6 the HSV2 sero-survey. Consent for follow-up interviews was provided separately. For  
7 participants aged <18 years, written parental consent and participant assent were provided.  
8 Individuals attending the clinics in the surveillance area provided informed consent to record  
9 the clinic visit and link to their surveillance identification number.  
10  
11  
12  
13  
14  
15

## 16 **Patient and public involvement**

17  
18 The study did not involve patients. AHRI has a Public Engagement Unit which conducts  
19 community engagement activities with the local communities as part of study finding  
20 dissemination. The Community Advisory Board provided feedback of the study including  
21 design before approval from ethics review board. Study findings are being made publicly  
22 available to funders, participants and the public through webinars, study reports and open  
23 access journal articles.  
24  
25  
26  
27  
28

## 29 **Results:**

### 30 **Participants**

31  
32 Of 3013 potentially eligible AGYW randomly selected from the surveillance data set, 85.5% of  
33 those eligible consented to participate at baseline (Figure 2). Of the 2184 eligible participants  
34 that were surveyed at baseline, 2016 (92.3%) had at least one follow-up visit and contributed  
35 data to this analysis. From the cross-sectional survey, 4127 (22.6%) eligible participants were  
36 surveyed.  
37  
38  
39  
40  
41  
42  
43

### 44 **Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019**

## Awareness and exposure to MTV Shuga

MTV Shuga exposure at baseline was low, with a total of 308 (14.1%) respondents reported watching at least one episode. In the cross-sectional analysis of the three districts, a total of 1477 (35.8%) reported watching any MTV Shuga. In the nested cohort 121 (5.5%) recalled any storyline. Similarly in the cross-sectional snapshot 276 (6.7%) recalled the storyline (high exposure).

## Social demographic characteristics of adolescents and young people by exposure to MTV Shuga (Table 1&2)

Table 1 summarises the profiles of the nested cohort (n=2184) and cross-sectional surveys (n=4127) AGYW comparing those exposed to MTV Shuga with those not exposed. In summary those who had seen any MTV Shuga were more likely to be from households in the highest socioeconomic tertile (p<0.001) and more urbanised areas (p<0.001). They were also more likely to have also received DREAMS (p=0.015) (Table 1). In the cross-sectional surveys (n=4127), MTV Shuga exposure was associated with older age (p<0.001), tertiary education (p <0.001) and never having sex (p< 0.001) Table 1.

**Table 1. Baseline socio-demographic characteristics of adolescent girls and young women (13-22) by exposure to MTV Shuga in the nested cohort (n=2184)**

	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
<b>Age group (4 cats), 2017</b>							
13-14	460/2184	21.1	72/308	23.4	388/1876	20.7	0.216
15-17	688/2184	31.5	107/308	34.7	581/1876	31	
18-19	475/2184	21.7	60/308	19.5	415/1876	22.1	
20-22	561/2184	25.7	69/308	22.4	492/1876	26.2	
<b>Currently in school</b>							
No	540/2184	24.7	67/308	21.8	473/1876	25.2	0.192
Yes	1644/2184	75.3	241/308	78.2	1403/1876	74.8	
<b>Socio-economic status, 2018</b>							
Low	255/2118	12	22/303	7.3	233/1815	12.8	<0.001
Middle	920/2118	43.4	110/303	36.3	810/1815	44.6	
High	943/2118	44.5	171/303	56.4	772/1815	42.5	
<b>Urban or rural</b>							
Rural	1388/2165	64.1	165/305	54.1	1223/1860	65.8	<0.001
Peri-urban/urban	777/2165	35.9	140/305	45.9	637/1860	34.2	
<b>Invited or received DREAMS, 2017/18</b>							
	1101/2184	50.4	175/308	56.8	926/1876	49.4	0.015



	Exposed		Not exposed		p-value		
	n/N	%	n/N	%	n/N	%	p-value
<b>Away from home in the last 12 months</b>	314/1853	17.0	45/228	15.6	269/1565	17.2	0.516
<b>Baseline socio-demographic characteristics of adolescent girls and young women (12-24) by exposure to MTV Shuga in the cross-sectional survey (n=4127)</b>							
	<b>Overall</b>		<b>Exposed</b>		<b>Not exposed</b>		
	n/N	%	n/N	%	n/N	%	p-value
<b>Age group, (N=4127)</b>							
12-14	958/4127	23.2	307/1477	20.1	651/2650	24.6	
15-19	1628/4127	39.5	599/1477	40.6	1029/2650	38.8	
20-24	1541/4127	37.3	571/1477	38.7	970/2650	36.6	0.022
<b>District</b>							
City of Johannesburg	1146/4127	27.8	476/1477	32.2	670/2650	25.3	
Ekurhuleni	1635/4127	39.6	521/1477	35.3	1114/2650	42.0	
eThekweni	1342/4127	32.5	480/1477	32.5	862/2650	32.5	<0.001
<b>Highest Education (N=4108)</b>							
No schooling	175/4108	4.3	99/1465	6.8	76/2646	2.9	
Grade R to 7	502/4108	12.2	142/1465	9.7	360/2646	13.6	
Grade 8 to 12	2978/4108	72.5	1022/1465	69.8	1956/2646	74.0	
Tertiary studies (complete/incomplete)	453/4108	11.0	202/1465	13.8	251/2646	9.5	<0.001
<b>Ever had sex with a boy/man (n=4108)</b>							
	1860/4108	45.3	621/1469	42.3	1239/2639	47.0	0.004
<b>Away from home in the last 12 months (n=4121)</b>							
	183/4121	4.4	66/1474	4.5	117/2647	4.4	0.932

After adjustment for confounders in nested cohorts (Table 2), AGYW from wealthier households (aOR=2.04 95%CI 1.27-3.30), peri-urban or urban areas (aOR=1.54 95%CI 1.19-1.98) and those invited to DREMS (aOR=1.48 95%CI 1.14-1.92) were more likely to be exposed to MTV Shuga than those from poor households, from rural areas and those not invited to DREAMS respectively. Similarly, after adjustment in the cross-sectional surveys (Table 2), AGYW with higher education were more likely to be exposed to MTV Shuga (aOR=2.58 95%CI 1.81-3.69) than those with less and those who ever had sex (aOR=0.68 95%CI 0.57-0.82) were less likely to be exposed to MTV Shuga.

**Table 2 Factors associated with exposure to MTV Shuga in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Adjusted - All		
	OR	95%CI	OR	95%CI	P-value
<b>Age group, 2017</b>					
13-14	1		1		
15-17	0.99	0.72 -1.37	0.93	0.66 -1.29	
18-19	0.78	0.54 -1.13	0.77	0.51 -1.14	
20-22	0.76	0.53 -1.08	0.78	0.50 -1.21	0.555
<b>Currently in school</b>					
No	1		1		
Yes	1.21	0.91 -1.62	1.06	0.78 -1.43	0.726
<b>Socio-economic status, 2018</b>					
Low	1		1		
Middle	1.44	0.89 -2.33	1.27	0.78 -2.07	
High	2.35	1.47 -3.74	2.04	1.27 -3.30	<0.001
<b>Site</b>					
Rural	1		1		
Peri-urban/ urban	1.63	1.28 -2.08	1.54	1.19 -1.98	0.001
<b>Invited or received DREAMS, 2017/18</b>					
No	1		1		
Yes	1.35	1.06 -1.72	1.48	1.14 -1.92	0.003
<b>Factors associated with exposure to MTV Shuga in the cross-sectional analysis of AGYW aged 12-24 (n=4127)</b>					
	Unadjusted		Adjusted - all		
	OR	95% CI	OR	95% CI	P-value
<b>District</b>					
City of Johannesburg	1		1		
Ekurhuleni	0.69	0.54 - 0.89	0.66	0.52- 0.84	0.001
eThekwini	0.79	0.60 - 1.04	0.78	0.59- 1.04	0.087
<b>Age group</b>					
12-14	1		1		
15-19	1.27	1.06 - 1.53	1.18	0.95- 1.46	0.126
20-24	1.22	1.01 - 1.48	1.16	0.90- 1.49	0.256
<b>Highest education level</b>					
Grade R to 7	1		1		
No schooling	2.88	1.81 - 4.58	3.29	2.01 - 5.38	<0.001
Grade 8 to 12	1.38	1.09 - 1.75	1.42	1.08 - 1.86	0.011

Complete or incomplete tertiary	2.29	1.70 - 3.09	2.58	1.81 - 3.69	<0.001
<b>Ever had sex with a boy/man</b>					
No	1		1		
Yes	0.82	0.71 - 0.95	0.68	0.57- 0.82	<0.001
<b>Away from home in last 12 months</b>					
No	1		1		
Yes	1.15	0.80 - 1.64	1.21	0.83- 1.77	0.309

### Relationship between MTV Shuga exposure and HIV and SRHR outcomes (Table 3&4)

In the nested cohorts by 2019, overall 63.3% of those aged 14-23 knew their HIV status, 13.4% were consistently using contraception, 20.0% were using condoms consistently, and about a third were aware of PrEP, 5% had a pregnancy and 15% acquired HSV2. There were higher proportions of contraception use, condom use and PrEP awareness among those exposed to MTV Shuga (Table 3). For survey sites (Table 3) overall, 85.0% knew their HIV status, over a fifth 22.6% were using contraception and about half using condoms 48.4%. About a tenth (7.5%) were aware of PrEP, with higher proportions of these being among those exposed to MTV Shuga.

**Table 3: HIV and SRHR outcomes by exposure to MTV Shuga nested cohort 13-22 year olds n= 2167)**

	Overall		Exposed (n=308)		Not exposed (n=1878)		P-value
	n/N	%	n/N	%	n/N	%	
Knowledge of HIV status, 2019	1083/1712	63.3	175/283	61.8	908/1429	63.5	0.587
Modern contraception, 2019	221/1651	13.4	56/271	20.7	165/1380	12	<0.001
Consistent condom use, 2019	168/838	20	41/141	29.1	127/697	18.2	0.003
Aware of PrEP, 2019	523/1712	30.5	124/283	43.8	399/1429	27.9	0.302
Pregnant in 2018/19	124/2184	5.7	20/308	6.5	104/1876	5.5	0.504
Teenage pregnancy	72/1395	5.16	55/1187	4.63	17/208	8.17	0.033
HSV-2 2018/19	241/1562	15.4	35/237	14.8	206/1325	15.5	0.760
<b>HIV and SRHR outcomes by exposure to MTV Shuga weighted for sampling (cross sectional survey 12-24 year olds n=4127)</b>							
	Overall		Exposed		Not exposed		
	n/N	%	n/N	%	n/N	%	p-value

PrEP awareness (N=4127)	310/4127	7.5	148/1477	10.0	162/2650	6.1	<0.001
HIV test (self-report) (N=4127)	2529/2156	85.3	656/797	82.3	1500/1732	86.6	0.005
Condom use at last sex (N=1898)‡	918/1898	48.4	320/640	50.0	598/1258	47.5	0.310
Contraception use (N=4127)	934/4127	22.6	302/1477	20.5	632/2650	23.9	0.012

‡Restricted to those who ever had sex with man

At follow up, incident HSV-2 and teenage pregnancy were high, HSV-2 incidence was 15.26 and teenage pregnancy incidence was 9.86 per 100 person-years, respectively (Table 4).

**Table 4: Rate of SRHR outcome by exposure to MTV Shuga (nested cohort 13-22 year olds n=2167)**

<b>HSV-2 incidence rate</b>						
	person-time	n with HSV-2	Rate/100 py	[95% Conf.	Interval]	
MTV Shuga Not exposed	1303.0	206	15.81	13.79	18.12	
MTV Shuga Exposed	276.3	35	12.67	9.09	17.64	
Total	1579.3	241	15.26	13.45	17.31	
<b>Pregnancy incidence rates among all AGYW</b>						
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]	
MTV Shuga Not exposed	1068.7	104	9.73	8.03	11.79	
MTV Shuga Exposed	188.5	20	10.61	6.84	16.44	
Total	1257.2	124	9.86	8.27	11.76	
<b>Pregnancy incidence rates among girls below 19 years</b>						
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]	
MTV Shuga Not exposed	668.7	55	8.22	6.31	10.71	
MTV Shuga Exposed	123.9	17	13.72	8.53	22.07	
Total	792.6	72	9.08	7.21	11.44	

## MTV Shuga and HIV prevention and SRHR awareness and uptake

In the nested cohort after adjusting for age, education, SES, area and DREAMS, MTV Shuga exposure in the AGYW cohort was associated with significantly greater awareness of PrEP (aOR=2.06, 95%CI: 1.57-2.70), contraception uptake (aOR=2.08, 95%CI: 1.45-2.98), and consistent condom use (aOR=1.84, 95%CI: 1.24-2.93). Watching MTV-Shuga was not associated with HIV testing (aOR=1.02,95%CI: 0.77-1.21) (Figure 3 and Supplementary Tables S1-S4). There was no effect modification by DREAMS exposure.

**Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.**

1  
2  
3 Similarly, in the cross-sectional analysis, after adjusting for age, education, district, migration  
4 and sexual history, exposure to MTV-Shuga watching was associated with greater awareness  
5 of PrEP (aOR=1.7, 95%CI 1.20 - 2.43). However, there was no association with contraception,  
6 lower self-reported HIV testing, or condom use as shown in Figure 4 below (Supplementary  
7 Table 5).  
8  
9  
10

11  
12  
13 **Figure 4 Forest plots showing association between MTV Shuga exposure and HIV**  
14 **prevention and SRHR awareness and uptake in the cross-sectional surveys**  
15

16 **Causal effect of MTV Shuga on health outcomes – HSV2**  
17

18 The causal analysis similarly finds no effect of MTV Shuga on HSV2, with a risk difference of  
19 1.10 95% CI (-2.82- 5.38)%. Findings in the younger age group (aged 13-17) and the older  
20 age group (18-22) was similar (Supplementary Table 6).  
21  
22  
23

24 **Discussion**  
25

26 In our study of the population-level effect of a national broadcast of a TV-based edu-drama on  
27 HIV prevention and SRHR, exposure to MTV Shuga was associated with higher awareness  
28 of a novel HIV prevention intervention (PrEP). However, despite a very high incidence of HSV-  
29 2 and teenage pregnancy, MTV Shuga exposure was not significantly associated with safer  
30 sexual behaviour, uptake of contraception and HIV-testing or prevention of teenage  
31 pregnancy. Notably though, the size of the relationship and direction of effect between  
32 exposure to MTV Shuga, condom use and markers of unprotected sex (HSV-2 and  
33 pregnancy) was consistent with a possible relationship. These findings may be partly  
34 explained by our finding that less than one in 12 of the target age group had any exposure to  
35 MTV Shuga and only half of these had high exposure (defined as watching the MTV Shuga  
36 South African series and being able to recall the content), suggesting that one of the limiting  
37 factors for the effective use of TV-based edu-drama maybe the dose that young people are  
38 exposed to, particularly in rural and resource-constrained settings most affected by HIV.  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Our inability to find a measurable population effect of mass-media edu-drama behaviour  
49 change campaign compared to the trial findings of the RCT is disappointing (15). However,  
50 firstly the direction and size of the relationships suggest that we may have been able to see  
51 an effect if the proportion exposed had been greater than 7%. Secondly, AGYW in urban  
52 settings were more likely to have been exposed to MTV Shuga and they are also more likely  
53 to be living in small towns and townships. Data from our settings suggest that young people  
54 in small towns and townships are more vulnerable to HIV (24) and sexual risk (25) and  
55 therefore it is possible that a real effect of MTV Shuga on this group was masked by their  
56  
57  
58  
59  
60

1  
2  
3 greater risk for the outcome. Due to the low numbers with high levels of exposure to MTV  
4 Shuga we did not have the power to explore this hypothesis by looking at effect modification  
5 by geography or socioeconomic status.  
6  
7

8  
9 The finding of a differential association of MTV Shuga exposure with awareness of PrEP,  
10 compared to uptake of HIV and contraception, suggests that whilst educational mass  
11 entertainment may be able to increase awareness and possibly demand for a service, it does  
12 not impact on accessibility of the service: i.e. it impacts the first two steps of the prevention  
13 cascade and not the final step(26). Well described barriers to uptake of HIV-testing and  
14 contraception in this area are internalized and externalized stigma, fear of judgement from  
15 health care workers and the social costs of accessing care in busy primary health care  
16 settings(27-29). Behaviour change intervention including mass communication campaigns  
17 can be constrained or facilitated by the context in which people live (14, 30). To optimise MTV  
18 Shuga's effect there may need to be parallel innovations in SRHR and HIV service delivery  
19 that makes the services easier to access. We aim to test this hypothesis by providing  
20 community-based delivery of HIV and SRHR services in the context of the MTV Shuga.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 The behaviour change theory that underpins edu-drama as a vehicle for mass behaviour  
31 change communication (13) explicitly suggests that the audience, and especially the early  
32 adopters, need to be actively watching, rather than passively watching or listening (14, 15).  
33 TV watching in rural homesteads can be in the context of large, often grandparent-led  
34 households and competing chores and priorities. This coupled with the relatively late timing of  
35 the shows may explain why so few girls and young women were sufficiently engaged or  
36 immersed to be able to recall characters or story lines. Moreover, the timing of this analysis  
37 may have allowed insufficient time for early adopters to convey the message of the show.  
38  
39  
40  
41  
42  
43

## 44 **Limitations**

45 The limitations of our study are that a meaningful exposure to MTV Shuga was low and so  
46 whilst the size of the relationship and direction of effect between exposure to MTV Shuga,  
47 condom use, and markers of unprotected sex (HSV-2 and pregnancy) suggested a possible  
48 effect we did not have the power to show a significant relationship between exposure to MTV  
49 Shuga and SRHR outcomes. We also do not have the power to see a difference by dose and  
50 immersion. Furthermore, as this is an observational study, we cannot exclude the possibility  
51 that those who are exposed to MTV Shuga are systematically different in ways that impact on  
52 the outcome of interest, for example more exposed to social media and sexual health  
53 promotion and innovative technologies to support sexual health than those who were not.  
54  
55  
56  
57  
58  
59  
60

## Conclusions and implications for the future

- Meaningful exposure to MTV Shuga was low across rural and urban settings in South Africa and so additional efforts need to be made to reach young people and increase their immersion in promising edu-drama if it is to have the desired effect, especially in rural and deprived settings.
- MTV Shuga was an effective vehicle to raise awareness and promote newer HIV prevention technologies such as HIV PrEP.
- There was some suggestion that MTV Shuga improved uptake of some HIV prevention and sexual health technologies (contraception and condoms)
- There was less evidence from this observational study that it improved SRHR and HIV outcomes

We highlight the importance of evaluating the real-world scale up of promising interventions to understand both the reach and population effect as well as inform interventions to increase impact and equity.

Efforts to increase exposure, which have been rolled out as part of MTV Shuga in SA, such as social media, school-based or community-based MTV Shuga film clubs will need to be evaluated, both to understand whether or not they increase exposure and coverage and improve SRH and HIV outcomes. However, to have a significant impact on the HIV and SRH prevention and treatment cascades, demand generation in AGYW needs to be delivered in parallel with accessible service delivery models that support adherence and retention (26).

## Contributorship

M.S., N.C., J.D., T.Z. N.K, G.H. and C.C. developed the study tools and performed the research. M.S., J.S. D.P., K.B., I.B., and S.F. designed the research study. T.S. and S.D. conducted the laboratory analysis. N.M. supported by K.B. conducted the statistical analysis and C.G. M.S wrote the first and final draft of the paper with input from N.C., N.M., G.H., J.S., I.B., G.C., K.B., C.C., T.S., and N.K. All authors have approved the final draft of the paper.

## Competing interests

All authors declare they have no conflict of interest

## Funding

The authors are grateful to the communities of the Hlabisa sub-district, Ekurhuleni district, Thekwini district and City of Johannesburg who contributed their data to this study and to all the staff at Africa Health Research Institute and EpiCentre who collected the data. We acknowledge Eskindir Shambullo for his input in this manuscript.

The impact evaluation of DREAMS and MTV Shuga is funded by the Bill and Melinda Gates Foundation (OPP1136774 and OPP1171600, <http://www.gatesfoundation.org>). Foundation staff advised the study team, but did not substantively affect the study design, instruments, interpretation of data, or decision to publish. The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union's seventh Framework Programme FP7/2007-2013 under REA grant agreement n° 612216. MS National Institutes of Health 5R01MH114560-03 funding acknowledgement Africa Health Research Institute is supported by core funding from the Wellcome Trust [Core grant number (201433/Z/16/Z)]. GH is supported by a fellowship from the Royal Society and the Wellcome Trust [Grant number 210479/Z/18/Z]. MS work is also supported by a BMGF 3ie grant at AHRI. This research was funded in whole, or in part, by the Wellcome Trust [Grant number 210479/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

## Data sharing statement

Data are available on reasonable request.

## References

1. HSRC. The fifth South African National HIV prevalence, incidence, behaviour and communication survey [Report]. [http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV\\_Impact\\_Assessment\\_Summary\\_ZA\\_ADS\\_cleared\\_PDFv4.pdf](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDFv4.pdf): South African Health Services Research Council 2017 [updated 01/11/2018].
2. Chimbindi N, Mthiyane N, Birdthistle I, Floyd S, McGrath N, Pillay D, et al. Persistently high incidence of HIV and poor service uptake in adolescent girls and young women in rural KwaZulu-Natal, South Africa prior to DREAMS. PLoS One. 2018;13(10):e0203193.
3. Department of Health RoSA. National Campaign for Young Women and Adolescent Girls. . 2016.



- 1  
2  
3 4. Saul J, Bachman G, Allen S, Toiv NF, Cooney C, Beamon TA. The DREAMS core  
4 package of interventions: A comprehensive approach to preventing HIV among adolescent  
5 girls and young women. PLOS ONE. 2018;13(12):e0208167.
- 6  
7  
8 5. PEPFAR. Preventing HIV in Adolescent Girls and Young Women: Guidance for  
9 PEPFAR Country  
10  
11 Teams on the DREAMS Partnership 2015.
- 12  
13 6. PEPFAR. South Africa DREAMS overview  
14 <https://www.pepfar.gov/documents/organization/253958.pdf>: PEPFAR; 2017 [
- 15  
16  
17 7. Chang L, Serwadda D, Quinn T, Wawer M, Gray R, Reynolds S. Combination  
18 implementation for HIV prevention: moving from clinical trial evidence to population-level  
19 effects. *The Lancet Infectious Diseases* 2013;13(1):65-76.
- 20  
21 8. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al.  
22 Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label,  
23 community cluster randomised trial. *Lancet HIV*. 2018;5(3):e116-e25.
- 24  
25  
26 9. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation  
27 of the impact of immediate versus WHO recommendations-guided antiretroviral therapy  
28 initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa  
29 sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled  
30 trial. *Trials*. 2013;14:230.
- 31  
32  
33 10. Birdthistle I, Schaffnit SB, Kwaro D, Shahmanesh M, Ziraba A, Kabiru CW, et al.  
34 Evaluating the impact of the DREAMS partnership to reduce HIV incidence among  
35 adolescent girls and young women in four settings: a study protocol. *BMC Public Health*.  
36 2018;18(1):912.
- 37  
38  
39 11. Shen F, Han J. Effectiveness of entertainment education in communicating health  
40 information: a systematic review. *Asian Journal of Communication*. 2014;24(6):605-16.
- 41  
42  
43 12. Noar SM, Palmgreen P, Chabot M, Dobransky N, Zimmerman RS. A 10-year  
44 systematic review of HIV/AIDS mass communication campaigns: have we made progress?  
45 *Journal of Health Communication*. 2009;14(1):15-42.
- 46  
47  
48 13. Barker K. Sex Soap and Social change- The Sabido methodology  
49 <https://www.populationmedia.org/product/sabido-theory/>;  
50 <http://www.comminit.com/content/sabido-methodology> [
- 51  
52  
53 14. Baker V, Birdthistle I, Seeley J, Arnold G, Piot S, Hajjiannis H. How can a TV drama  
54 about Love, Sex and Growing up Increase Knowledge and Shape the Sexual Health  
55 Behaviours of Young People? . *AIDS Impact*; Cape Town, South Africa 2017.
- 56  
57  
58  
59  
60

15. MTV Shuga Soap Opera Turns Edutainment into a Tool to Fight HIV and Gender-Based Violence <http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-violence2017> [
16. National Department of Health. The National Antenatal Sentinel HIV prevalence survey, South Africa, <http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-10/2015-04-30-08-21-56?download=2584:2015-national-antenatal-hiv-prevalence-survey-final-23oct17>, 2013 [
17. Herbst K, Law M, Geldsetzer P, Tanser F, Harling G, Barnighausen T. Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. *Current Opinion on HIV AIDS*. 2015;10(6):483-94.
18. Garetta D, Baisley K, Mngomezulu T, Smit T, Khoza T, Nxumalo S, et al. Cohort Profile Update: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *Int J Epidemiol*. 2021;50(1):33-4.
19. Filmer D, Pritchett LH. Estimating Wealth Effects Without Expenditure Data—Or Tears: An Application To Educational Enrollments In States Of India\*. *Demography*. 2001;38:115-32.
20. Arvin A, Prober C. Herpes Simplex Viruses. In: Murray P, Baron E, Pfaller M, Tenover F, Tenover F, Tenover R, editors. *Manual of Clinical Microbiology 6th Ed* Washington D.C.: ASM; 1995. p. 876-83.
21. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of Focus HerpeSelect ® and Kalon TM HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 (HSV-2) antibodies in a South African population. *Sexually Transmitted Infections*. 2009;86(1):46-50.
22. Ashley-Morrow R, Nolkemper J, Robinson N, Bishop N, Smith J. Performance of Focus ELISA test for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical Microbiology and Infection* 2004;10(6):530-6.
23. STROBE Statement. STROBE Checklists 2007 [Available from: <http://www.strobe-statement.org/index.php?id=available-checklists>].
24. Cuadros DF, Li J, Branscum AJ, Akullian A, Jia P, Mziray EN, et al. Mapping the spatial variability of HIV infection in Sub-Saharan Africa: Effective information for localized HIV prevention and control. *Scientific Reports*. 2017;7(1):9093.
25. Ngwenya N, Gumede D, Shahmanesh M, McGrath N, Grant A, Seeley J. Community perceptions of the socio-economic structural context influencing HIV and TB risk, prevention and treatment in a high prevalence area in the era of antiretroviral therapy. *African Journal of AIDS Research*. 2018;17(1):72-81.

- 1  
2  
3 26. Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S, Bhattacharjee  
4 P, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural,  
5 and social science into programme design and monitoring. *Lancet HIV*. 2016;3(7):e318-22.  
6  
7 27. Hargreaves JR, Krishnaratne S, Mathema H, Lilleston PS, Sievwright K, Mandla N,  
8 et al. Individual and community-level risk factors for HIV stigma in 21 Zambian and South  
9 African communities: analysis of data from the HPTN071 (PopART) study. *AIDS*.  
10 2018;32(6):783-93.  
11  
12 28. Chimbindi N, Zuma T, Nakasone S, Birdthistle I, Mthiyane N, Dreyer J, et al.  
13 Platforms, Processes and Perceptions of PrEP Delivery Through DREAMS in a Rural  
14 Setting in KwaZulu-Natal, South Africa. . *Research for Prevention 2018 (HIVR4P 2018)*  
15 Madrid, Spain 2018.  
16  
17 29. Adeagbo O, Herbst C, Dlamini N, Mhlongo T, Luthuli M, Xulu S, et al. "If she tests  
18 negative, it means I am also negative": Men's construction of HIV testing in KwaZulu-Natal,  
19 South Africa. . *HIV Research for Prevention (HIVR4P) 23 October 2018.*; Madrid, Spain  
20  
21 **2018**  
22  
23 30. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for  
24 characterising and designing behaviour change interventions. *Implementation Science*.  
25 2011;6(42).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure legends

Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Conceptual framework for MTV Shuga impact on HIV prevention in uMkhanyakude




Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

338x190mm (96 x 96 DPI)




Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

338x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

338x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

338x190mm (96 x 96 DPI)



**Supplementary Table 1 Exposure to MTV Shuga and PrEP awareness in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	2.01	1.55 -2.62				2.06	1.57 -2.70	<0.001
<b>Age</b>	1.12	1.08-1.16	1.12	1.08-1.17	<0.001	1.11	1.06-1.17	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.47 -0.76	0.59	0.46 -0.75	<0.001	0.89	0.65 -1.23	0.488
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.99	0.71 -1.39	0.96	0.68 -1.35		1.01	0.71 -1.44	
High	1.13	0.81 -1.58	1.05	0.75 -1.47	0.744	1.11	0.78 -1.58	0.699
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.98	0.79 -1.22	0.93	0.75 -1.16	0.525	0.92	0.73 -1.15	0.459
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.89	0.73 -1.10	0.88	0.71 -1.08	0.212	0.99	0.79 -1.23	0.897

**Supplementary Table 2 Exposure to MTV Shuga and contraception uptake in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.92	1.37 -2.68				2.08	1.45-2.98	<0.001
<b>Age</b>	1.26	1.19-1.33	1.27	1.20-1.34	<0.001	1.32	1.24-1.42	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.44 -0.83	0.59	0.43-0.82	0.001	1.7	1.13-2.55	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.79	0.51 -1.22	0.76	0.49-1.19		0.8	0.51-1.28	
High	0.86	0.55 -1.34	0.8	0.51-1.24	0.489	0.83	0.52-1.32	0.646
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.91	0.68 -1.24	0.86	0.64-1.17	0.345	0.89	0.64-1.24	0.49
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.63 -1.11	0.83	0.62-1.10	0.191	1.04	0.76-1.42	0.813

**Supplementary Table 3 Exposure to MTV Shuga and consistent condom use in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		p-value
	OR	95%CI	OR	95%CI		OR	95%CI	
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.84	1.22-2.78				1.9	1.24-2.93	0.003
<b>Age</b>	0.94	0.86-1.01	0.94	0.87-1.02	0.157	1	0.91-1.10	0.984
<b>Currently in school</b>								
No	1		1			1		
Yes	1.76	1.22-2.53	1.73	1.20-2.49	0.003	1.78	1.15-2.76	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	1.01	0.60-1.70	0.97	0.58-1.63		0.98	0.58-1.67	
High	0.87	0.52-1.47	0.8	0.47-1.36	0.552	0.86	0.50-1.48	0.753
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.7	0.48-1.02	0.67	0.46-0.97	0.035	0.71	0.48-1.05	0.088
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	1.13	0.81-1.59	1.13	0.80-1.59	0.486	0.97	0.67-1.40	0.875

**Supplementary Table 4 Exposure to MTV Shuga and HIV testing in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	0.93	0.71-1.21				1.02	0.77-1.36	0.885
<b>Age</b>	1.3	1.25-1.35	1.3	1.24-1.35	<0.001	1.3	1.24-1.37	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.37	0.28-0.48	0.37	0.28-0.48	0	1.07	0.74-1.53	0.726
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.67	0.48-0.94	0.67	0.48-0.95		0.71	0.49-1.02	
High	0.58	0.41-0.81	0.58	0.41-0.81	0.007	0.6	0.41-0.86	0.018
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.84	0.68-1.03	0.84	0.69-1.04	0.104	0.89	0.71-1.11	0.298
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.69-1.02	0.84	0.69-1.02	0.081	0.98	0.79-1.23	0.89

**Supplementary Table 5: Exposure to MTV Shuga with HIV prevention and SRHR awareness and uptake in the cross-sectional analysis of AGYW aged 12-24 (n=4127)**

	aOR (95% Confidence Interval)	P-value
<b>District</b>		
City of Johannesburg	1	
Ekurhuleni	0.66 (0.47-0.91)	0.013
eThekweni	0.78 (0.54-1.13)	0.186
<b>Age group</b>		
12-14	1	
15-19	1.75 (0.35-8.84)	0.499
20-24	1.60 (0.32-8.07)	0.570
<b>Highest education level</b>		
Grade R to 7	1	
No schooling	3.84 (1.05-14.02)	0.041
Grade 8 to 12	3.17 (0.93-10.77)	0.065
Complete or incomplete tertiary	6.52 (1.90-22.33)	0.003
<b>Ever had sex with a boy/man</b>		
No	1	
Yes	0.67 (0.32-1.40)	0.286
<b>Away from home</b>		
No	1	
Yes	1.48 (0.93-2.37)	0.099
<b>PrEP awareness</b>		
No	1	
Yes	1.71 (1.20-2.43)	0.003
<b>Contraception use</b>		
No	1	
Yes	0.95 (0.74-1.23)	0.718
<b>Condom use at last sex</b>		
No	1	
Yes	1.19 (0.92-1.55)	0.183
<b>HIV test (self-report)</b>		
No	1	
Yes	0.88 (0.63-1.24)	0.471

Supplementary Table 6 Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group

Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group											
	% Outcome in total study population	Estimated % Outcome if no Shuga	95% CI	Estimated % Outcome if all get Shuga	95% CI	Risk Difference (%; PS adjusted)	95% CI	Prevalence Ratio (%; PS adjusted)	95% CI	Odds Ratio (%; PS adjusted)	95% CI
<b>PS adjustment: Primary results</b>											
Overall	17.3	17.2	14.71 - 19.67	18.0	14.51 - 22.32	0.80	-3.24 - 5.71	1.05	0.82 - 1.36	1.06	0.79 - 1.46
13-17 Years	13.2	12.4	9.85 - 15.16	15.7	11.63 - 20.26	3.34	-1.60 - 8.25	1.27	0.89 - 1.79	1.32	0.87 - 1.98
18-22 Years	24.3	25.8	21.01 - 30.74	22.0	15.19 - 30.17	-3.76	-11.92 - 5.68	0.85	0.59 - 1.24	0.81	0.51 - 1.34
<b>Sensitivity analyses</b>											
<u>Regression under counterfactual framework</u>											
Overall	17.3	17.2	14.74 - 19.66	17.8	14.50 - 22.08	0.65	-3.42 - 5.72	1.04	0.82 - 1.36	1.05	0.78 - 1.46
13-17 Years	13.2	12.42	9.86 - 15.21	15.9	11.85 - 20.49	3.47	-1.54 - 8.63	1.28	0.89 - 1.80	1.33	0.88 - 1.99
18-22 Years	24.3	25.7	20.78 - 30.63	21.3	14.88 - 28.28	-4.42	-12.28 - 4.95	0.83	0.57 - 1.22	0.78	0.48 - 1.31
<u>PS stratification</u>											
Overall	17.3	17.1	14.68 - 19.68	17.9	14.53 - 22.13	0.80	-3.21 - 5.52	1.09	0.84 - 1.40	1.11	0.82 - 1.51
<u>PS weighting</u>											

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Overall	17.3	17.08	14.74 - 19.48	17.22	13.99 - 21.10	0.13	-3.76 - 4.63	1.01	0.79 - 1.30	1.01	0.76 - 1.37
---------	------	-------	------------------	-------	------------------	------	-----------------	------	----------------	------	----------------

For peer review only

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	10

Continued on next page



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	12
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-16
		(b) Report category boundaries when continuous variables were categorized	12-16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	17-18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-19
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-19
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Evaluating use of mass-media communication intervention 'MTV-Shuga' on increased awareness and demand for HIV and sexual health services by adolescent girls and young women in South Africa: An observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062804.R1
Article Type:	Original research
Date Submitted by the Author:	07-Sep-2022
Complete List of Authors:	Chimbindi, Natsayi; Africa Health Research Institute; University College London, Mthiyane, Nondumiso; Africa Health Research Institute Chidumwa, Glory ; Africa Health Research Institute Zuma, Thembelihle; Africa Health Research Institute; University College London, Dreyer, Jaco; Africa Health Research Institute Birdthistle, Isolde; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Floyd, Sian; London School of Hygiene & Tropical Medicine, Infectious Disease Epidemiology Kwegombe, Nambusi; London School of Hygiene & Tropical Medicine Grundt, Chris; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Cawood, Cherie; Epicentre Health Research Danaviah, Siva; Africa Health Research Institute Smit, Theresa; Africa Health Research Institute Pillay, Deenan; University College London, Baisley, Kathy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health; Africa Health Research Institute Harling, Guy; Africa Health Research Institute Seeley, Janet; London School of Hygiene and Tropical Medicine, Department of Global Health & Development; Africa Health Research Institute Shahmanesh, Maryam; University College London, Institute for Global Health; Africa Health Research Institute,
<b>Primary Subject Heading</b>:	Sexual health
Secondary Subject Heading:	HIV/AIDS, Public health, Sexual health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH, PREVENTIVE MEDICINE

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 Title page  
5  
6

7 Revised Title: **Evaluating use of mass-media communication intervention ‘MTV-**  
8 **Shuga’ on increased awareness and demand for HIV and sexual health**  
9 **services by adolescent girls and young women in South Africa: An**  
10 **observational study**  
11  
12  
13

14  
15 Authors: Natsayi Chimbindi\*<sup>1,2,3</sup>, Nondumiso Mthiyane\*<sup>2</sup>, Glory Chidumwa<sup>1</sup>,  
16 Thembelihle Zuma<sup>1,2,3</sup>, Jaco Dreyer<sup>1</sup>, Isolde Birdthistle<sup>4</sup>, Sian Floyd<sup>4</sup>, Nambusi  
17 Kyegombe<sup>4</sup>, Chris Grundy<sup>4</sup>, Cherie Cawood<sup>5</sup>, Siva Danaviah<sup>1</sup>, Theresa Smit<sup>1</sup>,  
18 Deenan Pillay<sup>2</sup>, Kathy Baisley<sup>1,3</sup>, Guy Harling<sup>1,2,3,6,7</sup>, Janet Seeley<sup>1,3,4</sup>, Maryam  
19 Shahmanesh<sup>§1,2,3</sup>  
20  
21  
22  
23

- 24  
25  
26 1. Africa Health Research Institute, KwaZulu-Natal, South Africa  
27 2. University College London, Institute for Global Health, London, UK  
28 3. University of KwaZulu-Natal, KwaZulu-Natal, South Africa  
29 4. London School of Hygiene and Tropical Medicine, London, UK  
30 5. Epicentre, South Africa  
31 6. MRC/Wits Rural Public Health & Health Transitions Research Unit  
32 (Agincourt), University of the Witwatersrand, Gauteng, South Africa  
33 7. Department of Epidemiology & Harvard Center for Population and  
34 Development Studies, Harvard T.H. Chan School of Public Health, Boston,  
35 USA  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 \*Joint authors  
46

47 §Corresponding author (full address details): Maryam Shahmanesh, Institute for  
48 Global Health, UCL, 3<sup>rd</sup> Floor, Mortimer Market Centre, Capper Street, London  
49 WC1E 6JB. [m.shahmanesh@ucl.ac.uk](mailto:m.shahmanesh@ucl.ac.uk). +44 7776 185 572  
50  
51  
52  
53

54 Key words (6): HIV, Adolescents, mass communication campaigns, Sexual Health,  
55 Teenage Pregnancy, South Africa.  
56

57 **Abstract (word count=300)**  
58  
59  
60

1  
2  
3 **Objectives:** Mass media edu-dramas have potential to increase demand for HIV and sexual  
4 and reproductive health(SRH) services among young people. MTVShuga:‘MTV Shuga:Down  
5 South’(MTV Shuga-DS) is a serial mass media edu-drama designed to reduce HIV-related  
6 risk-behaviour and improve SRH outcomes in adolescents and young adults in South Africa.  
7 We investigate the effect of exposure to MTVShuga-DS during the scale-up of combination  
8 HIV-prevention interventions(DREAMS) on awareness and uptake of SRH and HIV-  
9 prevention services by adolescent girls and young women(AGYW).  
10

11 **Design:** One longitudinal and three cross-sectional surveys of representative samples of  
12 AGYW  
13

14 **Setting:** AGYW in four South African districts with high HIV-prevalence(>10%) (May 2017 and  
15 September 2019)  
16

17 **Participants:** 6311AGYW aged 12-24  
18

19 **Measures:** Using logistic-regression we measured the relationship between exposure to MTV  
20 Shuga-DS and awareness of Pre-Exposure Prophylaxis(PrEP), condom-use at last sex,  
21 uptake of HIV-testing or contraception, and incident pregnancy or HSV-2 infection.  
22

23 **Results:** Within the rural cohort 2184(85.5%) of eligible sampled individuals were enrolled, of  
24 whom 92.6% had at least one follow-up visit; the urban cross-sectional surveys enrolled  
25 4127(22.6%) of eligible sampled individuals. Self-report of watching at least one MTV Shuga-  
26 DS episode was 14.1%(cohort) and 35.8%(cross-section), while storyline recall was  
27 5.5%(cohort) and 6.7%(cross-section).  
28

29 In the cohort, after adjustment (for DREAMS-exposure, age, education, SES), MTVShuga-DS  
30 exposure was associated with increased PrEP awareness(aOR=2.06,95%CI:1.57-2.70),  
31 contraception uptake(aOR=2.08,95%CI:1.45-2.98) and consistent condom-use(aOR=1.84,  
32 95%CI:1.24-2.93), but not with HIV-testing(aOR=1.02,95%CI:0.77-1.21) or acquiring HSV-2  
33 (aOR=0.92, 95%CI:0.61-1.38). In the cross-sections, MTVShuga-DS was associated with  
34 greater PrEP awareness(aOR=1.7, 95%CI:1.20-2.43), but no other outcome.  
35

36 **Conclusions:** Among both urban and rural AGYW in South Africa, MTVShuga-DS exposure  
37 was associated with increased PrEP awareness and improved demand for some HIV-  
38 prevention and SRH technologies but not sexual health outcomes. However, exposure to  
39 MTVShuga-DS was low. Given these positive indications, supportive programming may be  
40 required to raise exposure and allow future evaluation of edu-drama impact in this setting.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- Evaluated the real-world reach of nationally broadcast edu-drama focusing on adolescent sexual health in South Africa.
- Data collection focused on a vulnerable population of AGYW across four diverse high HIV-burden districts of South Africa that included both rural and urban settings.
- Study measured the reach of MTV-Shuga and the relationship between exposure to the edu-drama on awareness and demand for HIV prevention technologies in representative longitudinal cohort and cross-sectional samples of young women.
- Observational studies give no opportunity to infer the cause–effect relationship, in this case exposure to MTV-Shuga and impact on uptake of sexual health promotion and innovative technologies.

1  
2  
3 **[word count 4531]**

## 4 **Introduction**

5 HIV remains one of the gravest health problems facing young people living in sub-Saharan  
6 Africa (SSA). There are over 7.7 million people living with HIV in South Africa, with more than  
7 200,000 new HIV infections annually in those aged 15-49 years (1). The highest incidence is  
8 in adolescent girls and young women (AGYW) (15-24 years) (1, 2). Although HIV incidence  
9 has been declining in South Africa, a 43% decline in the overall incidence rate between 2012  
10 and 2017, from 4.0 to 2.3 seroconversion events per 100 person-years among 15-49 year old;  
11 it still remains high among AGYW in South Africa (3). In uMkhanyakude, HIV incidence was  
12 lower during roll-out of combination HIV prevention for AGYW (2016 to 2018) than in the  
13 previous 5-year period among 15- to 19-year-old females (4.5 new infections per 100 person-  
14 years as compared with 2.8; and lower among 20- to 24-year-olds (7.1/100 person-years as  
15 compared with 5.8) (4).  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 In response to the high HIV incidence in young people, the South African government  
26 launched the 'She Conquers Campaign', and the US President's Emergency Fund for AIDS  
27 Relief and others are supporting the roll-out of Determined, Resilient, Empowered, AIDS free,  
28 Mentored, and Safe (DREAMS)(5-7). These programmes provide an evidence-based  
29 combination HIV prevention package, including HIV-testing and counselling for adolescent  
30 girls and young women (AGYW) and their male sexual partners, alongside universal test and  
31 treat and improved sexual health services (8, 9).  
32  
33  
34  
35  
36  
37

38 However, the key ingredient to the success of these multicomponent interventions will be the  
39 extent to which AGYW and their male partners at most risk of HIV will uptake and adhere to  
40 the active components of the intervention. This is challenging: uptake and retention of  
41 contraception and HIV treatment cascade by young people, even within population-wide  
42 Universal Test and Treat trials, has been suboptimal (2, 10, 11). Data from the baseline  
43 analysis for the DREAMS impact evaluation in uMkhanyakude district, rural KwaZulu-Natal  
44 (KZN) in 2015 suggest that less than 40% of girls (15-19 years) and boys and young men (15-  
45 29 years) had ever tested for HIV; linkage to HIV treatment was even lower (12).  
46 Contraception use prevalence was 20% in girls (15-19 years) and 50% in young women (20-  
47 24 years) and 21% of 15-19 year old girls had ever been pregnant (2).  
48  
49  
50  
51  
52  
53  
54

55 It is against this backdrop that the fifth series of Shuga: 'MTV Shuga: Down South' (MTV  
56 Shuga-DS), a mass media serial edu-drama designed for SA, was broadcast on free-to-air  
57 South Africa National television. From March 8<sup>th</sup> 2017, MTV Shuga aired one episode per  
58 week for 12 weeks (with repeats). MTV Shuga is a mass media behaviour change campaign  
59  
60



1  
2  
3 that aims to improve sexual and reproductive health rights (SRHR). At the centre of the  
4 campaign, which includes radio and social media, is a TV-drama that weaves messages about  
5 HIV, family planning, transactional and intergenerational sex, safer and healthy sexual  
6 relationships, into storylines with young characters ([http://www.mtvshuga.com/show/series-5/MTV Shuga-down-south/](http://www.mtvshuga.com/show/series-5/MTV-Shuga-down-south/)).  
7  
8  
9

10  
11 Mass media campaigns, have the potential to reach a large number of people and have been  
12 shown to improve knowledge and health behaviour of a range of health conditions, with more  
13 recent data suggesting that theoretically informed and targeted interventions are more likely  
14 to have an effect (13, 14). MTV Shuga-DS was designed to reduce HIV-related risk behaviour  
15 and improve SRHR outcomes in adolescents and young adults in SA. This was expected to  
16 be achieved through increasing young people's awareness of their sexual and reproductive  
17 health rights and demand for, and uptake of HIV and SRH prevention and treatment  
18 technologies. The show's characters explicitly model how to discuss issues that are sensitive  
19 or taboo. MTV Shuga use the technique of 'melodramas', where drama is created through  
20 the battles between stereotypical goodies and baddies, and the way in which the 'transitional'  
21 (often empathetic) character, begins as ambivalent but changes into a positive role model to  
22 promote positive behaviour change(15). This is a deliberate method to immerse the audience  
23 in the action, rather than passively watching or listening (16). AGYW, or at least early adopters,  
24 are anticipated to be immersed in the serial, able to classify and identify with the transitional  
25 characters and their outcomes. Pathways to behaviour change through MTV Shuga, therefore  
26 relate to the extent to which the observer, including early adopters, are immersed and critically  
27 engaged with the story. It also depends on a context which is supportive rather than disruptive  
28 (see the conceptual framework Figure 1 below) (17).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40  
41 **Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on**  
42 **AGYW in uMkhanyakude**  
43

44  
45 A cluster randomised controlled trial of community-viewings of MTV Shuga in Nigeria found  
46 that exposure to MTV Shuga significantly improved HIV knowledge and testing in both sexes,  
47 the intervention arm showing 35% more likely to test for HIV than the control arm. There was  
48 also a 60% reduction in genital chlamydia as a marker of recent sexual risk in women, amongst  
49 those exposed to MTV Shuga compared to those who were not (18). There were, however,  
50 fewer changes in social norms, particularly around gender-based violence. Further work  
51 suggested that the impact was greatest in those who were immersed in the narrative. The  
52 importance of immersion (classification of characters and identifying with them and observing  
53 outcomes) coupled with critical participation and an enabling context were also found in a  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 thematic analysis looking at how storylines in MTV Shuga-DS shaped awareness, knowledge  
4 and opinions of sexual health and personal relationships among young people in SA (17).  
5  
6  
7

8 Whilst the Nigerian and SA studies provide evidence for the efficacy of MTV Shuga impacting  
9 on SRHR and HIV-testing behaviours in exposed individuals, there is little evidence of how  
10 this will translate into a population-level effect when nationally broadcast and in less controlled  
11 environments. In particular, it is not clear how the impact will spill-over to non-viewers and  
12 how innovations will diffuse when shown and watched by adolescents and young adults in a  
13 real-world scale-up. It is also unclear how such impact will differ according to: setting (rural or  
14 urban); differential digital literacy and access to social media (geographically and  
15 socioeconomically), and the dose and context of watching (shared viewing with family, friends  
16 or individual experience through social media).  
17  
18  
19  
20  
21  
22

23 We use the opportunity of MTV Shuga being broadcast in the context of an impact evaluation  
24 of DREAMS roll out (January 2016-September 2019) in a representative, population-based  
25 sample of young people (12) to describe the real-world reach of nationally broadcast MTV  
26 Shuga-DS. Further, we explore the hypothesis that exposure to a mass-media serial edu-  
27 drama, like MTV Shuga, will improve SRHR outcomes by increasing demand for, and uptake  
28 of, existing combination individual and community-based SRH and HIV prevention services  
29 for AGYW in four diverse settings including uMkhanyakude, a socioeconomically deprived  
30 rural district with an extremely high burden of HIV: 40% antenatal HIV prevalence and an  
31 annual HIV incidence of 5% in girls (15-19 years) and 8% in young women (20-24 years) (2,  
32 19) and in three high-prevalence urban districts (HIV prevalence of greater than 10%) of City  
33 of Johannesburg, Ekurhuleni, and eThekweni.  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 **Methods**

### 44 **Study design**

45  
46  
47  
48 We employed a longitudinal cohort and cross-sectional surveys of representative samples of  
49 AGYW aged 12-24 in four districts of South Africa with a high burden of HIV to measure the  
50 reach of MTV Shuga-DS. Data were collected between May 2017 and September 2019.  
51  
52  
53

54 We used baseline and follow-up data from a nested cohort of 2184 AGYW aged 13-22 years,  
55 enrolled in 2017 for the DREAMS impact evaluation. The cohort is nested in a large  
56 population-based longitudinal HIV surveillance study, in the uMkhanyakude district of  
57 KwaZulu-Natal (20, 21). A random sample of 3013 AGYW was selected from the surveillance  
58  
59  
60

1  
2  
3 population, stratified by age (13-17 years and 18-22 years) and geography, and invited to  
4 enrol in the nested cohort. Baseline interviews were conducted between May 2017 and  
5 February 2018 and follow-up interviews April 2018 and September 2019 in the local language  
6 (isiZulu) using a structured quantitative questionnaire programmed in REDCap (12).  
7  
8  
9

10  
11 The cross-sectional survey was conducted on a household-based representative sample of  
12 4127 AGYW (between the ages 12-24 years) in three high prevalence (City of Johannesburg,  
13 Ekurhuleni and eThekweni) districts. Between August 2017 and July 2018, a stratified cluster-  
14 based sampling strategy was used to select 18500 AGYW aged 12-24 eligible for a cross-  
15 sectional survey of individuals, based on an expected response rate of 80% (22).  
16  
17  
18

19  
20 The interview included questions on socio-demographics, general health, exposure to  
21 DREAMS and to MTV Shuga, sexual relationships, awareness and uptake of DREAMS and  
22 DREAMS-like services, migration, and gender norms across the four districts. A Dried Blood  
23 Spot (DBS) was taken at baseline and follow-up for Herpes Simplex Virus type 2 (HSV-2)  
24 antibody testing in the uMkhanyakude district. For sexual behaviour questions, participants  
25 were given a tablet computer to complete a self-interview; the fieldworker was available to  
26 provide support as needed.  
27  
28  
29  
30  
31

### 32 33 **Study setting and population**

34  
35 The cohort was nested within the Africa Health Research Institute (AHRI) triannual  
36 demographic surveillance of a population of approximately 150,000 people who are members  
37 of 15,000 geocoded households in an area of 845 km<sup>2</sup> (20). The study area is mostly rural  
38 and poor with high levels of youth unemployment (over 85% of those aged 18-24 are  
39 unemployed) (2, 19).  
40  
41  
42  
43

44  
45 The cross-sectional survey was conducted in three districts which were mostly urban with  
46 more towns and townships compared to AHRI surveillance area. The three study districts (City  
47 of Johannesburg, Ekurhuleni and eThekweni) consist of an estimated 12,073,421 individuals.  
48 The eThekweni district in KZN province is among those with the highest HIV prevalence (16.8%  
49 HIV prevalence in 2016) in South Africa. Over two-thirds (68%) of eThekweni is considered  
50 rural and 32% urban. About 11 963 (3%) AGYW in eThekweni are estimated to be living with  
51 HIV. The Gauteng province (GP), whilst geographically the smallest, is the most populous  
52 province in South Africa. GP has the fifth highest provincial HIV prevalence in the country with  
53 a prevalence of 11.1% among those aged 15 to 49 years old in 2016. The HIV prevalence in  
54 the two districts, City of Johannesburg and Ekurhuleni, is 11.1% and 14.3% among 15- to 49-  
55  
56  
57  
58  
59  
60

1  
2  
3 year-olds, respectively. Both districts are densely populated and have high levels of  
4 industrialisation. The HIV prevalence amongst AGYW (15 to 24 years old) in the City of  
5 Johannesburg is 3%, and similarly 3% in Ekurhuleni in 2012.  
6  
7  
8  
9

## 10 **Variables and Measurement:**

### 11 ***Outcomes definitions:***

12 We measured the effect of exposure to MTV Shuga on awareness and uptake of HIV  
13 prevention and SRHR outcomes at the follow-up visit. Our outcomes were: 1) self-reported  
14 HIV-testing in the past 12 months; 2) awareness of Pre-Exposure Prophylaxis (PrEP) for HIV  
15 prevention; 3) condom use at last sex; 4) use of contraception; 5) any new pregnancy since  
16 baseline; and 6) any new teenage pregnancy (restricted to those under the age of 20). AGYW  
17 were considered to use contraception if they self-reported using pill, injection, Intrauterine  
18 Device (IUD), implant, sterilisation or self-reported consistent condom use (using condoms  
19 as a contraceptive method and at last sex). Condomless sex was calculated using 2019 data  
20 among participants who reported having had sex with the most recent partner in the past 12  
21 months. Recent pregnancy was calculated as any new pregnancy that occurred between  
22 baseline and 2019, while teenage pregnancy was calculated as any new pregnancy that  
23 occurred between baseline and 2019 among participants aged below 20 years. We also  
24 examined the effect of exposure to MTV Shuga on incident HSV-2 infections, among those  
25 who were HSV2 negative at baseline.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 ***Exposure definitions:***

39 Exposure to MTV Shuga was defined as ever watched MTV Shuga between 2017 and 2018.  
40 The level of exposure was measured based on the content of the series MTV Shuga, defined  
41 using 15 questions used to assess knowledge of content of MTV Shuga series. A composite  
42 score was developed summing-up the correct responses. The scores ranged between 2 and  
43 14, and the median being 4. The median was used as a cut-off to define level of exposure  
44 among those who watched the series. Consequently, the level of exposure was categorized  
45 into 3 levels: High (watching a MTV Shuga and being able to correctly respond to 5 or more  
46 questions on content); Medium (watching programme and being able to correctly respond to  
47 less than 5 questions); and None (not watched any MTV Shuga). This was further categorised  
48 into 3 levels: High (watching MTV Shuga and being able to recall the content from MTV  
49 Shuga); Medium (watching programme, but unable to recall content); and None (not being  
50 aware of and not watched any MTV Shuga).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Potential confounding variables:**

We included socio-demographic and sexual behaviour characteristics of AGYW that were measured at baseline and exposure to HIV prevention. The socio-demographic variables included age (as measured at follow-up), household socio-economic status, education broken down by those who are still in school and those who have completed school, geographic area (rural or peri-urban/urban), and migration in the last 12 months. The socio-economic status (SES) variable was constructed using Principal Component Analysis (PCA) based on ownership of household assets and characteristics such as access to piped water, type of toilet, electricity and type of cooking fuel (23). Further, potential individual-level confounders measured included exposure to DREAMS (defined either as ever been invited to participate in any of the DREAMS activities or ever used any of the DREAMS HIV prevention interventions in the past 12 months or since 2016 and phone ownership at baseline.

**Laboratory:**

The HerpeSelect® 2 ELISA IgG assay (FOCUS Diagnostics, Cypress, California, USA) for the qualitative detection of human IgG class antibodies to HSV-2 was used on Dried blood Spot (DBS) samples collected on Whatman 903 filter cards. The HerpeSelect® 2 ELISA IgG assay uses purified type-specific gG-2 antigen immobilized on polystyrene microwells reducing the cross-reactivity issues as seen with viral lysate assays(24). The assay is validated for use with serum samples but was optimised for use with DBS in the AHRI Diagnostic Research Laboratory following comparative testing with plasma samples. During the initial evaluation of the HerpeSelect® 2 ELISA IgG a select number of plasma samples were also tested by an external accredited pathology laboratory. A 6mm diameter punch of a DBS spot was incubated overnight in 150ul Assay Diluent for no more than 16 hours at 4°C. The assay was performed with 50ul of the eluent in accordance with the manufacturer's instructions. Following a disproportionately high number of positive results based on other studies and our experience we multiplied the mean cut-off calibrator absorbance values by a factor of 1.5 before determining the index value for each sample (25, 26). The HerpeSelect® 2 ELISA IgG results are reported as positive (index value >1.10), equivocal (index value of  $\geq 0.90$  but  $\leq 1.10$ ) or negative (index value <0.90). All initial equivocal results were re-tested and those that re-tested equivocal are reported as equivocal. An incident HSV-2 was defined as having been negative at baseline and positive at follow-up. Those who were equivocal at either baseline or follow-up were not considered as a sero-conversions.

## Statistical analyses:

We conducted two separate analyses for cohort and cross-sectional data. For the nested cohort, we included only participants who had data available at baseline and follow-up. We used Chi-square tests to compare baseline characteristics between AGYW who did and did not have any exposure to MTV Shuga. We used logistic regression to examine the effect of MTV Shuga on health outcomes, adjusting for exposure to DREAMS and all other potential confounders. Potential effect-modification of MTV Shuga by exposure to DREAMS was examined by fitting an interaction term to fully adjusted model: likelihood ratio tests were used to compare models with and without interaction terms.

We calculated the proportion of AGYW who reported an outcome (condomless-sex, recent pregnant) or tested positive for HSV-2 at 12-month or 24-month follow-up; and estimated associations between MTV Shuga and each outcome using a logistic regression, adjusting for potential confounders (age, household and individual socio-demographic characteristics and sexual behaviour). For HSV-2 incidence, we included participants who tested negative at baseline and had at least 1 follow-up test result. For DREAMS exposure, we included data collected at baseline and 12-month follow-up. For health outcomes (consistent condom use, modern contraception, HIV testing, PrEP awareness), we used data collected at 24-month follow-up; and for HSV-2 and pregnancy incidence we used data collected at 12 and 24-month follow-up.

Propensity score logistic regression adjustment was used to estimate the causal effect of MTV Shuga on health outcomes. A propensity or probability of being exposed to MTV Shuga was measured by fitting a logistic regression with MTV Shuga exposure as an outcome and potential confounders. A logistic regression models adjusting for propensity scores were then used to predict the probability of an outcome for all participants and separately by age group, under two scenario (1) exposed to MTV Shuga and (2) Not exposed to MTV Shuga. The predicted probabilities were then used to calculate the marginal risk difference, prevalence ratio and odds ratio. Confidence intervals were generated by using a bootstrap procedure, repeating the estimation procedure described above in 1000 samples that were drawn with replacement from the complete dataset and calculating 95% confidence intervals from the resulting bootstrap distribution using the 2.5% and 97.5% percentiles. We also used propensity score stratification and probability weighting methods to check the consistency of our findings.

1  
2  
3 For cross-sectional survey, we used Chi square test to compare the characteristics of AGYW  
4 who did and did not have any exposure to MTV Shuga; and logistic regression models  
5 adjusting for potential confounders were used to examine the association between exposure  
6 to MTV Shuga and health outcomes. Sampling weights were applied to achieve proportionality  
7 between groups of participants in the survey.

8 All analyses were performed using Stata version 15 (StataCorp LP, College Station, Texas  
9 USA).

## 16 Reporting

17 The STROBE reporting guidelines were used to guide synthesis and standardise reporting of  
18 our results(27)

## 23 Patient and public involvement

24 The study did not involve patients. AHRI has a Public Engagement Unit which conducts  
25 community engagement activities with the local communities as part of study findings  
26 dissemination. The Community Advisory Board provided feedback of the study including  
27 design before approval from ethics review board. Study findings are being made publicly  
28 available to funders, participants and the public through webinars, study reports and open  
29 access journal articles.

## 36 Results:

### 39 Participants

40 Of 3013 potentially eligible AGYW randomly selected from the surveillance data set, 85.5% of  
41 those eligible consented to participate at baseline (Figure 2). Of the 2184 eligible participants  
42 that were surveyed at baseline, 2016 (92.3%) had at least one follow-up visit and contributed  
43 data to this analysis. From the cross-sectional survey, 4127 (22.6%) eligible participants were  
44 surveyed.

### 51 Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

### 54 Awareness and exposure to MTV Shuga

55 MTV Shuga exposure at baseline was low, with a total of 308 (14.1%) respondents reported  
56 watching at least one episode. In the cross-sectional analysis of the three districts, a total of  
57 1477 (35.8%) reported watching any MTV Shuga. In the nested cohort 121 (5.5%) recalled  
58  
59  
60

any storyline. Similarly in the cross-sectional snapshot 276 (6.7%) recalled the storyline (high exposure).

## Social demographic characteristics of adolescents and young people by exposure to MTV Shuga (Table 1&2)

Table 1 summarises the profiles of the nested cohort (n=2184) and cross-sectional surveys (n=4127) AGYW comparing those exposed to MTV Shuga with those not exposed. In summary those who had seen any MTV Shuga were more likely to be from households in the highest socioeconomic tertile (p<0.001) and more urbanised areas (p<0.001). They were also more likely to have also received DREAMS (p=0.015) (Table 1). In the cross-sectional surveys (n=4127), MTV Shuga exposure was associated with older age (p<0.001), tertiary education (p <0.001) and never having sex (p< 0.001) Table 1.

**Table 1. Baseline socio-demographic characteristics of adolescent girls and young women (13-22) by exposure to MTV Shuga in the nested cohort (n=2184)**

	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
<b>Age group (4 cats), 2017</b>							
13-14	460/2184	21.1	72/308	23.4	388/1876	20.7	
15-17	688/2184	31.5	107/308	34.7	581/1876	31	
18-19	475/2184	21.7	60/308	19.5	415/1876	22.1	
20-22	561/2184	25.7	69/308	22.4	492/1876	26.2	0.216
<b>Currently in school</b>							
No	540/2184	24.7	67/308	21.8	473/1876	25.2	
Yes	1644/2184	75.3	241/308	78.2	1403/1876	74.8	0.192
<b>Socio-economic status, 2018</b>							
Low	255/2118	12	22/303	7.3	233/1815	12.8	
Middle	920/2118	43.4	110/303	36.3	810/1815	44.6	
High	943/2118	44.5	171/303	56.4	772/1815	42.5	<0.001
<b>Urban or rural</b>							
Rural	1388/2165	64.1	165/305	54.1	1223/1860	65.8	
Peri-urban/urban	777/2165	35.9	140/305	45.9	637/1860	34.2	<0.001
<b>Invited or received DREAMS, 2017/18</b>							
	1101/2184	50.4	175/308	56.8	926/1876	49.4	0.015
<b>Away from home in the last 12 months</b>							
	314/1853	17.0	45/228	15.6	269/1565	17.2	0.516
<b>Baseline socio-demographic characteristics of adolescent girls and young women (12-24) by exposure to MTV Shuga in the cross-sectional survey (n=4127)</b>							
	<b>Overall</b>		<b>Exposed</b>		<b>Not exposed</b>		



	n/N	%	n/N	%	n/N	%	p-value
<b>Age group, (N=4127)</b>							
12-14	958/4127	23.2	307/1477	20.1	651/2650	24.6	0.022
15-19	1628/4127	39.5	599/1477	40.6	1029/2650	38.8	
20-24	1541/4127	37.3	571/1477	38.7	970/2650	36.6	
<b>District</b>							
City of Johannesburg	1146/4127	27.8	476/1477	32.2	670/2650	25.3	<0.001
Ekurhuleni	1635/4127	39.6	521/1477	35.3	1114/2650	42.0	
eThekweni	1342/4127	32.5	480/1477	32.5	862/2650	32.5	
<b>Highest Education (N=4108)</b>							
No schooling	175/4108	4.3	99/1465	6.8	76/2646	2.9	<0.001
Grade R to 7	502/4108	12.2	142/1465	9.7	360/2646	13.6	
Grade 8 to 12	2978/4108	72.5	1022/1465	69.8	1956/2646	74.0	
Tertiary studies (complete/incomplete)	453/4108	11.0	202/1465	13.8	251/2646	9.5	
<b>Ever had sex with a boy/man (n=4108)</b>	1860/4108	45.3	621/1469	42.3	1239/2639	47.0	0.004
<b>Away from home in the last 12 months (n=4121)</b>	183/4121	4.4	66/1474	4.5	117/2647	4.4	0.932

After adjustment for confounders in nested cohorts (Table 2), AGYW from wealthier households (aOR=2.04 95%CI 1.27-3.30), peri-urban or urban areas (aOR=1.54 95%CI 1.19-1.98) and those invited to DREAMS (aOR=1.48 95%CI 1.14-1.92) were more likely to be exposed to MTV Shuga than those from poor households, from rural areas and those not invited to DREAMS respectively. Similarly, after adjustment in the cross-sectional surveys (Table 2), AGYW with higher education were more likely to be exposed to MTV Shuga (aOR=2.58 95%CI 1.81-3.69) than those with less and those who ever had sex (aOR=0.68 95%CI 0.57-0.82) were less likely to be exposed to MTV Shuga.

**Table 2 Factors associated with exposure to MTV Shuga in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Adjusted - All		
	OR	95%CI	OR	95%CI	P-value
<b>Age group, 2017</b>					
13-14	1		1		
15-17	0.99	0.72 -1.37	0.93	0.66 -1.29	
18-19	0.78	0.54 -1.13	0.77	0.51 -1.14	
20-22	0.76	0.53 -1.08	0.78	0.50 -1.21	0.555
<b>Currently in school</b>					
No	1		1		
Yes	1.21	0.91 -1.62	1.06	0.78 -1.43	0.726

<b>Socio-economic status, 2018</b>					
Low	1		1		
Middle	1.44	0.89 -2.33	1.27	0.78 -2.07	
High	2.35	1.47 -3.74	2.04	1.27 -3.30	<0.001
<b>Site</b>					
Rural	1		1		
Peri-urban/ urban	1.63	1.28 -2.08	1.54	1.19 -1.98	0.001
<b>Invited or received DREAMS, 2017/18</b>					
No	1		1		
Yes	1.35	1.06 -1.72	1.48	1.14 -1.92	0.003
<b>Factors associated with exposure to MTV Shuga in the cross-sectional analysis of AGYW aged 12-24 (n=4127)</b>					
	<b>Unadjusted</b>		<b>Adjusted - all</b>		
	<b>OR</b>	<b>95% CI</b>	<b>OR</b>	<b>95% CI</b>	<b>P-value</b>
<b>District</b>					
City of Johannesburg	1		1		
Ekurhuleni	0.69	0.54 - 0.89	0.66	0.52- 0.84	0.001
eThekweni	0.79	0.60 - 1.04	0.78	0.59- 1.04	0.087
<b>Age group</b>					
12-14	1		1		
15-19	1.27	1.06 - 1.53	1.18	0.95- 1.46	0.126
20-24	1.22	1.01 - 1.48	1.16	0.90- 1.49	0.256
<b>Highest education level</b>					
Grade R to 7	1		1		
No schooling	2.88	1.81 - 4.58	3.29	2.01 - 5.38	<0.001
Grade 8 to 12	1.38	1.09 - 1.75	1.42	1.08 - 1.86	0.011
Complete or incomplete tertiary	2.29	1.70 - 3.09	2.58	1.81 - 3.69	<0.001
<b>Ever had sex with a boy/man</b>					
No	1		1		
Yes	0.82	0.71 - 0.95	0.68	0.57- 0.82	<0.001
<b>Away from home in last 12 months</b>					
No	1		1		
Yes	1.15	0.80 - 1.64	1.21	0.83- 1.77	0.309

## Relationship between MTV Shuga exposure and HIV and SRHR outcomes (Table 3&4)

In the nested cohorts by 2019, overall 63.3% of those aged 14-23 knew their HIV status, 13.4% were consistently using contraception, 20.0% were using condoms consistently, and about a third were aware of PrEP, 5% had a pregnancy and 15% acquired HSV2. There were higher proportions of contraception use, condom use and PrEP awareness among those exposed to MTV Shuga (Table 3). For survey sites (Table 3) overall, 85.0% knew their HIV status, over a fifth 22.6% were using contraception and about half using condoms 48.4%. About a tenth (7.5%) were aware of PrEP, with higher proportions of these being among those exposed to MTV Shuga.

**Table 3: HIV and SRHR outcomes by exposure to MTV Shuga nested cohort 13-22 year olds (n= 2167)**

	Overall		Exposed (n=308)		Not exposed (n=1878)		P-value
	n/N	%	n/N	%	n/N	%	
Knowledge of HIV status, 2019	1083/1712	63.3	175/283	61.8	908/1429	63.5	0.587
Modern contraception, 2019	221/1651	13.4	56/271	20.7	165/1380	12	<0.001
Consistent condom use, 2019	168/838	20	41/141	29.1	127/697	18.2	0.003
Aware of PrEP, 2019	523/1712	30.5	124/283	43.8	399/1429	27.9	0.302
Pregnant in 2018/19	124/2184	5.7	20/308	6.5	104/1876	5.5	0.504
Teenage pregnancy	72/1395	5.16	55/1187	4.63	17/208	8.17	0.033
HSV-2 2018/19	241/1562	15.4	35/237	14.8	206/1325	15.5	0.760
<b>HIV and SRHR outcomes by exposure to MTV Shuga weighted for sampling cross sectional survey 12-24 year olds (n=4127)</b>							
	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
PrEP awareness (N=4127)	310/4127	7.5	148/1477	10.0	162/2650	6.1	<0.001
HIV test (self-report) (N=2529)	2156/2529	85.3	656/797	82.3	1500/1732	86.6	0.005
Condom use at last sex (N=1898)‡	918/1898	48.4	320/640	50.0	598/1258	47.5	0.310
Contraception use (N=4127)	934/4127	22.6	302/1477	20.5	632/2650	23.9	0.012

‡Restricted to those who ever had sex with man

At follow up, incident HSV-2 and teenage pregnancy were high, HSV-2 incidence was 15.26 and teenage pregnancy incidence was 9.86 per 100 person-years, respectively (Table 4).

**Table 4: Rate of SRHR outcome by exposure to MTV Shuga (nested cohort 13-22 year olds n=2167)**

<b>HSV-2 incidence rate</b>					
	person-time	n with HSV-2	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	1303.0	206	15.81	13.79	18.12
MTV Shuga Exposed	276.3	35	12.67	9.09	17.64
Total	1579.3	241	15.26	13.45	17.31
<b>Pregnancy incidence rates among all AGYW</b>					
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	1068.7	104	9.73	8.03	11.79
MTV Shuga Exposed	188.5	20	10.61	6.84	16.44
Total	1257.2	124	9.86	8.27	11.76
<b>Pregnancy incidence rates among girls below 19 years</b>					
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	668.7	55	8.22	6.31	10.71
MTV Shuga Exposed	123.9	17	13.72	8.53	22.07
Total	792.6	72	9.08	7.21	11.44

### **MTV Shuga and HIV prevention and SRHR awareness and uptake**

In the nested cohort after adjusting for age, education, SES, area and DREAMS, MTV Shuga exposure in the AGYW cohort was associated with significantly greater awareness of PrEP (aOR=2.06, 95%CI: 1.57-2.70), contraception uptake (aOR=2.08, 95%CI: 1.45-2.98), and consistent condom use (aOR=1.84, 95%CI: 1.24-2.93). Watching MTV-Shuga was not associated with HIV testing (aOR=1.02,95%CI: 0.77-1.21) (Figure 3 and Supplementary Tables S1-S4). There was no effect modification by DREAMS exposure.

### **Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.**

Similarly, in the cross-sectional analysis, after adjusting for age, education, district, migration and sexual history, exposure to MTV-Shuga watching was associated with greater awareness of PrEP (aOR=1.70, 95%CI 1.20 - 2.43). However, there was no association with contraception, lower self-reported HIV testing, or condom use as shown in Figure 4 below (Supplementary Table 5).

1  
2  
3 **Figure 4 Forest plots showing association between MTV Shuga exposure and**  
4 **HIV prevention and SRHR awareness and uptake in the cross-sectional**  
5 **surveys**  
6  
7  
8

9 **Causal effect of MTV Shuga on health outcomes – HSV2**

10  
11 The causal analysis similarly finds no effect of MTV Shuga on HSV2, with a risk difference of  
12 1.10 95% CI (-2.82- 5.38)%. Findings in the younger age group (aged 13-17) and the older  
13 age group (18-22) was similar (Supplementary Table 6).  
14  
15  
16

17  
18 **Discussion**  
19

20 In our study of the population-level effect of a national broadcast of a TV-based edu-drama on  
21 HIV prevention and SRHR, exposure to MTV Shuga was associated with higher awareness  
22 of a novel HIV prevention intervention (PrEP). However, despite a very high incidence of HSV-  
23 2 and teenage pregnancy, MTV Shuga exposure was not significantly associated with safer  
24 sexual behaviour, uptake of contraception and HIV-testing or prevention of teenage  
25 pregnancy. Notably though, the size of the relationship and direction of effect between  
26 exposure to MTV Shuga, condom use and markers of unprotected sex (HSV-2 and  
27 pregnancy) was consistent with a possible relationship. These findings may be partly  
28 explained by our finding that less than one in 12 of the target age group had any exposure to  
29 MTV Shuga and only half of these had high exposure (defined as watching the MTV Shuga  
30 South African series and being able to recall the content), suggesting that one of the limiting  
31 factors for the effective use of TV-based edu-drama maybe the dose that young people are  
32 exposed to, particularly in rural and resource-constrained settings most affected by HIV.  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Our inability to find a measurable population effect of mass-media edu-drama behaviour  
43 change campaign compared to the trial findings of the RCT is disappointing (18). However,  
44 firstly the direction and size of the relationships suggest that we may have been able to see  
45 an effect if the proportion exposed had been greater than 7%. Secondly, AGYW in urban  
46 settings were more likely to have been exposed to MTV Shuga and they are also more likely  
47 to be living in small towns and townships. Data from our settings suggest that young people  
48 in small towns and townships are more vulnerable to HIV (28) and sexual risk (29) and  
49 therefore it is possible that a real effect of MTV Shuga on this group was masked by their  
50 greater risk for the outcome. Due to the low numbers with high levels of exposure to MTV  
51 Shuga we did not have the power to explore this hypothesis by looking at effect modification  
52 by geography or socioeconomic status.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The finding of a differential association of MTV Shuga exposure with awareness of PrEP,  
4 compared to uptake of HIV and contraception, suggests that whilst educational mass  
5 entertainment may be able to increase awareness and possibly demand for a service, it does  
6 not impact on accessibility of the service: i.e. it impacts the first two steps of the prevention  
7 cascade and not the final step(30). Well described barriers to uptake of HIV-testing and  
8 contraception in this area are internalized and externalized stigma, fear of judgement from  
9 health care workers and the social costs of accessing care in busy primary health care  
10 settings(31-33). Behaviour change intervention including mass communication campaigns  
11 can be constrained or facilitated by the context in which people live (17, 34). To optimise MTV  
12 Shuga's effect there may need to be parallel innovations in SRHR and HIV service delivery  
13 that makes the services easier to access. We aim to test this hypothesis by providing  
14 community-based delivery of HIV and SRHR services in the context of the MTV Shuga.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 The behaviour change theory that underpins edu-drama as a vehicle for mass behaviour  
25 change communication (16) explicitly suggests that the audience, and especially the early  
26 adopters, need to be actively watching, rather than passively watching or listening (17, 18).  
27 TV watching in rural homesteads can be in the context of large, often grandparent-led  
28 households and competing chores and priorities. This coupled with the relatively late timing of  
29 the shows may explain why so few girls and young women were sufficiently engaged or  
30 immersed to be able to recall characters or story lines. Moreover, the timing of this analysis  
31 may have allowed insufficient time for early adopters to convey the message of the show.  
32  
33  
34  
35  
36  
37

## 38 **Limitations**

39  
40 The limitations of our study are that a meaningful exposure to MTV Shuga was low and so  
41 whilst the size of the relationship and direction of effect between exposure to MTV Shuga,  
42 condom use, and markers of unprotected sex (HSV-2 and pregnancy) suggested a possible  
43 effect we did not have the power to show a significant relationship between exposure to MTV  
44 Shuga and SRHR outcomes. We also do not have the power to see a difference by dose and  
45 immersion. Furthermore, as this is an observational study, we cannot exclude the possibility  
46 that those who are exposed to MTV Shuga are systematically different in ways that impact on  
47 the outcome of interest, for example more exposed to social media and sexual health  
48 promotion and innovative technologies to support sexual health than those who were not.  
49  
50  
51  
52  
53  
54  
55

## 56 **Conclusions and implications for the future**

- 57 • Meaningful exposure to MTV Shuga was low across rural and urban settings in  
58 South Africa and so additional efforts need to be made to reach young people and  
59  
60

1  
2  
3 increase their immersion in promising edu-drama if it is to have the desired effect,  
4 especially in rural and deprived settings.

- 5  
6 • MTV Shuga was an effective vehicle to raise awareness and promote newer HIV  
7 prevention technologies such as HIV PrEP.
- 8  
9 • There was some suggestion that MTV Shuga improved uptake of some HIV  
10 prevention and sexual health technologies (contraception and condoms)
- 11  
12 • There was less evidence from this observational study that it improved SRHR and  
13 HIV outcomes
- 14  
15
- 16
- 17

18 We highlight the importance of evaluating the real-world scale up of promising interventions  
19 to understand both the reach and population effect as well as inform interventions to increase  
20 impact and equity.  
21

22  
23  
24 Efforts to increase exposure, which have been rolled out as part of MTV Shuga in SA, such  
25 as social media, school-based or community-based MTV Shuga film clubs will need to be  
26 evaluated, both to understand whether or not they increase exposure and coverage and  
27 improve SRH and HIV outcomes. However, to have a significant impact on the HIV and SRH  
28 prevention and treatment cascades, demand generation in AGYW needs to be delivered in  
29 parallel with accessible service delivery models that support adherence and retention (30).  
30  
31  
32  
33

## 34 35 36 **Contributorship**

37  
38 M.S., N.C., J.D., T.Z. N.K, G.H. and C.C. developed the study tools and performed the  
39 research. M.S., J.S. D.P., K.B., I.B., and S.F. designed the research study. T.S. and S.D.  
40 conducted the laboratory analysis. N.M. supported by K.B. conducted the statistical analysis  
41 and G.C. M.S wrote the first and final draft of the paper with input from N.C., N.M., G.H., J.S.,  
42 I.B., G.C., K.B., C.C., T.S., T.Z, D.P and N.K. All the authors critically reviewed the manuscript.  
43  
44  
45 All authors have approved the final draft of the paper.  
46  
47  
48

## 49 50 **Competing interests**

51 All authors declare they have no conflict of interest  
52

## 53 54 **Funding**

55  
56 The impact evaluation of DREAMS and MTV Shuga is funded by the Bill and Melinda Gates  
57 Foundation (OPP1136774 and OPP1171600, <http://www.gatesfoundation.org>). Foundation  
58 staff advised the study team, but did not substantively affect the study design, instruments,  
59  
60

1  
2  
3 interpretation of data, or decision to publish. The research leading to these results has  
4 received funding from the People Programme (Marie Curie Actions) of the European Union's  
5 seventh Framework Programme FP7/2007-2013 under REA grant agreement n° 612216.  
6 MS National Institutes of Health 5R01MH114560-03 funding acknowledgement. This  
7 research was funded in whole, or in part, by the Africa Health Research Institute through the  
8 Wellcome [Strategic Core award: 201433/Z/16/A]. For the purpose of open access, the  
9 author has applied a CC BY public copyright licence to any Author Accepted Manuscript  
10 version arising from this submission. N.C is supported by a training fellowship from the  
11 National Institute for Health Research (NIHR) (using the UK's Official Development  
12 Assistance (ODA) Funding) and Wellcome [grant reference number 224309/Z/21/Z] under  
13 the NIHR-Wellcome Partnership for Global Health Research. The views expressed are  
14 those of the authors and not necessarily those of Wellcome, the NIHR or the Department of  
15 Health and Social Care. GH is supported by a fellowship from the Royal Society and the  
16 Wellcome Trust [Grant number 210479/Z/18/Z]. MS work is also supported by a BMGF 3ie  
17 grant at AHRI. This research was funded in whole, or in part, by the Wellcome Trust [Grant  
18 number 210479/Z/18/Z]. For the purpose of open access, the author has applied a CC BY  
19 public copyright licence to any Author Accepted Manuscript version arising from this  
20 submission.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 **Data sharing statement**

34 Data are available on reasonable request.  
35  
36  
37

### 38 **Ethics statement**

39 The DREAMS Partnership impact evaluation protocol was reviewed and approved by the  
40 University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (BFC  
41 339/16), the London School of Hygiene & Tropical Medicine Research Ethics Committee (Ref  
42 11835) and the AHRI Somkhele Community Advisory Board, the Associate Director of Science  
43 of the Center for Global Health (CGH) at the United States Centers for Disease Control and  
44 Prevention (CDC) in Atlanta and the Department of Health, Province of KZN and Gauteng.  
45 Approval for the demographic surveillance and data collection in the clinics was granted by  
46 UKZN BREC. All participants provided separate informed consent for the questionnaires and  
47 the HSV2 sero-survey. Consent for follow-up interviews was provided separately. For  
48 participants aged <18 years, written parental consent and participant assent were provided.  
49 Individuals attending the clinics in the surveillance area provided informed consent to record  
50 the clinic visit and link to their surveillance identification number.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Acknowledgements

The authors are grateful to the communities of the Hlabisa sub-district, Ekurhuleni district, Thekwini district and City of Johannesburg who contributed their data to this study and to all the staff at Africa Health Research Institute and EpiCentre who collected the data. We acknowledge Eskindir Shambullo for his input in this manuscript.

## References

1. HSRC. The fifth South African National HIV prevalence, incidence, behaviour and communication survey [Report].  
[http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV\\_Impact\\_Assessment\\_Summary\\_ZA\\_ADS\\_cleared\\_PDF4.pdf](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDF4.pdf): South African Health Services Research Council 2017 [updated 01/11/2018].
2. Chimbindi N, Mthiyane N, Birdthistle I, Floyd S, McGrath N, Pillay D, et al. Persistently high incidence of HIV and poor service uptake in adolescent girls and young women in rural KwaZulu-Natal, South Africa prior to DREAMS. *PLoS One*. 2018;13(10):e0203193.
3. Vandormael A, Akullian A, Siedner M, de Oliveira T, Bärnighausen T, Tanser F. Declines in HIV incidence among men and women in a South African population-based cohort. *Nature Communications*. 2019;10(1):5482.
4. Birdthistle I, Kwaro D, Shahmanesh M, Baisley K, Khagayi S, Chimbindi N, et al. Evaluating the impact of DREAMS on HIV incidence among adolescent girls and young women: A population-based cohort study in Kenya and South Africa. *PLoS medicine*. 2021;18(10):e1003837.
5. Department of Health RoSA. National Campaign for Young Women and Adolescent Girls. . 2016.
6. Saul J, Bachman G, Allen S, Toiv NF, Cooney C, Beamon TA. The DREAMS core package of interventions: A comprehensive approach to preventing HIV among adolescent girls and young women. *PLOS ONE*. 2018;13(12):e0208167.
7. PEPFAR. Preventing HIV in Adolescent Girls and Young Women: Guidance for PEPFAR Country Teams on the DREAMS Partnership 2015.
8. PEPFAR. South Africa DREAMS overview  
<https://www.pepfar.gov/documents/organization/253958.pdf>: PEPFAR; 2017 [
9. Chang L, Serwadda D, Quinn T, Wawer M, Gray R, Reynolds S. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects *The Lancet Infectious Diseases* 2013;13(1):65-76.

10. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. *Lancet HIV*. 2018;5(3):e116-e25.
11. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. *Trials*. 2013;14:230.
12. Birdthistle I, Schaffnit SB, Kwaro D, Shahmanesh M, Ziraba A, Kabiru CW, et al. Evaluating the impact of the DREAMS partnership to reduce HIV incidence among adolescent girls and young women in four settings: a study protocol. *BMC Public Health*. 2018;18(1):912.
13. Shen F, Han J. Effectiveness of entertainment education in communicating health information: a systematic review. *Asian Journal of Communication*. 2014;24(6):605-16.
14. Noar SM, Palmgreen P, Chabot M, Dobransky N, Zimmerman RS. A 10-year systematic review of HIV/AIDS mass communication campaigns: have we made progress? *Journal of Health Communication*. 2009;14(1):15-42.
15. Kyegombe N, Zuma T, Hlongwane S, Nhlenyama M, Chimbindi N, Birdthistle I, et al. A qualitative exploration of the salience of MTV-Shuga, an edutainment programme, and adolescents' engagement with sexual and reproductive health information in rural KwaZulu-Natal, South Africa. *Sexual and Reproductive Health Matters*. 2022;30(1):2083809.
16. Barker K. Sex Soap and Social change- The Sabedo methodology <https://www.populationmedia.org/product/sabido-theory/>; <http://www.comminit.com/content/sabido-methodology> [
17. Baker V, Birdthistle I, Seeley J, Arnold G, Piot S, Hajiyanis H. How can a TV drama about Love, Sex and Growing up Increase Knowledge and Shape the Sexual Health Behaviours of Young People? . *AIDS Impact*; Cape Town, South Africa 2017.
18. MTV Shuga Soap Opera Turns Edutainment into a Tool to Fight HIV and Gender-Based Violence <http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-violence2017> [
19. National Department of Health. The National Antenatal Sentinel HIV prevalence survey, South Africa, <http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-10/2015-04-30-08-21-56?download=2584:2015-national-antenatal-hiv-prevalence-survey-final-23oct17>, 2013 [

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Herbst K, Law M, Geldsetzer P, Tanser F, Harling G, Barnighausen T. Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. *Current Opinion on HIV AIDS*. 2015;10(6):483-94.
21. Gareta D, Baisley K, Mngomezulu T, Smit T, Khoza T, Nxumalo S, et al. Cohort Profile Update: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *Int J Epidemiol*. 2021;50(1):33-4.
22. George G, Cawood C, Puren A, Khanyile D, Gerritsen A, Govender K, et al. Evaluating DREAMS HIV prevention interventions targeting adolescent girls and young women in high HIV prevalence districts in South Africa: protocol for a cross-sectional study. *BMC Women's Health*. 2020;20(1):7.
23. Filmer D, Pritchett LH. Estimating Wealth Effects Without Expenditure Data—Or Tears: An Application To Educational Enrollments In States Of India\*. *Demography*. 2001;38:115-32.
24. Arvin A, Prober C. Herpes Simplex Viruses. In: Murray P, Baron E, Pfaller M, Tenover F, Tenover F, Tenover R, editors. *Manual of Clinical Microbiology* 6th Ed Washington D.C.: ASM; 1995. p. 876-83.
25. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of Focus HerpeSelect® and Kalon™ HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 (HSV-2) antibodies in a South African population. *Sexually Transmitted Infections*. 2009;86(1):46-50.
26. Ashley-Morrow R, Nolkamper J, Robinson N, Bishop N, Smith J. Performance of Focus ELISA test for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical Microbiology and Infection* 2004;10(6):530-6.
27. STROBE Statement. STROBE Checklists 2007 [Available from: <http://www.strobe-statement.org/index.php?id=available-checklists>].
28. Cuadros DF, Li J, Branscum AJ, Akullian A, Jia P, Mziray EN, et al. Mapping the spatial variability of HIV infection in Sub-Saharan Africa: Effective information for localized HIV prevention and control. *Scientific Reports*. 2017;7(1):9093.
29. Ngwenya N, Gumede D, Shahmanesh M, McGrath N, Grant A, Seeley J. Community perceptions of the socio-economic structural context influencing HIV and TB risk, prevention and treatment in a high prevalence area in the era of antiretroviral therapy. *African Journal of AIDS Research*. 2018;17(1):72-81.
30. Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S, Bhattacharjee P, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. *Lancet HIV*. 2016;3(7):e318-22.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
31. Hargreaves JR, Krishnaratne S, Mathema H, Lilleston PS, Sievwright K, Mandla N, et al. Individual and community-level risk factors for HIV stigma in 21 Zambian and South African communities: analysis of data from the HPTN071 (PopART) study. *AIDS*. 2018;32(6):783-93.
  32. Chimbindi N, Zuma T, Nakasone S, Birdthistle I, Mthiyane N, Dreyer J, et al. Platforms, Processes and Perceptions of PrEP Delivery Through DREAMS in a Rural Setting in KwaZulu-Natal, South Africa. . *Research for Prevention 2018 (HIVR4P 2018)* Madrid, Spain 2018.
  33. Adeagbo O, Herbst C, Dlamini N, Mhlongo T, Luthuli M, Xulu S, et al. “If she tests negative, it means I am also negative”: Men’s construction of HIV testing in KwaZulu-Natal, South Africa. . *HIV Research for Prevention (HIVR4P)* 23 October 2018.; Madrid, Spain **2018**
  34. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. *Implementation Science*. 2011;6(42).

## Figure legends

Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

Figure 1: Conceptual framework for MTV Shuga impact on HIV prevention in uMkhanyakude




Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

98x51mm (300 x 300 DPI)




Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

71x64mm (300 x 300 DPI)




Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

95x46mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

101x54mm (300 x 300 DPI)

**Supplementary Table 1 Exposure to MTV Shuga and PrEP awareness in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		p-value
	OR	95%CI	OR	95%CI		OR	95%CI	
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	2.01	1.55 -2.62				2.06	1.57 -2.70	<0.001
<b>Age</b>	1.12	1.08-1.16	1.12	1.08-1.17	<0.001	1.11	1.06-1.17	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.47 -0.76	0.59	0.46 -0.75	<0.001	0.89	0.65 -1.23	0.488
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.99	0.71 -1.39	0.96	0.68 -1.35		1.01	0.71 -1.44	
High	1.13	0.81 -1.58	1.05	0.75 -1.47	0.744	1.11	0.78 -1.58	0.699
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.98	0.79 -1.22	0.93	0.75 -1.16	0.525	0.92	0.73 -1.15	0.459
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.89	0.73 -1.10	0.88	0.71 -1.08	0.212	0.99	0.79 -1.23	0.897

**Supplementary Table 2 Exposure to MTV Shuga and contraception uptake in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.92	1.37 -2.68				2.08	1.45-2.98	<0.001
<b>Age</b>	1.26	1.19-1.33	1.27	1.20-1.34	<0.001	1.32	1.24-1.42	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.44 -0.83	0.59	0.43-0.82	0.001	1.7	1.13-2.55	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.79	0.51 -1.22	0.76	0.49-1.19		0.8	0.51-1.28	
High	0.86	0.55 -1.34	0.8	0.51-1.24	0.489	0.83	0.52-1.32	0.646
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.91	0.68 -1.24	0.86	0.64-1.17	0.345	0.89	0.64-1.24	0.49
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.63 -1.11	0.83	0.62-1.10	0.191	1.04	0.76-1.42	0.813

**Supplementary Table 3 Exposure to MTV Shuga and consistent condom use in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		p-value
	OR	95%CI	OR	95%CI		OR	95%CI	
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.84	1.22-2.78				1.9	1.24-2.93	0.003
<b>Age</b>	0.94	0.86-1.01	0.94	0.87-1.02	0.157	1	0.91-1.10	0.984
<b>Currently in school</b>								
No	1		1			1		
Yes	1.76	1.22-2.53	1.73	1.20-2.49	0.003	1.78	1.15-2.76	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	1.01	0.60-1.70	0.97	0.58-1.63		0.98	0.58-1.67	
High	0.87	0.52-1.47	0.8	0.47-1.36	0.552	0.86	0.50-1.48	0.753
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.7	0.48-1.02	0.67	0.46-0.97	0.035	0.71	0.48-1.05	0.088
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	1.13	0.81-1.59	1.13	0.80-1.59	0.486	0.97	0.67-1.40	0.875

**Supplementary Table 4 Exposure to MTV Shuga and HIV testing in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	0.93	0.71-1.21				1.02	0.77-1.36	0.885
<b>Age</b>	1.3	1.25-1.35	1.3	1.24-1.35	<0.001	1.3	1.24-1.37	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.37	0.28-0.48	0.37	0.28-0.48	0	1.07	0.74-1.53	0.726
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.67	0.48-0.94	0.67	0.48-0.95		0.71	0.49-1.02	
High	0.58	0.41-0.81	0.58	0.41-0.81	0.007	0.6	0.41-0.86	0.018
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.84	0.68-1.03	0.84	0.69-1.04	0.104	0.89	0.71-1.11	0.298
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.69-1.02	0.84	0.69-1.02	0.081	0.98	0.79-1.23	0.89

**Supplementary Table 5: Exposure to MTV Shuga with HIV prevention and SRHR awareness and uptake in the cross-sectional analysis of AGYW aged 12-24 (n=4127)**

	aOR (95% Confidence Interval)	P-value
<b>District</b>		
City of Johannesburg	1	
Ekurhuleni	0.66 (0.47-0.91)	0.013
eThekweni	0.78 (0.54-1.13)	0.186
<b>Age group</b>		
12-14	1	
15-19	1.75 (0.35-8.84)	0.499
20-24	1.60 (0.32-8.07)	0.570
<b>Highest education level</b>		
Grade R to 7	1	
No schooling	3.84 (1.05-14.02)	0.041
Grade 8 to 12	3.17 (0.93-10.77)	0.065
Complete or incomplete tertiary	6.52 (1.90-22.33)	0.003
<b>Ever had sex with a boy/man</b>		
No	1	
Yes	0.67 (0.32-1.40)	0.286
<b>Away from home</b>		
No	1	
Yes	1.48 (0.93-2.37)	0.099
<b>PrEP awareness</b>		
No	1	
Yes	1.71 (1.20-2.43)	0.003
<b>Contraception use</b>		
No	1	
Yes	0.95 (0.74-1.23)	0.718
<b>Condom use at last sex</b>		
No	1	
Yes	1.19 (0.92-1.55)	0.183
<b>HIV test (self-report)</b>		
No	1	
Yes	0.88 (0.63-1.24)	0.471

Supplementary Table 6 Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group

Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group											
	% Outcome in total study population	Estimated % Outcome if no Shuga	95% CI	Estimated % Outcome if all get Shuga	95% CI	Risk Difference (%; PS adjusted)	95% CI	Prevalence Ratio (%; PS adjusted)	95% CI	Odds Ratio (%; PS adjusted)	95% CI
<b>PS adjustment: Primary results</b>											
Overall	17.3	17.2	14.71 - 19.67	18.0	14.51 - 22.32	0.80	-3.24 - 5.71	1.05	0.82 - 1.36	1.06	0.79 - 1.46
13-17 Years	13.2	12.4	9.85 - 15.16	15.7	11.63 - 20.26	3.34	-1.60 - 8.25	1.27	0.89 - 1.79	1.32	0.87 - 1.98
18-22 Years	24.3	25.8	21.01 - 30.74	22.0	15.19 - 30.17	-3.76	-11.92 - 5.68	0.85	0.59 - 1.24	0.81	0.51 - 1.34
<b>Sensitivity analyses</b>											
<u>Regression under counterfactual framework</u>											
Overall	17.3	17.2	14.74 - 19.66	17.8	14.50 - 22.08	0.65	-3.42 - 5.72	1.04	0.82 - 1.36	1.05	0.78 - 1.46
13-17 Years	13.2	12.42	9.86 - 15.21	15.9	11.85 - 20.49	3.47	-1.54 - 8.63	1.28	0.89 - 1.80	1.33	0.88 - 1.99
18-22 Years	24.3	25.7	20.78 - 30.63	21.3	14.88 - 28.28	-4.42	-12.28 - 4.95	0.83	0.57 - 1.22	0.78	0.48 - 1.31
<u>PS stratification</u>											
Overall	17.3	17.1	14.68 - 19.68	17.9	14.53 - 22.13	0.80	-3.21 - 5.52	1.09	0.84 - 1.40	1.11	0.82 - 1.51
<u>PS weighting</u>											

Overall	17.3	17.08	14.74 - 19.48	17.22	13.99 - 21.10	0.13	-3.76 - 4.63	1.01	0.79 - 1.30	1.01	0.76 - 1.37
---------	------	-------	------------------	-------	------------------	------	-----------------	------	----------------	------	----------------

For peer review only



## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	10

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	12
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12- 16
		(b) Report category boundaries when continuous variables were categorized	12- 16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	17- 18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18- 19
Generalisability	21	Discuss the generalisability (external validity) of the study results	17- 19
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Evaluating use of mass-media communication intervention 'MTV-Shuga' on increased awareness and demand for HIV and sexual health services by adolescent girls and young women in South Africa: An observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062804.R2
Article Type:	Original research
Date Submitted by the Author:	03-Jan-2023
Complete List of Authors:	Chimbindi, Natsayi; Africa Health Research Institute; University College London, Mthiyane, Nondumiso; Africa Health Research Institute Chidumwa, Glory ; Africa Health Research Institute Zuma, Thembelihle; Africa Health Research Institute; University College London, Dreyer, Jaco; Africa Health Research Institute Birdthistle, Isolde; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Floyd, Sian; London School of Hygiene & Tropical Medicine, Infectious Disease Epidemiology Kwegombe, Nambusi; London School of Hygiene & Tropical Medicine Grundy, Chris; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Cawood, Cherie; Epicentre Health Research Danaviah, Siva; Africa Health Research Institute Smit, Theresa; Africa Health Research Institute Pillay, Deenan; University College London, Baisley, Kathy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health; Africa Health Research Institute Harling, Guy; Africa Health Research Institute Seeley, Janet; London School of Hygiene and Tropical Medicine, Department of Global Health & Development; Africa Health Research Institute Shahmanesh, Maryam; University College London, Institute for Global Health; Africa Health Research Institute,
<b>Primary Subject Heading</b>:	Sexual health
Secondary Subject Heading:	HIV/AIDS, Public health, Sexual health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH, PREVENTIVE MEDICINE

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 Title page  
4

5 Revised Title: **Evaluating use of mass-media communication intervention ‘MTV-  
6 Shuga’ on increased awareness and demand for HIV and sexual health  
7 services by adolescent girls and young women in South Africa: An  
8 observational study**  
9  
10  
11

12  
13 Authors: Natsayi Chimbindi\*<sup>1,2,3</sup>, Nondumiso Mthiyane\*<sup>2</sup>, Glory Chidumwa<sup>1</sup>,  
14 Thembelihle Zuma<sup>1,2,3</sup>, Jaco Dreyer<sup>1</sup>, Isolde Birdthistle<sup>4</sup>, Sian Floyd<sup>4</sup>, Nambusi  
15 Kyegombe<sup>4</sup>, Chris Grundy<sup>4</sup>, Cherie Cawood<sup>5</sup>, Siva Danaviah<sup>1</sup>, Theresa Smit<sup>1</sup>,  
16 Deenan Pillay<sup>2</sup>, Kathy Baisley<sup>1,3</sup>, Guy Harling<sup>1,2,3,6,7</sup>, Janet Seeley<sup>1,3,4</sup>, Maryam  
17 Shahmanesh<sup>§1,2,3</sup>  
18  
19  
20  
21  
22

- 23  
24 1. Africa Health Research Institute, KwaZulu-Natal, South Africa  
25 2. University College London, Institute for Global Health, London, UK  
26 3. University of KwaZulu-Natal, KwaZulu-Natal, South Africa  
27 4. London School of Hygiene and Tropical Medicine, London, UK  
28 5. Epicentre, South Africa  
29 6. MRC/Wits Rural Public Health & Health Transitions Research Unit  
30 (Agincourt), University of the Witwatersrand, Gauteng, South Africa  
31 7. Department of Epidemiology & Harvard Center for Population and  
32 Development Studies, Harvard T.H. Chan School of Public Health, Boston,  
33 USA  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 \*Joint authors

45  
46 §Corresponding author (full address details): Maryam Shahmanesh, Institute for  
47 Global Health, UCL, 3<sup>rd</sup> Floor, Mortimer Market Centre, Capper Street, London  
48 WC1E 6JB. [m.shahmanesh@ucl.ac.uk](mailto:m.shahmanesh@ucl.ac.uk). +44 7776 185 572  
49  
50  
51

52  
53 Key words (6): HIV, Adolescents, mass communication campaigns, Sexual Health,  
54 Teenage Pregnancy, South Africa.  
55  
56  
57  
58  
59  
60

**Abstract (word count=272)**

**Objective:** To investigate the effect of exposure to MTV Shuga:Down South' (MTVShuga-DS) during the scale-up of combination HIV-prevention interventions on awareness and uptake of SRH and HIV-prevention services by adolescent girls and young women (AGYW).

**Design:** One longitudinal and three cross-sectional surveys of representative samples of AGYW.

**Setting:** AGYW in four South African districts with high HIV-prevalence (>10%) (May 2017 and September 2019).

**Participants:** 6311 AGYW aged 12-24.

**Measures:** Using logistic-regression we measured the relationship between exposure to MTV Shuga-DS and awareness of Pre-Exposure Prophylaxis (PrEP), condom-use at last sex, uptake of HIV-testing or contraception, and incident pregnancy or HSV-2 infection.

**Results:** Within the rural cohort 2184 (85.5%) of eligible sampled individuals were enrolled, of whom 92.6% had at least one follow-up visit; the urban cross-sectional surveys enrolled 4127 (22.6%) of eligible sampled individuals. Self-report of watching at least one MTV Shuga-DS episode was 14.1% (cohort) and 35.8% (cross-section), while storyline recall was 5.5% (cohort) and 6.7% (cross-section).

In the cohort, after adjustment (for HIV-prevention intervention-exposure, age, education, SES), MTVShuga-DS exposure was associated with increased PrEP awareness (aOR=2.06,95%CI:1.57-2.70), contraception uptake (aOR=2.08,95%CI:1.45-2.98) and consistent condom-use (aOR=1.84, 95%CI:1.24-2.93), but not with HIV-testing (aOR=1.02,95%CI:0.77-1.21) or acquiring HSV-2 (aOR=0.92, 95%CI:0.61-1.38). In the cross-sections, MTVShuga-DS was associated with greater PrEP awareness (aOR=1.7, 95%CI:1.20-2.43), but no other outcome.

**Conclusions:** Among both urban and rural AGYW in South Africa, MTVShuga-DS exposure was associated with increased PrEP awareness and improved demand for some HIV-prevention and SRH technologies but not sexual health outcomes. However, exposure to MTVShuga-DS was low. Given these positive indications, supportive programming may be required to raise exposure and allow future evaluation of edu-drama impact in this setting.

### Strengths and limitations of this study

- Evaluated the real-world reach of nationally broadcast edu-drama focusing on adolescent sexual health in South Africa.
- Data collection focused on a vulnerable population of AGYW across four diverse high HIV-burden districts of South Africa that included both rural and urban settings.
- The strength of this study is the use of longitudinal data from a cohort of AGYW nested in a larger population-based longitudinal HIV surveillance. In addition data were drawn from cross-sectional representative samples of AGYW from four districts of South Africa. These data enabled us to measure the reach of MTV-Shuga and the relationship between exposure to the edu-drama on awareness and demand for HIV prevention technologies in young women.
- The limitation of observational studies is that they do not infer the cause–effect relationship, in this case we cannot ascertain causality/impact of exposure to MTV-Shuga on uptake of sexual health promotion and innovative technologies.



1  
2  
3 **[word count 4531]**

## 4 **Introduction**

5 HIV remains one of the gravest health problems facing young people living in sub-Saharan  
6 Africa (SSA). There are over 7.7 million people living with HIV in South Africa, with more than  
7 200,000 new HIV infections annually in those aged 15-49 years (1). The highest incidence is  
8 in adolescent girls and young women (AGYW) (15-24 years) (1, 2). Although HIV incidence  
9 has been declining in South Africa, a 43% decline in the overall incidence rate between 2012  
10 and 2017, from 4.0 to 2.3 seroconversion events per 100 person-years among 15-49 year old;  
11 it still remains high among AGYW in South Africa (3). In uMkhanyakude, HIV incidence was  
12 lower during roll-out of combination HIV prevention for AGYW (2016 to 2018) than in the  
13 previous 5-year period among 15- to 19-year-old females (4.5 new infections per 100 person-  
14 years as compared with 2.8; and lower among 20- to 24-year-olds (7.1/100 person-years as  
15 compared with 5.8) (4).

16  
17  
18  
19  
20  
21  
22  
23  
24  
25 In response to the high HIV incidence in young people, the South African government  
26 launched the 'She Conquers Campaign', and the US President's Emergency Fund for AIDS  
27 Relief and others are supporting the roll-out of Determined, Resilient, Empowered, AIDS free,  
28 Mentored, and Safe (DREAMS)(5-7). These programmes provide an evidence-based  
29 combination HIV prevention package, including HIV-testing and counselling for adolescent  
30 girls and young women (AGYW) and their male sexual partners, alongside universal test and  
31 treat and improved sexual health services (8, 9).

32  
33  
34  
35  
36  
37  
38 However, the key ingredient to the success of these multicomponent interventions will be the  
39 extent to which AGYW and their male partners at most risk of HIV will uptake and adhere to  
40 the active components of the intervention. This is challenging: uptake and retention of  
41 contraception and HIV treatment cascade by young people, even within population-wide  
42 Universal Test and Treat trials, has been suboptimal (2, 10, 11). Data from the baseline  
43 analysis for the DREAMS impact evaluation in uMkhanyakude district, rural KwaZulu-Natal  
44 (KZN) in 2015 suggest that less than 40% of girls (15-19 years) and boys and young men (15-  
45 29 years) had ever tested for HIV; linkage to HIV treatment was even lower (12).  
46 Contraception use prevalence was 20% in girls (15-19 years) and 50% in young women (20-  
47 24 years) and 21% of 15-19 year old girls had ever been pregnant (2).

48  
49  
50  
51  
52  
53  
54  
55 It is against this backdrop that the fifth series of Shuga: 'MTV Shuga: Down South' (MTV  
56 Shuga-DS), a mass media serial edu-drama designed for SA, was broadcast on free-to-air  
57 South Africa National television. From March 8<sup>th</sup> 2017, MTV Shuga aired one episode per  
58 week for 12 weeks (with repeats). MTV Shuga is a mass media behaviour change campaign  
59  
60

1  
2  
3 that aims to improve sexual and reproductive health rights (SRHR). At the centre of the  
4 campaign, which includes radio and social media, is a TV-drama that weaves messages about  
5 HIV, family planning, transactional and intergenerational sex, sexual identity, safer and healthy  
6 sexual relationships, into storylines with young characters  
7  
8 ([http://www.mtvshuga.com/show/series-5/MTV Shuga-down-south/](http://www.mtvshuga.com/show/series-5/MTV_Shuga-down-south/)).

9  
10  
11 Mass media campaigns, have the potential to reach a large number of people and have been  
12 shown to improve knowledge and health behaviour of a range of health conditions, with more  
13 recent data suggesting that theoretically informed and targeted interventions are more likely  
14 to have an effect (13, 14). MTV Shuga-DS was designed to reduce HIV-related risk behaviour  
15 and improve SRHR outcomes in adolescents and young adults in SA. This was expected to  
16 be achieved through increasing young people's awareness of their sexual and reproductive  
17 health rights and demand for, and uptake of HIV and SRH prevention and treatment  
18 technologies. The show's characters explicitly model how to discuss issues that are sensitive  
19 or taboo. MTV Shuga use the technique of 'melodramas', where drama is created through  
20 the battles between stereotypical goodies and baddies, and the way in which the 'transitional'  
21 (often empathetic) character, begins as ambivalent but changes into a positive role model to  
22 promote positive behaviour change(15). This is a deliberate method to immerse the audience  
23 in the action, rather than passively watching or listening (16). AGYW, or at least early adopters,  
24 are anticipated to be immersed in the serial, able to classify and identify with the transitional  
25 characters and their outcomes. Pathways to behaviour change through MTV Shuga, therefore  
26 relate to the extent to which the observer, including early adopters, are immersed and critically  
27 engaged with the story. It also depends on a context which is supportive rather than disruptive  
28 (see the conceptual framework Figure 1 below) (17).

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 **Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on**  
42 **AGYW in uMkhanyakude**

43  
44  
45 A cluster randomised controlled trial of community-viewings of MTV Shuga in Nigeria found  
46 that exposure to MTV Shuga significantly improved HIV knowledge and testing in both sexes,  
47 the intervention arm showing 35% more likely to test for HIV than the control arm. There was  
48 also a 60% reduction in genital chlamydia as a marker of recent sexual risk in women, amongst  
49 those exposed to MTV Shuga compared to those who were not (18). There were, however,  
50 fewer changes in social norms, particularly around gender-based violence. Further work  
51 suggested that the impact was greatest in those who were immersed in the narrative. The  
52 importance of immersion (classification of characters and identifying with them and observing  
53 outcomes) coupled with critical participation and an enabling context were also found in a  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 thematic analysis looking at how storylines in MTV Shuga-DS shaped awareness, knowledge  
4 and opinions of sexual health and personal relationships among young people in SA (17).  
5  
6  
7

8 Whilst the Nigerian and SA studies provide evidence for the efficacy of MTV Shuga impacting  
9 on SRHR and HIV-testing behaviours in exposed individuals, there is little evidence of how  
10 this will translate into a population-level effect when nationally broadcast and in less controlled  
11 environments. In particular, it is not clear how the impact will spill-over to non-viewers and  
12 how innovations will diffuse when shown and watched by adolescents and young adults in a  
13 real-world scale-up. It is also unclear how such impact will differ according to: setting (rural or  
14 urban); differential digital literacy and access to social media (geographically and  
15 socioeconomically), and the dose and context of watching (shared viewing with family, friends  
16 or individual experience through social media).  
17  
18  
19  
20  
21  
22

23 We use the opportunity of MTV Shuga being broadcast in the context of an impact evaluation  
24 of DREAMS roll out (January 2016-September 2019) in a representative, population-based  
25 sample of young people (12) to describe the real-world reach of nationally broadcast MTV  
26 Shuga-DS. Further, we explore the hypothesis that exposure to a mass-media serial edu-  
27 drama, like MTV Shuga, will improve SRHR outcomes by increasing demand for, and uptake  
28 of, existing combination individual and community-based SRH and HIV prevention services  
29 for AGYW in four diverse settings including uMkhanyakude, a socioeconomically deprived  
30 rural district with an extremely high burden of HIV: 40% antenatal HIV prevalence and an  
31 annual HIV incidence of 5% in girls (15-19 years) and 8% in young women (20-24 years) (2,  
32 19) and in three high-prevalence urban districts (HIV prevalence of greater than 10%) of City  
33 of Johannesburg, Ekurhuleni, and eThekweni.  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 **Methods**

### 44 **Study design**

45  
46  
47  
48 We employed a longitudinal cohort and cross-sectional surveys of representative samples of  
49 AGYW aged 12-24 in four districts of South Africa with a high burden of HIV to measure the  
50 reach of MTV Shuga-DS. Data were collected between May 2017 and September 2019.  
51  
52  
53

54 We used baseline and follow-up data from a nested cohort of 2184 AGYW aged 13-22 years,  
55 enrolled in 2017 for the DREAMS impact evaluation. The cohort is nested in a large  
56 population-based longitudinal HIV surveillance study, in the uMkhanyakude district of  
57 KwaZulu-Natal (20, 21). A random sample of 3013 AGYW was selected from the surveillance  
58  
59  
60

1  
2  
3 population, stratified by age (13-17 years and 18-22 years) and geography, and invited to  
4 enrol in the nested cohort. Baseline interviews were conducted between May 2017 and  
5 February 2018 and follow-up interviews April 2018 and September 2019 in the local language  
6 (isiZulu) using a structured quantitative questionnaire programmed in REDCap (12).  
7  
8  
9

10  
11 The cross-sectional survey was conducted on a household-based representative sample of  
12 4127 AGYW (between the ages 12-24 years) in three high prevalence (City of Johannesburg,  
13 Ekurhuleni and eThekweni) districts. Between August 2017 and July 2018, a stratified cluster-  
14 based sampling strategy was used to select 18500 AGYW aged 12-24 eligible for a cross-  
15 sectional survey of individuals, based on an expected response rate of 80% (22).  
16  
17  
18

19  
20 The interview included questions on socio-demographics, general health, exposure to  
21 DREAMS and to MTV Shuga, sexual relationships, awareness and uptake of DREAMS and  
22 DREAMS-like services, migration, and gender norms across the four districts. A Dried Blood  
23 Spot (DBS) was taken at baseline and follow-up for Herpes Simplex Virus type 2 (HSV-2)  
24 antibody testing in the uMkhanyakude district. For sexual behaviour questions, participants  
25 were given a tablet computer to complete a self-interview; the fieldworker was available to  
26 provide support as needed.  
27  
28  
29  
30  
31

### 32 33 **Study setting and population**

34  
35 The cohort was nested within the Africa Health Research Institute (AHRI) triannual  
36 demographic surveillance of a population of approximately 150,000 people who are members  
37 of 15,000 geocoded households in an area of 845 km<sup>2</sup> (20). The study area is mostly rural  
38 and poor with high levels of youth unemployment (over 85% of those aged 18-24 are  
39 unemployed) (2, 19).  
40  
41  
42  
43

44  
45 The cross-sectional survey was conducted in three districts which were mostly urban with  
46 more towns and townships compared to AHRI surveillance area. The three study districts (City  
47 of Johannesburg, Ekurhuleni and eThekweni) consist of an estimated 12,073,421 individuals.  
48 The eThekweni district in KZN province is among those with the highest HIV prevalence (16.8%  
49 HIV prevalence in 2016) in South Africa. Over two-thirds (68%) of eThekweni is considered  
50 rural and 32% urban. About 11 963 (3%) AGYW in eThekweni are estimated to be living with  
51 HIV. The Gauteng province (GP), whilst geographically the smallest, is the most populous  
52 province in South Africa. GP has the fifth highest provincial HIV prevalence in the country with  
53 a prevalence of 11.1% among those aged 15 to 49 years old in 2016. The HIV prevalence in  
54 the two districts, City of Johannesburg and Ekurhuleni, is 11.1% and 14.3% among 15- to 49-  
55  
56  
57  
58  
59  
60

1  
2  
3 year-olds, respectively. Both districts are densely populated and have high levels of  
4 industrialisation. The HIV prevalence amongst AGYW (15 to 24 years old) in the City of  
5 Johannesburg is 3%, and similarly 3% in Ekurhuleni in 2012.  
6  
7  
8  
9

## 10 **Variables and Measurement:**

### 11 ***Outcomes definitions:***

12 We measured the effect of exposure to MTV Shuga on awareness and uptake of HIV  
13 prevention and SRHR outcomes at the follow-up visit. Our outcomes were: 1) self-reported  
14 HIV-testing in the past 12 months; 2) awareness of Pre-Exposure Prophylaxis (PrEP) for HIV  
15 prevention; 3) condom use at last sex; 4) use of contraception; 5) any new pregnancy since  
16 baseline; and 6) any new teenage pregnancy (restricted to those under the age of 20). AGYW  
17 were considered to use contraception if they self-reported using pill, injection, Intrauterine  
18 Device (IUD), implant, sterilisation or self-reported consistent condom use (using condoms  
19 as a contraceptive method and at last sex). Condomless sex was calculated using 2019 data  
20 among participants who reported having had sex with the most recent partner in the past 12  
21 months. Recent pregnancy was calculated as any new pregnancy that occurred between  
22 baseline and 2019, while teenage pregnancy was calculated as any new pregnancy that  
23 occurred between baseline and 2019 among participants aged below 20 years. We also  
24 examined the effect of exposure to MTV Shuga on incident HSV-2 infections, among those  
25 who were HSV2 negative at baseline.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 ***Exposure definitions:***

39 Exposure to MTV Shuga was defined as ever watched MTV Shuga between 2017 and 2018.  
40 The level of exposure was measured based on the content of the series MTV Shuga, defined  
41 using 15 questions used to assess knowledge of content of MTV Shuga series. A composite  
42 score was developed summing-up the correct responses. The scores ranged between 2 and  
43 14, and the median being 4. The median was used as a cut-off to define level of exposure  
44 among those who watched the series. Consequently, the level of exposure was categorized  
45 into 3 levels: High (watching a MTV Shuga and being able to correctly respond to 5 or more  
46 questions on content); Medium (watching programme and being able to correctly respond to  
47 less than 5 questions); and None (not watched any MTV Shuga). This was further categorised  
48 into 3 levels: High (watching MTV Shuga and being able to recall the content from MTV  
49 Shuga); Medium (watching programme, but unable to recall content); and None (not being  
50 aware of and not watched any MTV Shuga).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Potential confounding variables:**

We included socio-demographic and sexual behaviour characteristics of AGYW that were measured at baseline and exposure to HIV prevention. The socio-demographic variables included age (as measured at follow-up), household socio-economic status, education broken down by those who are still in school and those who have completed school, geographic area (rural or peri-urban/urban), and migration in the last 12 months. The socio-economic status (SES) variable was constructed using Principal Component Analysis (PCA) based on ownership of household assets and characteristics such as access to piped water, type of toilet, electricity and type of cooking fuel (23). Further, potential individual-level confounders measured included exposure to DREAMS (defined either as ever been invited to participate in any of the DREAMS activities or ever used any of the DREAMS HIV prevention interventions in the past 12 months or since 2016 and phone ownership at baseline.

**Laboratory:**

The HerpeSelect® 2 ELISA IgG assay (FOCUS Diagnostics, Cypress, California, USA) for the qualitative detection of human IgG class antibodies to HSV-2 was used on Dried blood Spot (DBS) samples collected on Whatman 903 filter cards. The HerpeSelect® 2 ELISA IgG assay uses purified type-specific gG-2 antigen immobilized on polystyrene microwells reducing the cross-reactivity issues as seen with viral lysate assays(24). The assay is validated for use with serum samples but was optimised for use with DBS in the AHRI Diagnostic Research Laboratory following comparative testing with plasma samples. During the initial evaluation of the HerpeSelect® 2 ELISA IgG a select number of plasma samples were also tested by an external accredited pathology laboratory. A 6mm diameter punch of a DBS spot was incubated overnight in 150ul Assay Diluent for no more than 16 hours at 4°C. The assay was performed with 50ul of the eluent in accordance with the manufacturer's instructions. Following a disproportionately high number of positive results based on other studies and our experience we multiplied the mean cut-off calibrator absorbance values by a factor of 1.5 before determining the index value for each sample (25, 26). The HerpeSelect® 2 ELISA IgG results are reported as positive (index value >1.10), equivocal (index value of  $\geq 0.90$  but  $\leq 1.10$ ) or negative (index value <0.90). All initial equivocal results were re-tested and those that re-tested equivocal are reported as equivocal. An incident HSV-2 was defined as having been negative at baseline and positive at follow-up. Those who were equivocal at either baseline or follow-up were not considered as a sero-conversions.

## Statistical analyses:

We conducted two separate analyses for cohort and cross-sectional data. For the nested cohort, we included only participants who had data available at baseline and follow-up. We used Chi-square tests to compare baseline characteristics between AGYW who did and did not have any exposure to MTV Shuga. We used logistic regression to examine the effect of MTV Shuga on health outcomes, adjusting for exposure to DREAMS and all other potential confounders. Potential effect-modification of MTV Shuga by exposure to DREAMS was examined by fitting an interaction term to fully adjusted model: likelihood ratio tests were used to compare models with and without interaction terms.

We calculated the proportion of AGYW who reported an outcome (condomless-sex, recent pregnant) or tested positive for HSV-2 at 12-month or 24-month follow-up; and estimated associations between MTV Shuga and each outcome using a logistic regression, adjusting for potential confounders (age, household and individual socio-demographic characteristics and sexual behaviour). For HSV-2 incidence, we included participants who tested negative at baseline and had at least 1 follow-up test result. For DREAMS exposure, we included data collected at baseline and 12-month follow-up. For health outcomes (consistent condom use, modern contraception, HIV testing, PrEP awareness), we used data collected at 24-month follow-up; and for HSV-2 and pregnancy incidence we used data collected at 12 and 24-month follow-up.

Propensity score logistic regression adjustment was used to estimate the causal effect of MTV Shuga on health outcomes. A propensity or probability of being exposed to MTV Shuga was measured by fitting a logistic regression with MTV Shuga exposure as an outcome and potential confounders. A logistic regression models adjusting for propensity scores were then used to predict the probability of an outcome for all participants and separately by age group, under two scenario (1) exposed to MTV Shuga and (2) Not exposed to MTV Shuga. The predicted probabilities were then used to calculate the marginal risk difference, prevalence ratio and odds ratio. Confidence intervals were generated by using a bootstrap procedure, repeating the estimation procedure described above in 1000 samples that were drawn with replacement from the complete dataset and calculating 95% confidence intervals from the resulting bootstrap distribution using the 2.5% and 97.5% percentiles. We also used propensity score stratification and probability weighting methods to check the consistency of our findings.

1  
2  
3 For cross-sectional survey, we used Chi square test to compare the characteristics of AGYW  
4 who did and did not have any exposure to MTV Shuga; and logistic regression models  
5 adjusting for potential confounders were used to examine the association between exposure  
6 to MTV Shuga and health outcomes. Sampling weights were applied to achieve proportionality  
7 between groups of participants in the survey.

8 All analyses were performed using Stata version 15 (StataCorp LP, College Station, Texas  
9 USA).

## 16 Reporting

17 The STROBE reporting guidelines were used to guide synthesis and standardise reporting of  
18 our results(27)

## 23 Patient and public involvement

24 The study did not involve patients. AHRI has a Public Engagement Unit which conducts  
25 community engagement activities with the local communities as part of study findings  
26 dissemination. The Community Advisory Board provided feedback of the study including  
27 design before approval from ethics review board. Study findings are being made publicly  
28 available to funders, participants and the public through webinars, study reports and open  
29 access journal articles.

## 36 Results:

### 39 Participants

40 Of 3013 potentially eligible AGYW randomly selected from the surveillance data set, 85.5% of  
41 those eligible consented to participate at baseline (Figure 2). Of the 2184 eligible participants  
42 that were surveyed at baseline, 2016 (92.3%) had at least one follow-up visit and contributed  
43 data to this analysis. From the cross-sectional survey, 4127 (22.6%) eligible participants were  
44 surveyed.

### 51 Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

### 54 Awareness and exposure to MTV Shuga

55 MTV Shuga exposure at baseline was limited, with a total of only 308 (14.1%) respondents  
56 reported watching at least one episode. In the cross-sectional analysis of the three districts, a  
57 total of 1477 (35.8%) reported watching any MTV Shuga. In the nested cohort 121 (5.5%)  
58  
59  
60



recalled any storyline. Similarly in the cross-sectional snapshot 276 (6.7%) recalled the storyline (high exposure).

## Social demographic characteristics of adolescents and young people by exposure to MTV Shuga (Table 1&2)

Table 1 summarises the profiles of the nested cohort (n=2184) and cross-sectional surveys (n=4127) AGYW comparing those exposed to MTV Shuga with those not exposed. In summary those who had seen any MTV Shuga were more likely to be from households in the highest socioeconomic tertile ( $p < 0.001$ ) and more urbanised areas ( $p < 0.001$ ). They were also more likely to have also received DREAMS ( $p = 0.015$ ) (Table 1). In the cross-sectional surveys (n=4127), MTV Shuga exposure was associated with older age ( $p < 0.001$ ), tertiary education ( $p < 0.001$ ) and never having sex ( $p < 0.001$ ) Table 1.

**Table 1. Baseline socio-demographic characteristics of adolescent girls and young women (13-22) by exposure to MTV Shuga in the nested cohort (n=2184)**

	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
<b>Age group (4 cats), 2017</b>							
13-14	460/2184	21.1	72/308	23.4	388/1876	20.7	
15-17	688/2184	31.5	107/308	34.7	581/1876	31	
18-19	475/2184	21.7	60/308	19.5	415/1876	22.1	
20-22	561/2184	25.7	69/308	22.4	492/1876	26.2	0.216
<b>Currently in school</b>							
No	540/2184	24.7	67/308	21.8	473/1876	25.2	
Yes	1644/2184	75.3	241/308	78.2	1403/1876	74.8	0.192
<b>Socio-economic status, 2018</b>							
Low	255/2118	12	22/303	7.3	233/1815	12.8	
Middle	920/2118	43.4	110/303	36.3	810/1815	44.6	
High	943/2118	44.5	171/303	56.4	772/1815	42.5	<0.001
<b>Urban or rural</b>							
Rural	1388/2165	64.1	165/305	54.1	1223/1860	65.8	
Peri-urban/urban	777/2165	35.9	140/305	45.9	637/1860	34.2	<0.001
<b>Invited or received DREAMS, 2017/18</b>							
	1101/2184	50.4	175/308	56.8	926/1876	49.4	0.015
<b>Away from home in the last 12 months</b>							
	314/1853	17.0	45/228	15.6	269/1565	17.2	0.516
<b>Baseline socio-demographic characteristics of adolescent girls and young women (12-24) by exposure to MTV Shuga in the cross-sectional survey (n=4127)</b>							
	<b>Overall</b>		<b>Exposed</b>		<b>Not exposed</b>		

	n/N	%	n/N	%	n/N	%	p-value
<b>Age group, (N=4127)</b>							
12-14	958/4127	23.2	307/1477	20.1	651/2650	24.6	0.022
15-19	1628/4127	39.5	599/1477	40.6	1029/2650	38.8	
20-24	1541/4127	37.3	571/1477	38.7	970/2650	36.6	
<b>District</b>							
City of Johannesburg	1146/4127	27.8	476/1477	32.2	670/2650	25.3	<0.001
Ekurhuleni	1635/4127	39.6	521/1477	35.3	1114/2650	42.0	
eThekweni	1342/4127	32.5	480/1477	32.5	862/2650	32.5	
<b>Highest Education (N=4108)</b>							
No schooling	175/4108	4.3	99/1465	6.8	76/2646	2.9	<0.001
Grade R to 7	502/4108	12.2	142/1465	9.7	360/2646	13.6	
Grade 8 to 12	2978/4108	72.5	1022/1465	69.8	1956/2646	74.0	
Tertiary studies (complete/incomplete)	453/4108	11.0	202/1465	13.8	251/2646	9.5	
<b>Ever had sex with a boy/man (n=4108)</b>	1860/4108	45.3	621/1469	42.3	1239/2639	47.0	0.004
<b>Away from home in the last 12 months (n=4121)</b>	183/4121	4.4	66/1474	4.5	117/2647	4.4	0.932

After adjustment for confounders in nested cohorts (Table 2), AGYW from wealthier households (aOR=2.04 95%CI 1.27-3.30), peri-urban or urban areas (aOR=1.54 95%CI 1.19-1.98) and those invited to DREAMS (aOR=1.48 95%CI 1.14-1.92) were more likely to be exposed to MTV Shuga than those from poor households, from rural areas and those not invited to DREAMS respectively. Similarly, after adjustment in the cross-sectional surveys (Table 2), AGYW with higher education were more likely to be exposed to MTV Shuga (aOR=2.58 95%CI 1.81-3.69) than those with less and those who ever had sex (aOR=0.68 95%CI 0.57-0.82) were less likely to be exposed to MTV Shuga.

**Table 2 Factors associated with exposure to MTV Shuga in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Adjusted - All		
	OR	95%CI	OR	95%CI	P-value
<b>Age group, 2017</b>					
13-14	1		1		
15-17	0.99	0.72 -1.37	0.93	0.66 -1.29	
18-19	0.78	0.54 -1.13	0.77	0.51 -1.14	
20-22	0.76	0.53 -1.08	0.78	0.50 -1.21	0.555
<b>Currently in school</b>					
No	1		1		
Yes	1.21	0.91 -1.62	1.06	0.78 -1.43	0.726

<b>Socio-economic status, 2018</b>					
Low	1		1		
Middle	1.44	0.89 -2.33	1.27	0.78 -2.07	
High	2.35	1.47 -3.74	2.04	1.27 -3.30	<0.001
<b>Site</b>					
Rural	1		1		
Peri-urban/ urban	1.63	1.28 -2.08	1.54	1.19 -1.98	0.001
<b>Invited or received DREAMS, 2017/18</b>					
No	1		1		
Yes	1.35	1.06 -1.72	1.48	1.14 -1.92	0.003
<b>Factors associated with exposure to MTV Shuga in the cross-sectional analysis of AGYW aged 12-24 (n=4127)</b>					
	<b>Unadjusted</b>		<b>Adjusted - all</b>		
	<b>OR</b>	<b>95% CI</b>	<b>OR</b>	<b>95% CI</b>	<b>P-value</b>
<b>District</b>					
City of Johannesburg	1		1		
Ekurhuleni	0.69	0.54 - 0.89	0.66	0.52- 0.84	0.001
eThekweni	0.79	0.60 - 1.04	0.78	0.59- 1.04	0.087
<b>Age group</b>					
12-14	1		1		
15-19	1.27	1.06 - 1.53	1.18	0.95- 1.46	0.126
20-24	1.22	1.01 - 1.48	1.16	0.90- 1.49	0.256
<b>Highest education level</b>					
Grade R to 7	1		1		
No schooling	2.88	1.81 - 4.58	3.29	2.01 - 5.38	<0.001
Grade 8 to 12	1.38	1.09 - 1.75	1.42	1.08 - 1.86	0.011
Complete or incomplete tertiary	2.29	1.70 - 3.09	2.58	1.81 - 3.69	<0.001
<b>Ever had sex with a boy/man</b>					
No	1		1		
Yes	0.82	0.71 - 0.95	0.68	0.57- 0.82	<0.001
<b>Away from home in last 12 months</b>					
No	1		1		
Yes	1.15	0.80 - 1.64	1.21	0.83- 1.77	0.309

## Relationship between MTV Shuga exposure and HIV and SRHR outcomes (Table 3&4)

In the nested cohorts by 2019, overall 63.3% of those aged 14-23 knew their HIV status, 13.4% were consistently using contraception, 20.0% were using condoms consistently, and about a third were aware of PrEP, 5% had a pregnancy and 15% acquired HSV2. There were higher proportions of contraception use, condom use and PrEP awareness among those exposed to MTV Shuga (Table 3). For survey sites (Table 3) overall, 85.0% knew their HIV status, over a fifth 22.6% were using contraception and about half using condoms 48.4%. About a tenth (7.5%) were aware of PrEP, with higher proportions of these being among those exposed to MTV Shuga.

**Table 3: HIV and SRHR outcomes by exposure to MTV Shuga nested cohort 13-22 year olds (n= 2167)**

	Overall		Exposed (n=308)		Not exposed (n=1878)		P-value
	n/N	%	n/N	%	n/N	%	
Knowledge of HIV status, 2019	1083/1712	63.3	175/283	61.8	908/1429	63.5	0.587
Modern contraception, 2019	221/1651	13.4	56/271	20.7	165/1380	12	<0.001
Consistent condom use, 2019	168/838	20	41/141	29.1	127/697	18.2	0.003
Aware of PrEP, 2019	523/1712	30.5	124/283	43.8	399/1429	27.9	0.302
Pregnant in 2018/19	124/2184	5.7	20/308	6.5	104/1876	5.5	0.504
Teenage pregnancy	72/1395	5.16	55/1187	4.63	17/208	8.17	0.033
HSV-2 2018/19	241/1562	15.4	35/237	14.8	206/1325	15.5	0.760
<b>HIV and SRHR outcomes by exposure to MTV Shuga weighted for sampling cross sectional survey 12-24 year olds (n=4127)</b>							
	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
PrEP awareness (N=4127)	310/4127	7.5	148/1477	10.0	162/2650	6.1	<0.001
HIV test (self-report) (N=2529)	2156/2529	85.3	656/797	82.3	1500/1732	86.6	0.005
Condom use at last sex (N=1898)‡	918/1898	48.4	320/640	50.0	598/1258	47.5	0.310
Contraception use (N=4127)	934/4127	22.6	302/1477	20.5	632/2650	23.9	0.012

‡Restricted to those who ever had sex with man

At follow up, incident HSV-2 and teenage pregnancy were high, HSV-2 incidence was 15.26 and teenage pregnancy incidence was 9.86 per 100 person-years, respectively (Table 4).

**Table 4: Rate of SRHR outcome by exposure to MTV Shuga (nested cohort 13-22 year olds n=2167)**

<b>HSV-2 incidence rate</b>					
	person-time	n with HSV-2	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	1303.0	206	15.81	13.79	18.12
MTV Shuga Exposed	276.3	35	12.67	9.09	17.64
Total	1579.3	241	15.26	13.45	17.31
<b>Pregnancy incidence rates among all AGYW</b>					
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	1068.7	104	9.73	8.03	11.79
MTV Shuga Exposed	188.5	20	10.61	6.84	16.44
Total	1257.2	124	9.86	8.27	11.76
<b>Pregnancy incidence rates among girls below 19 years</b>					
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	668.7	55	8.22	6.31	10.71
MTV Shuga Exposed	123.9	17	13.72	8.53	22.07
Total	792.6	72	9.08	7.21	11.44

### MTV Shuga and HIV prevention and SRHR awareness and uptake

In the nested cohort after adjusting for age, education, SES, area and DREAMS, MTV Shuga exposure in the AGYW cohort was associated with significantly greater awareness of PrEP (aOR=2.06, 95%CI: 1.57-2.70), contraception uptake (aOR=2.08, 95%CI: 1.45-2.98), and consistent condom use (aOR=1.84, 95%CI: 1.24-2.93). Watching MTV-Shuga was not associated with HIV testing (aOR=1.02,95%CI: 0.77-1.21) (Figure 3 and Supplementary Tables S1-S4). There was no effect modification by DREAMS exposure.

### Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

Similarly, in the cross-sectional analysis, after adjusting for age, education, district, migration and sexual history, exposure to MTV-Shuga watching was associated with greater awareness of PrEP (aOR=1.70, 95%CI 1.20 - 2.43). However, there was no association with contraception, lower self-reported HIV testing, or condom use as shown in Figure 4 below (Supplementary Table 5).

1  
2  
3 **Figure 4 Forest plots showing association between MTV Shuga exposure and**  
4 **HIV prevention and SRHR awareness and uptake in the cross-sectional**  
5 **surveys**  
6  
7  
8

9 **Causal effect of MTV Shuga on health outcomes – HSV2**

10  
11 The causal analysis similarly finds no effect of MTV Shuga on HSV2, with a risk difference of  
12 1.10 95% CI (-2.82- 5.38)%. Findings in the younger age group (aged 13-17) and the older  
13 age group (18-22) was similar (Supplementary Table 6).  
14  
15  
16

17  
18 **Discussion**  
19

20 In our study of the population-level effect of a national broadcast of a TV-based edu-drama on  
21 HIV prevention and SRHR, exposure to MTV Shuga was associated with higher awareness  
22 of a novel HIV prevention intervention (PrEP). However, despite a very high incidence of HSV-  
23 2 and teenage pregnancy, MTV Shuga exposure was not significantly associated with safer  
24 sexual behaviour, uptake of contraception and HIV-testing or prevention of teenage  
25 pregnancy. Notably though, the size of the relationship and direction of effect between  
26 exposure to MTV Shuga, condom use and markers of unprotected sex (HSV-2 and  
27 pregnancy) was consistent with a possible relationship. These findings may be partly  
28 explained by our finding that less than one in 12 of the target age group had any exposure to  
29 MTV Shuga and only half of these had high exposure (defined as watching the MTV Shuga  
30 South African series and being able to recall the content), suggesting that one of the limiting  
31 factors for the effective use of TV-based edu-drama maybe the dose that young people are  
32 exposed to, particularly in rural and resource-constrained settings most affected by HIV.  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Our inability to find a measurable population effect of mass-media edu-drama behaviour  
43 change campaign compared to the trial findings of the RCT is disappointing (18). However,  
44 firstly the direction and size of the relationships suggest that we may have been able to see  
45 an effect if the proportion exposed had been greater than 7%. Secondly, AGYW in urban  
46 settings were more likely to have been exposed to MTV Shuga and they are also more likely  
47 to be living in small towns and townships. Data from our settings suggest that young people  
48 in small towns and townships are more vulnerable to HIV (28) and sexual risk (29) and  
49 therefore it is possible that a real effect of MTV Shuga on this group was masked by their  
50 greater risk for the outcome. Due to the low numbers with high levels of exposure to MTV  
51 Shuga we did not have the power to explore this hypothesis by looking at effect modification  
52 by geography or socioeconomic status.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The finding of a differential association of MTV Shuga exposure with awareness of PrEP,  
4 compared to uptake of HIV and contraception, suggests that whilst educational mass  
5 entertainment may be able to increase awareness and possibly demand for a service, it does  
6 not impact on accessibility of the service: i.e. it impacts the first two steps of the prevention  
7 cascade and not the final step(30). Well described barriers to uptake of HIV-testing and  
8 contraception in this area are internalized and externalized stigma, fear of judgement from  
9 health care workers and the social costs of accessing care in busy primary health care  
10 settings(31-33). Behaviour change intervention including mass communication campaigns  
11 can be constrained or facilitated by the context in which people live (17, 34). To optimise MTV  
12 Shuga's effect there may need to be parallel innovations in SRHR and HIV service delivery  
13 that makes the services easier to access. We aim to test this hypothesis by providing  
14 community-based delivery of HIV and SRHR services in the context of the MTV Shuga.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 The behaviour change theory that underpins edu-drama as a vehicle for mass behaviour  
25 change communication (16) explicitly suggests that the audience, and especially the early  
26 adopters, need to be actively watching, rather than passively watching or listening (17, 18).  
27 TV watching in rural homesteads can be in the context of large, often grandparent-led  
28 households and competing chores and priorities. This coupled with the relatively late timing of  
29 the shows may explain why so few girls and young women were sufficiently engaged or  
30 immersed to be able to recall characters or story lines. Moreover, the timing of this analysis  
31 may have allowed insufficient time for early adopters to convey the message of the show.  
32  
33  
34  
35  
36  
37

## 38 **Limitations**

39 The limitations of our study are that a meaningful exposure to MTV Shuga was low and so  
40 whilst the size of the relationship and direction of effect between exposure to MTV Shuga,  
41 condom use, and markers of unprotected sex (HSV-2 and pregnancy) suggested a possible  
42 effect, but we did not have the power to show a significant relationship between exposure to  
43 MTV Shuga and SRHR outcomes. We also do not have the power to see a difference by  
44 dose and immersion. Furthermore, as this is an observational study, we cannot exclude the  
45 possibility that those who are exposed to MTV Shuga are systematically different in ways that  
46 impact on the outcome of interest, for example more exposed to social media and sexual  
47 health promotion and innovative technologies to support sexual health than those who were  
48 not.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusions and implications for the future

- Meaningful exposure to MTV Shuga was low across rural and urban settings in South Africa and so additional efforts need to be made to reach young people and increase their immersion in promising edu-drama if it is to have the desired effect, especially in rural and deprived settings.
- MTV Shuga was an effective vehicle to raise awareness and promote newer HIV prevention technologies such as HIV PrEP.
- There was some suggestion that MTV Shuga improved uptake of some HIV prevention and sexual health technologies (contraception and condoms)
- There was less evidence from this observational study that it improved SRHR and HIV outcomes

We highlight the importance of evaluating the real-world scale up of promising interventions to understand both the reach and population effect as well as inform interventions to increase impact and equity.

Efforts to increase exposure, which have been rolled out as part of MTV Shuga in SA, such as social media, school-based or community-based MTV Shuga film clubs will need to be evaluated, both to understand whether or not they increase exposure and coverage and improve SRH and HIV outcomes. However, to have a significant impact on the HIV and SRH prevention and treatment cascades, demand generation in AGYW needs to be delivered in parallel with accessible service delivery models that support adherence and retention (30).

## Contributorship

M.S., N.C., J.D., T.Z. N.K, G.H. and C.C. developed the study tools and performed the research. M.S., J.S. D.P., K.B., I.B., and S.F. designed the research study. T.S. and S.D. conducted the laboratory analysis. N.M. supported by K.B. conducted the statistical analysis and G.C. M.S wrote the first and final draft of the paper with input from N.C., N.M., G.H., J.S., I.B., G.C., K.B., C.C., T.S., T.Z, D.P and N.K. All the authors critically reviewed the manuscript. All authors have approved the final draft of the paper.

## Competing interests

All authors declare they have no conflict of interest



## Funding

The impact evaluation of DREAMS and MTV Shuga is funded by the Bill and Melinda Gates Foundation (OPP1136774 and OPP1171600, <http://www.gatesfoundation.org>). Foundation staff advised the study team, but did not substantively affect the study design, instruments, interpretation of data, or decision to publish. The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union's seventh Framework Programme FP7/2007-2013 under REA grant agreement n° 612216. MS National Institutes of Health 5R01MH114560-03 funding acknowledgement. This research was funded in whole, or in part, by the Africa Health Research Institute through the Wellcome [Strategic Core award: 201433/Z/16/A]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. N.C is supported by a training fellowship from the National Institute for Health Research (NIHR) (using the UK's Official Development Assistance (ODA) Funding) and Wellcome [grant reference number 224309/Z/21/Z] under the NIHR-Wellcome Partnership for Global Health Research. The views expressed are those of the authors and not necessarily those of Wellcome, the NIHR or the Department of Health and Social Care. GH is supported by a fellowship from the Royal Society and the Wellcome Trust [Grant number 210479/Z/18/Z]. MS work is also supported by a BMGF 3ie grant at AHRI. This research was funded in whole, or in part, by the Wellcome Trust [Grant number 210479/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

## Data sharing statement

Data are available on reasonable request.

## Ethics statement

The DREAMS Partnership impact evaluation protocol was reviewed and approved by the University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (BFC 339/16), the London School of Hygiene & Tropical Medicine Research Ethics Committee (Ref 11835) and the AHRI Somkhele Community Advisory Board, the Associate Director of Science of the Center for Global Health (CGH) at the United States Centers for Disease Control and Prevention (CDC) in Atlanta and the Department of Health, Province of KZN and Gauteng. Approval for the demographic surveillance and data collection in the clinics was granted by UKZN BREC. Participation in the study was voluntary. All participants provided separate informed consent to take part in data collection through the questionnaires and the HSV2 sero-

1  
2  
3 survey. Consent for follow-up interviews was provided separately. For participants aged <18  
4 years, written parental consent and participant assent were provided. All data were  
5 anonymised for analysis.  
6  
7  
8  
9

## 10 Acknowledgements

11 The authors are grateful to the communities of the Hlabisa sub-district, Ekurhuleni district,  
12 Thekwini district and City of Johannesburg who contributed their data to this study and to all  
13 the staff at Africa Health Research Institute and EpiCentre who collected the data. We  
14 acknowledge Eskindir Shambullo for his input in this manuscript.  
15  
16  
17  
18  
19

## 20 References

- 21 1. HSRC. The fifth South African National HIV prevalence, incidence, behaviour and  
22 communication survey [Report].  
23 [http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV\\_Impact\\_Assessment\\_Summary\\_ZA\\_ADS\\_cleared\\_PDFA4.pdf](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDFA4.pdf): South African Health Services Research  
24 Council 2017 [updated 01/11/2018].  
25
- 26 2. Chimbindi N, Mthiyane N, Birdthistle I, Floyd S, McGrath N, Pillay D, et al.  
27 Persistently high incidence of HIV and poor service uptake in adolescent girls and  
28 young women in rural KwaZulu-Natal, South Africa prior to DREAMS. PLoS One.  
29 2018;13(10):e0203193.  
30
- 31 3. Vandormael A, Akullian A, Siedner M, de Oliveira T, Bärnighausen T, Tanser F.  
32 Declines in HIV incidence among men and women in a South African population-  
33 based cohort. Nature Communications. 2019;10(1):5482.  
34
- 35 4. Birdthistle I, Kwaro D, Shahmanesh M, Baisley K, Khagayi S, Chimbindi N, et al.  
36 Evaluating the impact of DREAMS on HIV incidence among adolescent girls and  
37 young women: A population-based cohort study in Kenya and South Africa. PLoS  
38 medicine. 2021;18(10):e1003837.  
39
- 40 5. Department of Health RoSA. National Campaign for Young Women and Adolescent  
41 Girls. . 2016.  
42
- 43 6. Saul J, Bachman G, Allen S, Toiv NF, Cooney C, Beamon TA. The DREAMS core  
44 package of interventions: A comprehensive approach to preventing HIV among  
45 adolescent girls and young women. PLOS ONE. 2018;13(12):e0208167.  
46
- 47 7. PEPFAR. Preventing HIV in Adolescent Girls and Young Women: Guidance for  
48 PEPFAR Country Teams on the DREAMS Partnership 2015.  
49
- 50 8. PEPFAR. South Africa DREAMS overview  
51 <https://www.pepfar.gov/documents/organization/253958.pdf>: PEPFAR; 2017 [  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 9. Chang L, Serwadda D, Quinn T, Wawer M, Gray R, Reynolds S. Combination  
4 implementation for HIV prevention: moving from clinical trial evidence to population-  
5 level effects *The Lancet Infectious Diseases* 2013;13(1):65-76.  
6  
7
- 8 10. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al.  
9 Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-  
10 label, community cluster randomised trial. *Lancet HIV*. 2018;5(3):e116-e25.  
11
- 12 11. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation  
13 of the impact of immediate versus WHO recommendations-guided antiretroviral  
14 therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention)  
15 trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster  
16 randomised controlled trial. *Trials*. 2013;14:230.  
17
- 18 12. Birdthistle I, Schaffnit SB, Kwaro D, Shahmanesh M, Ziraba A, Kabiru CW, et al.  
19 Evaluating the impact of the DREAMS partnership to reduce HIV incidence among  
20 adolescent girls and young women in four settings: a study protocol. *BMC Public*  
21 *Health*. 2018;18(1):912.  
22
- 23 13. Shen F, Han J. Effectiveness of entertainment education in communicating health  
24 information: a systematic review. *Asian Journal of Communication*. 2014;24(6):605-  
25 16.  
26
- 27 14. Noar SM, Palmgreen P, Chabot M, Dobransky N, Zimmerman RS. A 10-year  
28 systematic review of HIV/AIDS mass communication campaigns: have we made  
29 progress? *Journal of Health Communication*. 2009;14(1):15-42.  
30
- 31 15. Kyegombe N, Zuma T, Hlongwane S, Nhlenyama M, Chimbindi N, Birdthistle I, et al.  
32 A qualitative exploration of the salience of MTV-Shuga, an edutainment programme,  
33 and adolescents' engagement with sexual and reproductive health information in  
34 rural KwaZulu-Natal, South Africa. *Sexual and Reproductive Health Matters*.  
35 2022;30(1):2083809.  
36
- 37 16. Barker K. Sex Soap and Social change- The Sabedo methodology  
38 <https://www.populationmedia.org/product/sabido-theory/>;  
39 <http://www.comminit.com/content/sabido-methodology> [  
40  
41  
42  
43
- 44 17. Baker V, Birdthistle I, Seeley J, Arnold G, Piot S, Hajiyanis H. How can a TV drama  
45 about Love, Sex and Growing up Increase Knowledge and Shape the Sexual Health  
46 Behaviours of Young People? . *AIDS Impact*; Cape Town, South Africa 2017.  
47  
48
- 49 18. MTV Shuga Soap Opera Turns Edutainment into a Tool to Fight HIV and Gender-  
50 Based Violence [http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-](http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-violence2017)  
51 [soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-](http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-violence2017)  
52 [violence2017](http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-violence2017) [  
53  
54  
55  
56  
57  
58  
59  
60

19. National Department of Health. The National Antenatal Sentinel HIV prevalence survey, South Africa, <http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-10/2015-04-30-08-21-56?download=2584:2015-national-antenatal-hiv-prevalence-survey-final-23oct17>, 2013 [
20. Herbst K, Law M, Geldsetzer P, Tanser F, Harling G, Barnighausen T. Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. *Current Opinion on HIV AIDS*. 2015;10(6):483-94.
21. Gareta D, Baisley K, Mngomezulu T, Smit T, Khoza T, Nxumalo S, et al. Cohort Profile Update: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *Int J Epidemiol*. 2021;50(1):33-4.
22. George G, Cawood C, Puren A, Khanyile D, Gerritsen A, Govender K, et al. Evaluating DREAMS HIV prevention interventions targeting adolescent girls and young women in high HIV prevalence districts in South Africa: protocol for a cross-sectional study. *BMC Women's Health*. 2020;20(1):7.
23. Filmer D, Pritchett LH. Estimating Wealth Effects Without Expenditure Data—Or Tears: An Application To Educational Enrollments In States Of India\*. *Demography*. 2001;38:115-32.
24. Arvin A, Prober C. Herpes Simplex Viruses. In: Murray P, Baron E, Pfaller M, Tenover F, Tenover F, Tenover R, editors. *Manual of Clinical Microbiology* 6th Ed Washington D.C.: ASM; 1995. p. 876-83.
25. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of Focus HerpeSelect ® and Kalon TM HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 (HSV-2) antibodies in a South African population. *Sexually Transmitted Infections*. 2009;86(1):46-50.
26. Ashley-Morrow R, Nolkamper J, Robinson N, Bishop N, Smith J. Performance of Focus ELISA test for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical Microbiology and Infection* 2004;10(6):530-6.
27. STROBE Statement. STROBE Checklists 2007 [Available from: <http://www.strobe-statement.org/index.php?id=available-checklists>].
28. Cuadros DF, Li J, Branscum AJ, Akullian A, Jia P, Mziray EN, et al. Mapping the spatial variability of HIV infection in Sub-Saharan Africa: Effective information for localized HIV prevention and control. *Scientific Reports*. 2017;7(1):9093.
29. Ngwenya N, Gumede D, Shahmanesh M, McGrath N, Grant A, Seeley J. Community perceptions of the socio-economic structural context influencing HIV and TB risk, prevention and treatment in a high prevalence area in the era of antiretroviral therapy. *African Journal of AIDS Research*. 2018;17(1):72-81.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
30. Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S, Bhattacharjee P, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. *Lancet HIV*. 2016;3(7):e318-22.
31. Hargreaves JR, Krishnaratne S, Mathema H, Lilleston PS, Sievwright K, Mandla N, et al. Individual and community-level risk factors for HIV stigma in 21 Zambian and South African communities: analysis of data from the HPTN071 (PopART) study. *AIDS*. 2018;32(6):783-93.
32. Chimbindi N, Zuma T, Nakasone S, Birdthistle I, Mthiyane N, Dreyer J, et al. Platforms, Processes and Perceptions of PrEP Delivery Through DREAMS in a Rural Setting in KwaZulu-Natal, South Africa. . Research for Prevention 2018 (HIVR4P 2018) Madrid, Spain 2018.
33. Adeagbo O, Herbst C, Dlamini N, Mhlongo T, Luthuli M, Xulu S, et al. "If she tests negative, it means I am also negative": Men's construction of HIV testing in KwaZulu-Natal, South Africa. . HIV Research for Prevention (HIVR4P) 23 October 2018.; Madrid, Spain **2018**
34. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. *Implementation Science*. 2011;6(42).

## Figure legends

Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

Figure 1: Conceptual framework for MTV Shuga impact on HIV prevention in uMkhanyakude




Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

98x51mm (400 x 400 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

71x64mm (400 x 400 DPI)






Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

95x46mm (400 x 400 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

101x54mm (400 x 400 DPI)

**Supplementary Table 1 Exposure to MTV Shuga and PrEP awareness in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	2.01	1.55 -2.62				2.06	1.57 -2.70	<0.001
<b>Age</b>	1.12	1.08-1.16	1.12	1.08-1.17	<0.001	1.11	1.06-1.17	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.47 -0.76	0.59	0.46 -0.75	<0.001	0.89	0.65 -1.23	0.488
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.99	0.71 -1.39	0.96	0.68 -1.35		1.01	0.71 -1.44	
High	1.13	0.81 -1.58	1.05	0.75 -1.47	0.744	1.11	0.78 -1.58	0.699
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.98	0.79 -1.22	0.93	0.75 -1.16	0.525	0.92	0.73 -1.15	0.459
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.89	0.73 -1.10	0.88	0.71 -1.08	0.212	0.99	0.79 -1.23	0.897

**Supplementary Table 2 Exposure to MTV Shuga and contraception uptake in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.92	1.37 -2.68				2.08	1.45-2.98	<0.001
<b>Age</b>	1.26	1.19-1.33	1.27	1.20-1.34	<0.001	1.32	1.24-1.42	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.44 -0.83	0.59	0.43-0.82	0.001	1.7	1.13-2.55	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.79	0.51 -1.22	0.76	0.49-1.19		0.8	0.51-1.28	
High	0.86	0.55 -1.34	0.8	0.51-1.24	0.489	0.83	0.52-1.32	0.646
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.91	0.68 -1.24	0.86	0.64-1.17	0.345	0.89	0.64-1.24	0.49
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.63 -1.11	0.83	0.62-1.10	0.191	1.04	0.76-1.42	0.813

**Supplementary Table 3 Exposure to MTV Shuga and consistent condom use in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		p-value
	OR	95%CI	OR	95%CI		OR	95%CI	
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.84	1.22-2.78				1.9	1.24-2.93	0.003
<b>Age</b>	0.94	0.86-1.01	0.94	0.87-1.02	0.157	1	0.91-1.10	0.984
<b>Currently in school</b>								
No	1		1			1		
Yes	1.76	1.22-2.53	1.73	1.20-2.49	0.003	1.78	1.15-2.76	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	1.01	0.60-1.70	0.97	0.58-1.63		0.98	0.58-1.67	
High	0.87	0.52-1.47	0.8	0.47-1.36	0.552	0.86	0.50-1.48	0.753
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.7	0.48-1.02	0.67	0.46-0.97	0.035	0.71	0.48-1.05	0.088
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	1.13	0.81-1.59	1.13	0.80-1.59	0.486	0.97	0.67-1.40	0.875

**Supplementary Table 4 Exposure to MTV Shuga and HIV testing in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	0.93	0.71-1.21				1.02	0.77-1.36	0.885
<b>Age</b>	1.3	1.25-1.35	1.3	1.24-1.35	<0.001	1.3	1.24-1.37	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.37	0.28-0.48	0.37	0.28-0.48	0	1.07	0.74-1.53	0.726
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.67	0.48-0.94	0.67	0.48-0.95		0.71	0.49-1.02	
High	0.58	0.41-0.81	0.58	0.41-0.81	0.007	0.6	0.41-0.86	0.018
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.84	0.68-1.03	0.84	0.69-1.04	0.104	0.89	0.71-1.11	0.298
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.69-1.02	0.84	0.69-1.02	0.081	0.98	0.79-1.23	0.89

**Supplementary Table 5: Exposure to MTV Shuga with HIV prevention and SRHR awareness and uptake in the cross-sectional analysis of AGYW aged 12-24 (n=4127)**

	aOR (95% Confidence Interval)	P-value
<b>District</b>		
City of Johannesburg	1	
Ekurhuleni	0.66 (0.47-0.91)	0.013
eThekweni	0.78 (0.54-1.13)	0.186
<b>Age group</b>		
12-14	1	
15-19	1.75 (0.35-8.84)	0.499
20-24	1.60 (0.32-8.07)	0.570
<b>Highest education level</b>		
Grade R to 7	1	
No schooling	3.84 (1.05-14.02)	0.041
Grade 8 to 12	3.17 (0.93-10.77)	0.065
Complete or incomplete tertiary	6.52 (1.90-22.33)	0.003
<b>Ever had sex with a boy/man</b>		
No	1	
Yes	0.67 (0.32-1.40)	0.286
<b>Away from home</b>		
No	1	
Yes	1.48 (0.93-2.37)	0.099
<b>PrEP awareness</b>		
No	1	
Yes	1.71 (1.20-2.43)	0.003
<b>Contraception use</b>		
No	1	
Yes	0.95 (0.74-1.23)	0.718
<b>Condom use at last sex</b>		
No	1	
Yes	1.19 (0.92-1.55)	0.183
<b>HIV test (self-report)</b>		
No	1	
Yes	0.88 (0.63-1.24)	0.471

Supplementary Table 6 Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group

Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group											
	% Outcome in total study population	Estimated % Outcome if no Shuga	95% CI	Estimated % Outcome if all get Shuga	95% CI	Risk Difference (%; PS adjusted)	95% CI	Prevalence Ratio (%; PS adjusted)	95% CI	Odds Ratio (%; PS adjusted)	95% CI
<b>PS adjustment: Primary results</b>											
Overall	17.3	17.2	14.71 - 19.67	18.0	14.51 - 22.32	0.80	-3.24 - 5.71	1.05	0.82 - 1.36	1.06	0.79 - 1.46
13-17 Years	13.2	12.4	9.85 - 15.16	15.7	11.63 - 20.26	3.34	-1.60 - 8.25	1.27	0.89 - 1.79	1.32	0.87 - 1.98
18-22 Years	24.3	25.8	21.01 - 30.74	22.0	15.19 - 30.17	-3.76	-11.92 - 5.68	0.85	0.59 - 1.24	0.81	0.51 - 1.34
<b>Sensitivity analyses</b>											
<u>Regression under counterfactual framework</u>											
Overall	17.3	17.2	14.74 - 19.66	17.8	14.50 - 22.08	0.65	-3.42 - 5.72	1.04	0.82 - 1.36	1.05	0.78 - 1.46
13-17 Years	13.2	12.42	9.86 - 15.21	15.9	11.85 - 20.49	3.47	-1.54 - 8.63	1.28	0.89 - 1.80	1.33	0.88 - 1.99
18-22 Years	24.3	25.7	20.78 - 30.63	21.3	14.88 - 28.28	-4.42	-12.28 - 4.95	0.83	0.57 - 1.22	0.78	0.48 - 1.31
<u>PS stratification</u>											
Overall	17.3	17.1	14.68 - 19.68	17.9	14.53 - 22.13	0.80	-3.21 - 5.52	1.09	0.84 - 1.40	1.11	0.82 - 1.51
<u>PS weighting</u>											



Overall	17.3	17.08	14.74 - 19.48	17.22	13.99 - 21.10	0.13	-3.76 - 4.63	1.01	0.79 - 1.30	1.01	0.76 - 1.37
---------	------	-------	------------------	-------	------------------	------	-----------------	------	----------------	------	----------------

For peer review only

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	10

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	12
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12- 16
		(b) Report category boundaries when continuous variables were categorized	12- 16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	17- 18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18- 19
Generalisability	21	Discuss the generalisability (external validity) of the study results	17- 19
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Evaluating use of mass-media communication intervention 'MTV-Shuga' on increased awareness and demand for HIV and sexual health services by adolescent girls and young women in South Africa: An observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062804.R3
Article Type:	Original research
Date Submitted by the Author:	21-Apr-2023
Complete List of Authors:	Chimbindi, Natsayi; Africa Health Research Institute; University College London, Mthiyane, Nondumiso; Africa Health Research Institute Chidumwa, Glory ; Africa Health Research Institute; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand Zuma, Thembelihle; Africa Health Research Institute; University College London, Dreyer, Jaco; Africa Health Research Institute Birdthistle, Isolde; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Floyd, Sian; London School of Hygiene & Tropical Medicine, Infectious Disease Epidemiology Kwegombe, Nambusi; London School of Hygiene & Tropical Medicine Grundy, Chris; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health, Department of Population Health Cawood, Cherie; Epicentre Health Research Danaviah, Siva; Africa Health Research Institute Smit, Theresa; Africa Health Research Institute Pillay, Deenan; University College London, Baisley, Kathy; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health; Africa Health Research Institute Harling, Guy; Africa Health Research Institute; University College London Seeley, Janet; London School of Hygiene and Tropical Medicine, Department of Global Health & Development; Africa Health Research Institute Shahmanesh, Maryam; University College London, Institute for Global Health; Africa Health Research Institute,
<b>Primary Subject Heading</b>:	Sexual health
Secondary Subject Heading:	HIV/AIDS, Public health, Sexual health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH, PREVENTIVE MEDICINE

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 Title page  
4

5 Revised Title: **Evaluating use of mass-media communication intervention ‘MTV-**  
6 **Shuga’ on increased awareness and demand for HIV and sexual health**  
7 **services by adolescent girls and young women in South Africa: An**  
8 **observational study**  
9  
10  
11

12  
13 Authors: Natsayi Chimbindi\*<sup>1,2,3</sup>, Nondumiso Mthiyane\*<sup>2</sup>, Glory Chidumwa<sup>1,4</sup>,  
14 Thembelihle Zuma<sup>1,2,3</sup>, Jaco Dreyer<sup>1</sup>, Isolde Birdthistle<sup>5</sup>, Sian Floyd<sup>5</sup>, Nambusi  
15 Kyegombe<sup>5</sup>, Chris Grundy<sup>5</sup>, Cherie Cawood<sup>6</sup>, Siva Danaviah<sup>1</sup>, Theresa Smit<sup>1</sup>,  
16 Deenan Pillay<sup>2</sup>, Kathy Baisley<sup>1,3</sup>, Guy Harling<sup>1,2,3,7</sup>, Janet Seeley<sup>1,3,5</sup>, Maryam  
17 Shahmanesh<sup>§1,2,3</sup>  
18  
19  
20  
21  
22

- 23  
24 1. Africa Health Research Institute, KwaZulu-Natal, South Africa  
25 2. University College London, Institute for Global Health, London, UK  
26 3. University of KwaZulu-Natal, KwaZulu-Natal, South Africa  
27 4. Wits Reproductive Health and HIV Institute, Faculty of Health Sciences,  
28 University of the Witwatersrand, Johannesburg, South Africa  
29 5. London School of Hygiene and Tropical Medicine, London, UK  
30 6. Epicentre Health Research, Durban, South Africa  
31 7. MRC/Wits Rural Public Health & Health Transitions Research Unit  
32 (Agincourt), University of the Witwatersrand, Gauteng, South Africa  
33  
34  
35  
36  
37  
38  
39

40 \*Joint authors

41  
42 §Corresponding author (full address details): Maryam Shahmanesh, Institute for  
43 Global Health, UCL, 3<sup>rd</sup> Floor, Mortimer Market Centre, Capper Street, London  
44 WC1E 6JB. [m.shahmanesh@ucl.ac.uk](mailto:m.shahmanesh@ucl.ac.uk). +44 7776 185 572  
45  
46  
47  
48  
49

50 Key words (6): HIV, Adolescents, mass communication campaigns, Sexual Health,  
51 Teenage Pregnancy, South Africa.  
52  
53  
54  
55  
56  
57

58 **Abstract (word count=272)**

59 **Objective:** To investigate the effect of exposure to MTV Shuga:Down South’ (MTVShuga-DS)  
60

1  
2  
3 during the scale-up of combination HIV-prevention interventions on awareness and uptake of  
4 sexual reproductive health (SRH) and HIV-prevention services by adolescent girls and young  
5 women (AGYW).  
6

7  
8 **Design:** One longitudinal and three cross-sectional surveys of representative samples of  
9 AGYW.  
10

11 **Setting:** AGYW in four South African districts with high HIV-prevalence (>10%) (May 2017  
12 and September 2019).  
13

14 **Participants:** 6311 AGYW aged 12-24.  
15

16 **Measures:** Using logistic-regression we measured the relationship between exposure to MTV  
17 Shuga-DS and awareness of Pre-Exposure Prophylaxis (PrEP), condom-use at last sex,  
18 uptake of HIV-testing or contraception, and incident pregnancy or Herpes simplex virus 2  
19 (HSV-2) infection.  
20  
21

22 **Results:** Within the rural cohort 2184 (85.5%) of eligible sampled individuals were enrolled,  
23 of whom 92.6% had at least one follow-up visit; the urban cross-sectional surveys enrolled  
24 4127 (22.6%) of eligible sampled individuals. Self-report of watching at least one MTV Shuga-  
25 DS episode was 14.1% (cohort) and 35.8% (cross-section), while storyline recall was 5.5%  
26 (cohort) and 6.7% (cross-section).  
27  
28  
29

30 In the cohort, after adjustment (for HIV-prevention intervention-exposure, age, education,  
31 socio-economic status (SES)), MTVShuga-DS exposure was associated with increased PrEP  
32 awareness (adjusted odds ratio (aOR)=2.06,95% confidence interval (CI):1.57-2.70),  
33 contraception uptake (aOR=2.08,95%CI:1.45-2.98) and consistent condom-use (aOR=1.84,  
34 95%CI:1.24-2.93), but not with HIV-testing (aOR=1.02,95%CI:0.77-1.21) or acquiring HSV-2  
35 (aOR=0.92, 95%CI:0.61-1.38). In the cross-sections, MTVShuga-DS was associated with  
36 greater PrEP awareness (aOR=1.7, 95%CI:1.20-2.43), but no other outcome.  
37  
38  
39

40 **Conclusions:** Among both urban and rural AGYW in South Africa, MTVShuga-DS exposure  
41 was associated with increased PrEP awareness and improved demand for some HIV-  
42 prevention and SRH technologies but not sexual health outcomes. However, exposure to  
43 MTVShuga-DS was low. Given these positive indications, supportive programming may be  
44 required to raise exposure and allow future evaluation of edu-drama impact in this setting.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Strengths and limitations of this study

- Evaluated the real-world reach of nationally broadcast edu-drama focusing on adolescent sexual health in South Africa.
- Data collection focused on a vulnerable population of AGYW across four diverse high HIV-burden districts of South Africa that included both rural and urban settings.
- Strength of the study is measurement of exposure to MTV Shuga on HIV and SRH outcomes in representative sample of AGYW during a real-world implementation in different South African settings.
- The limitation of observational studies is that they do not infer the cause-effect relationship, in this case we cannot ascertain causality/impact of exposure to MTV-Shuga on uptake of sexual health promotion and innovative technologies.

1  
2  
3 **[word count 4531]**

## 4 **Introduction**

5 HIV remains one of the gravest health problems facing young people living in sub-Saharan  
6 Africa (SSA). There are over 7.7 million people living with HIV in South Africa (SA), with more  
7 than 200,000 new HIV infections annually in those aged 15-49 years (1). The highest  
8 incidence is in adolescent girls and young women (AGYW) (15-24 years) (1, 2). Although HIV  
9 incidence has been declining in South Africa, a 43% decline in the overall incidence rate  
10 between 2012 and 2017, from 4.0 to 2.3 seroconversion events per 100 person-years among  
11 15-49 year old; it still remains high among AGYW in South Africa (3). In uMkhanyakude, HIV  
12 incidence was lower during roll-out of combination HIV prevention for AGYW (2016 to 2018)  
13 than in the previous 5-year period among 15- to 19-year-old females (4.5 new infections per  
14 100 person-years as compared with 2.8; and lower among 20- to 24-year-olds (7.1/100  
15 person-years as compared with 5.8) (4).

16  
17  
18  
19  
20  
21  
22  
23  
24  
25 In response to the high HIV incidence in young people, the South African government  
26 launched the 'She Conquers Campaign', and the US President's Emergency Fund for AIDS  
27 Relief and others are supporting the roll-out of Determined, Resilient, Empowered, AIDS free,  
28 Mentored, and Safe (DREAMS)(5-7). These programmes provide an evidence-based  
29 combination HIV prevention package, including HIV-testing and counselling for adolescent  
30 girls and young women (AGYW) and their male sexual partners, alongside universal test and  
31 treat and improved sexual health services (8, 9).

32  
33  
34  
35  
36  
37  
38 However, the key ingredient to the success of these multicomponent interventions will be the  
39 extent to which AGYW and their male partners at most risk of HIV will uptake and adhere to  
40 the active components of the intervention. This is challenging: uptake and retention of  
41 contraception and HIV treatment cascade by young people, even within population-wide  
42 Universal Test and Treat trials, has been suboptimal (2, 10, 11). Data from the baseline  
43 analysis for the DREAMS impact evaluation in uMkhanyakude district, rural KwaZulu-Natal  
44 (KZN) in 2015 suggest that less than 40% of girls (15-19 years) and boys and young men (15-  
45 29 years) had ever tested for HIV; linkage to HIV treatment was even lower (12).  
46 Contraception use prevalence was 20% in girls (15-19 years) and 50% in young women (20-  
47 24 years) and 21% of 15-19 year old girls had ever been pregnant (2).

48  
49  
50  
51  
52  
53  
54  
55 It is against this backdrop that the fifth series of Shuga: 'MTV Shuga: Down South' (MTV  
56 Shuga-DS), a mass media serial edu-drama designed for SA, was broadcast on free-to-air  
57 South Africa National television. From March 8<sup>th</sup> 2017, MTV Shuga aired one episode per  
58 week for 12 weeks (with repeats). MTV Shuga is a mass media behaviour change campaign  
59  
60

1  
2  
3 that aims to improve sexual and reproductive health rights (SRHR). At the centre of the  
4 campaign, which includes radio and social media, is a TV-drama that weaves messages about  
5 HIV, family planning, transactional and intergenerational sex, sexual identity, safer and healthy  
6 sexual relationships, into storylines with young characters  
7  
8 ([http://www.mtvshuga.com/show/series-5/MTV Shuga-down-south/](http://www.mtvshuga.com/show/series-5/MTV_Shuga-down-south/)).

9  
10  
11 Mass media campaigns, have the potential to reach a large number of people and have been  
12 shown to improve knowledge and health behaviour of a range of health conditions, with more  
13 recent data suggesting that theoretically informed and targeted interventions are more likely  
14 to have an effect (13, 14). MTV Shuga-DS was designed to reduce HIV-related risk behaviour  
15 and improve SRHR outcomes in adolescents and young adults in SA. This was expected to  
16 be achieved through increasing young people's awareness of their sexual and reproductive  
17 health rights and demand for, and uptake of HIV and sexual reproductive health (SRH)  
18 prevention and treatment technologies. The show's characters explicitly model how to discuss  
19 issues that are sensitive or taboo. MTV Shuga use the technique of 'melodramas', where  
20 drama is created through the battles between stereotypical goodies and baddies, and the way  
21 in which the 'transitional' (often empathetic) character, begins as ambivalent but changes into  
22 a positive role model to promote positive behaviour change(15). This is a deliberate method  
23 to immerse the audience in the action, rather than passively watching or listening (16). AGYW,  
24 or at least early adopters, are anticipated to be immersed in the serial, able to classify and  
25 identify with the transitional characters and their outcomes. Pathways to behaviour change  
26 through MTV Shuga, therefore relate to the extent to which the observer, including early  
27 adopters, are immersed and critically engaged with the story. It also depends on a context  
28 which is supportive rather than disruptive (see the conceptual framework Figure 1 below) (17).

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 **Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on**  
42 **AGYW in uMkhanyakude**

43  
44  
45 A cluster randomised controlled trial of community-viewings of MTV Shuga in Nigeria found  
46 that exposure to MTV Shuga significantly improved HIV knowledge and testing in both sexes,  
47 the intervention arm showing 35% more likely to test for HIV than the control arm. There was  
48 also a 60% reduction in genital chlamydia as a marker of recent sexual risk in women, amongst  
49 those exposed to MTV Shuga compared to those who were not (18). There were, however,  
50 fewer changes in social norms, particularly around gender-based violence. Further work  
51 suggested that the impact was greatest in those who were immersed in the narrative. The  
52 importance of immersion (classification of characters and identifying with them and observing  
53 outcomes) coupled with critical participation and an enabling context were also found in a  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 thematic analysis looking at how storylines in MTV Shuga-DS shaped awareness, knowledge  
4 and opinions of sexual health and personal relationships among young people in SA (17).  
5  
6  
7

8 Whilst the Nigerian and SA studies provide evidence for the efficacy of MTV Shuga impacting  
9 on SRHR and HIV-testing behaviours in exposed individuals, there is little evidence of how  
10 this will translate into a population-level effect when nationally broadcast and in less controlled  
11 environments. In particular, it is not clear how the impact will spill-over to non-viewers and  
12 how innovations will diffuse when shown and watched by adolescents and young adults in a  
13 real-world scale-up. It is also unclear how such impact will differ according to: setting (rural or  
14 urban); differential digital literacy and access to social media (geographically and  
15 socioeconomically), and the dose and context of watching (shared viewing with family, friends  
16 or individual experience through social media).  
17  
18  
19  
20  
21  
22

23 We use the opportunity of MTV Shuga being broadcast in the context of an impact evaluation  
24 of DREAMS roll out (January 2016-September 2019) in a representative, population-based  
25 sample of young people (12) to describe the real-world reach of nationally broadcast MTV  
26 Shuga-DS. Further, we explore the hypothesis that exposure to a mass-media serial edu-  
27 drama, like MTV Shuga, will improve SRHR outcomes by increasing demand for, and uptake  
28 of, existing combination individual and community-based SRH and HIV prevention services  
29 for AGYW in four diverse settings including uMkhanyakude, a socioeconomically deprived  
30 rural district with an extremely high burden of HIV: 40% antenatal HIV prevalence and an  
31 annual HIV incidence of 5% in girls (15-19 years) and 8% in young women (20-24 years) (2,  
32 19) and in three high-prevalence urban districts (HIV prevalence of greater than 10%) of City  
33 of Johannesburg, Ekurhuleni, and eThekweni.  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 **Methods**

### 44 **Study design**

45  
46  
47  
48 We employed a longitudinal cohort and cross-sectional surveys of representative samples of  
49 AGYW aged 12-24 in four districts of South Africa with a high burden of HIV to measure the  
50 reach of MTV Shuga-DS. Data were collected between May 2017 and September 2019.  
51  
52  
53

54 We used baseline and follow-up data from a nested cohort of 2184 AGYW aged 13-22 years,  
55 enrolled in 2017 for the DREAMS impact evaluation. The cohort is nested in a large  
56 population-based longitudinal HIV surveillance study, in the uMkhanyakude district of  
57 KwaZulu-Natal (20, 21). A random sample of 3013 AGYW was selected from the surveillance  
58  
59  
60

1  
2  
3 population, stratified by age (13-17 years and 18-22 years) and geography, and invited to  
4 enrol in the nested cohort. Baseline interviews were conducted between May 2017 and  
5 February 2018 and follow-up interviews April 2018 and September 2019 in the local language  
6 (isiZulu) using a structured quantitative questionnaire programmed in REDCap software (12).  
7  
8  
9

10  
11 The cross-sectional survey was conducted on a household-based representative sample of  
12 4127 AGYW (between the ages 12-24 years) in three high prevalence (City of Johannesburg,  
13 Ekurhuleni and eThekweni) districts. Between August 2017 and July 2018, a stratified cluster-  
14 based sampling strategy was used to select 18500 AGYW aged 12-24 eligible for a cross-  
15 sectional survey of individuals, based on an expected response rate of 80% (22).  
16  
17  
18

19  
20 The interview included questions on socio-demographics, general health, exposure to  
21 DREAMS and to MTV Shuga, sexual relationships, awareness and uptake of DREAMS and  
22 DREAMS-like services, migration, and gender norms across the four districts. A Dried Blood  
23 Spot (DBS) was taken at baseline and follow-up for Herpes Simplex Virus type 2 (HSV-2)  
24 antibody testing in the uMkhanyakude district. For sexual behaviour questions, participants  
25 were given a tablet computer to complete a self-interview; the fieldworker was available to  
26 provide support as needed.  
27  
28  
29  
30  
31

### 32 33 **Study setting and population**

34  
35 The cohort was nested within the Africa Health Research Institute (AHRI) triannual  
36 demographic surveillance of a population of approximately 150,000 people who are members  
37 of 15,000 geocoded households in an area of 845 km<sup>2</sup> (20). The study area is mostly rural  
38 and poor with high levels of youth unemployment (over 85% of those aged 18-24 are  
39 unemployed) (2, 19).  
40  
41  
42  
43

44  
45 The cross-sectional survey was conducted in three districts which were mostly urban with  
46 more towns and townships compared to AHRI surveillance area. The three study districts (City  
47 of Johannesburg, Ekurhuleni and eThekweni) consist of an estimated 12,073,421 individuals.  
48 The eThekweni district in KZN province is among those with the highest HIV prevalence (16.8%  
49 HIV prevalence in 2016) in South Africa. Over two-thirds (68%) of eThekweni is considered  
50 rural and 32% urban. About 11 963 (3%) AGYW in eThekweni are estimated to be living with  
51 HIV. The Gauteng province (GP), whilst geographically the smallest, is the most populous  
52 province in South Africa. GP has the fifth highest provincial HIV prevalence in the country with  
53 a prevalence of 11.1% among those aged 15 to 49 years old in 2016. The HIV prevalence in  
54 the two districts, City of Johannesburg and Ekurhuleni, is 11.1% and 14.3% among 15- to 49-  
55  
56  
57  
58  
59  
60

1  
2  
3 year-olds, respectively. Both districts are densely populated and have high levels of  
4 industrialisation. The HIV prevalence amongst AGYW (15 to 24 years old) in the City of  
5 Johannesburg is 3%, and similarly 3% in Ekurhuleni in 2012.  
6  
7  
8  
9

## 10 **Variables and Measurement:**

### 11 ***Outcomes definitions:***

12 We measured the effect of exposure to MTV Shuga on awareness and uptake of HIV  
13 prevention and SRHR outcomes at the follow-up visit. Our outcomes were: 1) self-reported  
14 HIV-testing in the past 12 months; 2) awareness of Pre-Exposure Prophylaxis (PrEP) for HIV  
15 prevention; 3) condom use at last sex; 4) use of contraception; 5) any new pregnancy since  
16 baseline; and 6) any new teenage pregnancy (restricted to those under the age of 20). AGYW  
17 were considered to use contraception if they self-reported using pill, injection, Intrauterine  
18 Device (IUD), implant, sterilisation or self-reported consistent condom use (using condoms as  
19 a contraceptive method and at last sex). Condomless sex was calculated using 2019 data  
20 among participants who reported having had sex with the most recent partner in the past 12  
21 months. Recent pregnancy was calculated as any new pregnancy that occurred between  
22 baseline and 2019, while teenage pregnancy was calculated as any new pregnancy that  
23 occurred between baseline and 2019 among participants aged below 20 years. We also  
24 examined the effect of exposure to MTV Shuga on incident HSV-2 infections, among those  
25 who were HSV-2 negative at baseline.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 ***Exposure definitions:***

39 Exposure to MTV Shuga was defined as ever watched MTV Shuga between 2017 and 2018.  
40 The level of exposure was measured based on the content of the series MTV Shuga, defined  
41 using 15 questions used to assess knowledge of content of MTV Shuga series. A composite  
42 score was developed summing-up the correct responses. The scores ranged between 2 and  
43 14, and the median being 4. The median was used as a cut-off to define level of exposure  
44 among those who watched the series. Consequently, the level of exposure was categorized  
45 into 3 levels: High (watching a MTV Shuga and being able to correctly respond to 5 or more  
46 questions on content); Medium (watching programme and being able to correctly respond to  
47 less than 5 questions); and None (not watched any MTV Shuga). This was further categorised  
48 into 3 levels: High (watching MTV Shuga and being able to recall the content from MTV  
49 Shuga); Medium (watching programme, but unable to recall content); and None (not being  
50 aware of and not watched any MTV Shuga).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Potential confounding variables:**

We included socio-demographic and sexual behaviour characteristics of AGYW that were measured at baseline and exposure to HIV prevention. The socio-demographic variables included age (as measured at follow-up), household socio-economic status (SES), education broken down by those who are still in school and those who have completed school, geographic area (rural or peri-urban/urban), and migration in the last 12 months. The socio-economic status (SES) variable was constructed using Principal Component Analysis (PCA) based on ownership of household assets and characteristics such as access to piped water, type of toilet, electricity and type of cooking fuel (23). Further, potential individual-level confounders measured included exposure to DREAMS (defined either as ever been invited to participate in any of the DREAMS activities or ever used any of the DREAMS HIV prevention interventions in the past 12 months or since 2016) and phone ownership at baseline.

**Laboratory:**

The HerpeSelect® 2 ELISA IgG assay (FOCUS Diagnostics, Cypress, California, USA) for the qualitative detection of human Immunoglobulin G (IgG) class antibodies to HSV-2 was used on Dried blood Spot (DBS) samples collected on Whatman 903 filter cards. The HerpeSelect® 2 ELISA IgG assay uses purified type-specific gG-2 antigen immobilized on polystyrene microwells reducing the cross-reactivity issues as seen with viral lysate assays(24). The assay is validated for use with serum samples but was optimised for use with DBS in the AHRI Diagnostic Research Laboratory following comparative testing with plasma samples. During the initial evaluation of the HerpeSelect® 2 ELISA IgG a select number of plasma samples were also tested by an external accredited pathology laboratory. A 6mm diameter punch of a DBS spot was incubated overnight in 150ul Assay Diluent for no more than 16 hours at 4°C. The assay was performed with 50ul of the eluent in accordance with the manufacturer's instructions. Following a disproportionately high number of positive results based on other studies and our experience we multiplied the mean cut-off calibrator absorbance values by a factor of 1.5 before determining the index value for each sample (25, 26). The HerpeSelect® 2 ELISA IgG results are reported as positive (index value >1.10), equivocal (index value of  $\geq 0.90$  but  $\leq 1.10$ ) or negative (index value <0.90). All initial equivocal results were re-tested and those that re-tested equivocal are reported as equivocal. An incident HSV-2 was defined as having been negative at baseline and positive at follow-up. Those who were equivocal at either baseline or follow-up were not considered as a sero-conversions.

## Statistical analyses:

We conducted two separate analyses for cohort and cross-sectional data. For the nested cohort, we included only participants who had data available at baseline and follow-up. We used Chi-square tests to compare baseline characteristics between AGYW who did and did not have any exposure to MTV Shuga. We used logistic regression to examine the effect of MTV Shuga on health outcomes, adjusting for exposure to DREAMS and all other potential confounders. Potential effect-modification of MTV Shuga by exposure to DREAMS was examined by fitting an interaction term to fully adjusted model: likelihood ratio tests were used to compare models with and without interaction terms.

We calculated the proportion of AGYW who reported an outcome (condomless-sex, recent pregnant) or tested positive for HSV-2 at 12-month or 24-month follow-up; and estimated associations between MTV Shuga and each outcome using a logistic regression, adjusting for potential confounders (age, household and individual socio-demographic characteristics and sexual behaviour). For HSV-2 incidence, we included participants who tested negative at baseline and had at least 1 follow-up test result. For DREAMS exposure, we included data collected at baseline and 12-month follow-up. For health outcomes (consistent condom use, modern contraception, HIV testing, PrEP awareness), we used data collected at 24-month follow-up; and for HSV-2 and pregnancy incidence we used data collected at 12 and 24-month follow-up.

Propensity score logistic regression adjustment was used to estimate the causal effect of MTV Shuga on health outcomes. A propensity or probability of being exposed to MTV Shuga was measured by fitting a logistic regression with MTV Shuga exposure as an outcome and potential confounders. A logistic regression models adjusting for propensity scores were then used to predict the probability of an outcome for all participants and separately by age group, under two scenario (1) exposed to MTV Shuga and (2) Not exposed to MTV Shuga. The predicted probabilities were then used to calculate the marginal risk difference, prevalence ratio and odds ratio (OR). Confidence intervals (CI) were generated by using a bootstrap procedure, repeating the estimation procedure described above in 1000 samples that were drawn with replacement from the complete dataset and calculating 95% confidence intervals from the resulting bootstrap distribution using the 2.5% and 97.5% percentiles. We also used propensity score stratification and probability weighting methods to check the consistency of our findings.



1  
2  
3 For cross-sectional survey, we used Chi square test to compare the characteristics of AGYW  
4 who did and did not have any exposure to MTV Shuga; and logistic regression models  
5 adjusting for potential confounders were used to examine the association between exposure  
6 to MTV Shuga and health outcomes. Sampling weights were applied to achieve proportionality  
7 between groups of participants in the survey.

8 All analyses were performed using Stata version 15 (StataCorp LP, College Station, Texas  
9 USA).

## 16 Reporting

17 The STROBE reporting guidelines were used to guide synthesis and standardise reporting of  
18 our results(27)

## 23 Patient and public involvement

24 The study did not involve patients. AHRI has a Public Engagement Unit which conducts  
25 community engagement activities with the local communities as part of study findings  
26 dissemination. The Community Advisory Board provided feedback of the study including  
27 design before approval from ethics review board. Study findings are being made publicly  
28 available to funders, participants and the public through webinars, study reports and open  
29 access journal articles.

## 36 Results:

### 39 Participants

40 Of 3013 potentially eligible AGYW randomly selected from the surveillance data set, 85.5% of  
41 those eligible consented to participate at baseline (Figure 2). Of the 2184 eligible participants  
42 that were surveyed at baseline, 2016 (92.3%) had at least one follow-up visit and contributed  
43 data to this analysis. From the cross-sectional survey, 4127 (22.6%) eligible participants were  
44 surveyed.

### 51 Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

### 54 Awareness and exposure to MTV Shuga

55 MTV Shuga exposure at baseline was limited, with a total of only 308 (14.1%) respondents  
56 reported watching at least one episode. In the cross-sectional analysis of the three districts, a  
57 total of 1477 (35.8%) reported watching any MTV Shuga. In the nested cohort 121 (5.5%)  
58  
59  
60

recalled any storyline. Similarly in the cross-sectional snapshot 276 (6.7%) recalled the storyline (high exposure).

## Social demographic characteristics of adolescents and young people by exposure to MTV Shuga (Table 1&2)

Table 1 summarises the profiles of the nested cohort (n=2184) and cross-sectional surveys (n=4127) AGYW comparing those exposed to MTV Shuga with those not exposed. In summary those who had seen any MTV Shuga were more likely to be from households in the highest socioeconomic tertile (p<0.001) and more urbanised areas (p<0.001). They were also more likely to have also received DREAMS (p=0.015) (Table 1). In the cross-sectional surveys (n=4127), MTV Shuga exposure was associated with older age (p<0.001), tertiary education (p <0.001) and never having sex (p< 0.001) Table 1.

**Table 1. Baseline socio-demographic characteristics of adolescent girls and young women (13-22) by exposure to MTV Shuga in the nested cohort (n=2184)**

	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
<b>Age group (4 cats), 2017</b>							
13-14	460/2184	21.1	72/308	23.4	388/1876	20.7	
15-17	688/2184	31.5	107/308	34.7	581/1876	31	
18-19	475/2184	21.7	60/308	19.5	415/1876	22.1	
20-22	561/2184	25.7	69/308	22.4	492/1876	26.2	0.216
<b>Currently in school</b>							
No	540/2184	24.7	67/308	21.8	473/1876	25.2	
Yes	1644/2184	75.3	241/308	78.2	1403/1876	74.8	0.192
<b>Socio-economic status, 2018</b>							
Low	255/2118	12	22/303	7.3	233/1815	12.8	
Middle	920/2118	43.4	110/303	36.3	810/1815	44.6	
High	943/2118	44.5	171/303	56.4	772/1815	42.5	<0.001
<b>Urban or rural</b>							
Rural	1388/2165	64.1	165/305	54.1	1223/1860	65.8	
Peri-urban/urban	777/2165	35.9	140/305	45.9	637/1860	34.2	<0.001
<b>Invited or received DREAMS, 2017/18</b>							
	1101/2184	50.4	175/308	56.8	926/1876	49.4	0.015
<b>Away from home in the last 12 months</b>							
	314/1853	17.0	45/228	15.6	269/1565	17.2	0.516
<b>Baseline socio-demographic characteristics of adolescent girls and young women (12-24) by exposure to MTV Shuga in the cross-sectional survey (n=4127)</b>							
	<b>Overall</b>		<b>Exposed</b>		<b>Not exposed</b>		

	n/N	%	n/N	%	n/N	%	p-value
<b>Age group, (N=4127)</b>							
12-14	958/4127	23.2	307/1477	20.1	651/2650	24.6	0.022
15-19	1628/4127	39.5	599/1477	40.6	1029/2650	38.8	
20-24	1541/4127	37.3	571/1477	38.7	970/2650	36.6	
<b>District</b>							
City of Johannesburg	1146/4127	27.8	476/1477	32.2	670/2650	25.3	<0.001
Ekurhuleni	1635/4127	39.6	521/1477	35.3	1114/2650	42.0	
eThekweni	1342/4127	32.5	480/1477	32.5	862/2650	32.5	
<b>Highest Education (N=4108)</b>							
No schooling	175/4108	4.3	99/1465	6.8	76/2646	2.9	<0.001
Grade R to 7	502/4108	12.2	142/1465	9.7	360/2646	13.6	
Grade 8 to 12	2978/4108	72.5	1022/1465	69.8	1956/2646	74.0	
Tertiary studies (complete/incomplete)	453/4108	11.0	202/1465	13.8	251/2646	9.5	
<b>Ever had sex with a boy/man (n=4108)</b>	1860/4108	45.3	621/1469	42.3	1239/2639	47.0	0.004
<b>Away from home in the last 12 months (n=4121)</b>	183/4121	4.4	66/1474	4.5	117/2647	4.4	0.932

After adjustment for confounders in nested cohorts (Table 2), AGYW from wealthier households (adjusted Odds Ratio (aOR)=2.04 95%CI 1.27-3.30), peri-urban or urban areas (aOR=1.54 95%CI 1.19-1.98) and those invited to DREAMS (aOR=1.48 95%CI 1.14-1.92) were more likely to be exposed to MTV Shuga than those from poor households, from rural areas and those not invited to DREAMS respectively. Similarly, after adjustment in the cross-sectional surveys (Table 2), AGYW with higher education were more likely to be exposed to MTV Shuga (aOR=2.58 95%CI 1.81-3.69) than those with less and those who ever had sex (aOR=0.68 95%CI 0.57-0.82) were less likely to be exposed to MTV Shuga.

**Table 2 Factors associated with exposure to MTV Shuga in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Adjusted - All		
	OR	95%CI	OR	95%CI	P-value
<b>Age group, 2017</b>					
13-14	1		1		
15-17	0.99	0.72 -1.37	0.93	0.66 -1.29	
18-19	0.78	0.54 -1.13	0.77	0.51 -1.14	
20-22	0.76	0.53 -1.08	0.78	0.50 -1.21	0.555
<b>Currently in school</b>					
No	1		1		
Yes	1.21	0.91 -1.62	1.06	0.78 -1.43	0.726

<b>Socio-economic status, 2018</b>					
Low	1		1		
Middle	1.44	0.89 -2.33	1.27	0.78 -2.07	
High	2.35	1.47 -3.74	2.04	1.27 -3.30	<0.001
<b>Site</b>					
Rural	1		1		
Peri-urban/ urban	1.63	1.28 -2.08	1.54	1.19 -1.98	0.001
<b>Invited or received DREAMS, 2017/18</b>					
No	1		1		
Yes	1.35	1.06 -1.72	1.48	1.14 -1.92	0.003
<b>Factors associated with exposure to MTV Shuga in the cross-sectional analysis of AGYW aged 12-24 (n=4127)</b>					
	<b>Unadjusted</b>		<b>Adjusted - all</b>		
	<b>OR</b>	<b>95% CI</b>	<b>OR</b>	<b>95% CI</b>	<b>P-value</b>
<b>District</b>					
City of Johannesburg	1		1		
Ekurhuleni	0.69	0.54 - 0.89	0.66	0.52- 0.84	0.001
eThekweni	0.79	0.60 - 1.04	0.78	0.59- 1.04	0.087
<b>Age group</b>					
12-14	1		1		
15-19	1.27	1.06 - 1.53	1.18	0.95- 1.46	0.126
20-24	1.22	1.01 - 1.48	1.16	0.90- 1.49	0.256
<b>Highest education level</b>					
Grade R to 7	1		1		
No schooling	2.88	1.81 - 4.58	3.29	2.01 - 5.38	<0.001
Grade 8 to 12	1.38	1.09 - 1.75	1.42	1.08 - 1.86	0.011
Complete or incomplete tertiary	2.29	1.70 - 3.09	2.58	1.81 - 3.69	<0.001
<b>Ever had sex with a boy/man</b>					
No	1		1		
Yes	0.82	0.71 - 0.95	0.68	0.57- 0.82	<0.001
<b>Away from home in last 12 months</b>					
No	1		1		
Yes	1.15	0.80 - 1.64	1.21	0.83- 1.77	0.309

## Relationship between MTV Shuga exposure and HIV and SRHR outcomes (Table 3&4)

In the nested cohorts by 2019, overall 63.3% of those aged 14-23 knew their HIV status, 13.4% were consistently using contraception, 20.0% were using condoms consistently, and about a third were aware of PrEP, 5% had a pregnancy and 15% acquired HSV-2. There were higher proportions of contraception use, condom use and PrEP awareness among those exposed to MTV Shuga (Table 3). For survey sites (Table 3) overall, 85.0% knew their HIV status, over a fifth 22.6% were using contraception and about half using condoms 48.4%. About a tenth (7.5%) were aware of PrEP, with higher proportions of these being among those exposed to MTV Shuga.

**Table 3: HIV and SRHR outcomes by exposure to MTV Shuga nested cohort 13-22 year olds (n= 2167)**

	Overall		Exposed (n=308)		Not exposed (n=1878)		P-value
	n/N	%	n/N	%	n/N	%	
Knowledge of HIV status, 2019	1083/1712	63.3	175/283	61.8	908/1429	63.5	0.587
Modern contraception, 2019	221/1651	13.4	56/271	20.7	165/1380	12	<0.001
Consistent condom use, 2019	168/838	20	41/141	29.1	127/697	18.2	0.003
Aware of PrEP, 2019	523/1712	30.5	124/283	43.8	399/1429	27.9	0.302
Pregnant in 2018/19	124/2184	5.7	20/308	6.5	104/1876	5.5	0.504
Teenage pregnancy	72/1395	5.16	55/1187	4.63	17/208	8.17	0.033
HSV-2 2018/19	241/1562	15.4	35/237	14.8	206/1325	15.5	0.760
<b>HIV and SRHR outcomes by exposure to MTV Shuga weighted for sampling cross sectional survey 12-24 year olds (n=4127)</b>							
	Overall		Exposed		Not exposed		p-value
	n/N	%	n/N	%	n/N	%	
PrEP awareness (N=4127)	310/4127	7.5	148/1477	10.0	162/2650	6.1	<0.001
HIV test (self-report) (N=2529)	2156/2529	85.3	656/797	82.3	1500/1732	86.6	0.005
Condom use at last sex (N=1898)‡	918/1898	48.4	320/640	50.0	598/1258	47.5	0.310
Contraception use (N=4127)	934/4127	22.6	302/1477	20.5	632/2650	23.9	0.012

‡Restricted to those who ever had sex with man

At follow up, incident HSV-2 and teenage pregnancy were high, HSV-2 incidence was 15.26 and teenage pregnancy incidence was 9.86 per 100 person-years, respectively (Table 4).

**Table 4: Rate of SRHR outcome by exposure to MTV Shuga (nested cohort 13-22 year olds n=2167)**

<b>HSV-2 incidence rate</b>					
	person-time	n with HSV-2	Rate/100 person-years (py)	[95% Conf.	Interval]
MTV Shuga Not exposed	1303.0	206	15.81	13.79	18.12
MTV Shuga Exposed	276.3	35	12.67	9.09	17.64
Total	1579.3	241	15.26	13.45	17.31
<b>Pregnancy incidence rates among all AGYW</b>					
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	1068.7	104	9.73	8.03	11.79
MTV Shuga Exposed	188.5	20	10.61	6.84	16.44
Total	1257.2	124	9.86	8.27	11.76
<b>Pregnancy incidence rates among girls below 19 years</b>					
	person-time	n pregnant	Rate/100 py	[95% Conf.	Interval]
MTV Shuga Not exposed	668.7	55	8.22	6.31	10.71
MTV Shuga Exposed	123.9	17	13.72	8.53	22.07
Total	792.6	72	9.08	7.21	11.44

### MTV Shuga and HIV prevention and SRHR awareness and uptake

In the nested cohort after adjusting for age, education, SES, area and DREAMS, MTV Shuga exposure in the AGYW cohort was associated with significantly greater awareness of PrEP (aOR=2.06, 95%CI: 1.57-2.70), contraception uptake (aOR=2.08, 95%CI: 1.45-2.98), and consistent condom use (aOR=1.84, 95%CI: 1.24-2.93). Watching MTV-Shuga was not associated with HIV testing (aOR=1.02,95%CI: 0.77-1.21) (Figure 3 and Supplementary Tables S1-S4). There was no effect modification by DREAMS exposure.

### Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

Similarly, in the cross-sectional analysis, after adjusting for age, education, district, migration and sexual history, exposure to MTV-Shuga watching was associated with greater awareness of PrEP (aOR=1.70, 95%CI 1.20 - 2.43). However, there was no association with contraception, lower self-reported HIV testing, or condom use as shown in Figure 4 below (Supplementary Table 5).

1  
2  
3  
4  
5 **Figure 4 Forest plots showing association between MTV Shuga exposure and**  
6 **HIV prevention and SRHR awareness and uptake in the cross-sectional**  
7 **surveys**  
8  
9

10  
11 **Causal effect of MTV Shuga on health outcomes – HSV-2**  
12

13 The causal analysis similarly finds no effect of MTV Shuga on HSV-2, with a risk difference  
14 of 1.10 95% CI (-2.82- 5.38)%. Findings in the younger age group (aged 13-17) and the  
15 older age group (18-22) was similar (Supplementary Table 6).  
16  
17  
18

19 **Discussion**  
20

21 In our study of the population-level effect of a national broadcast of a TV-based edu-drama on  
22 HIV prevention and SRHR, exposure to MTV Shuga was associated with higher awareness  
23 of a novel HIV prevention intervention (PrEP). However, despite a very high incidence of HSV-  
24 2 and teenage pregnancy, MTV Shuga exposure was not significantly associated with safer  
25 sexual behaviour, uptake of contraception and HIV-testing or prevention of teenage  
26 pregnancy. Notably though, the size of the relationship and direction of effect between  
27 exposure to MTV Shuga, condom use and markers of unprotected sex (HSV-2 and  
28 pregnancy) was consistent with a possible relationship. These findings may be partly  
29 explained by our finding that less than one in 12 of the target age group had any exposure to  
30 MTV Shuga and only half of these had high exposure (defined as watching the MTV Shuga  
31 South African series and being able to recall the content), suggesting that one of the limiting  
32 factors for the effective use of TV-based edu-drama maybe the dose that young people are  
33 exposed to, particularly in rural and resource-constrained settings most affected by HIV.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Our inability to find a measurable population effect of mass-media edu-drama behaviour  
45 change campaign compared to the trial findings of the randomised controlled trial is  
46 disappointing (18). However, firstly the direction and size of the relationships suggest that we  
47 may have been able to see an effect if the proportion exposed had been greater than 7%.  
48 Secondly, AGYW in urban settings were more likely to have been exposed to MTV Shuga and  
49 they are also more likely to be living in small towns and townships. Data from our settings  
50 suggest that young people in small towns and townships are more vulnerable to HIV (28) and  
51 sexual risk (29) and therefore it is possible that a real effect of MTV Shuga on this group was  
52 masked by their greater risk for the outcome. Due to the low numbers with high levels of  
53 exposure to MTV Shuga we did not have the power to explore this hypothesis by looking at  
54 effect modification by geography or socioeconomic status.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 The finding of a differential association of MTV Shuga exposure with awareness of PrEP,  
6 compared to uptake of HIV and contraception, suggests that whilst educational mass  
7 entertainment may be able to increase awareness and possibly demand for a service, it does  
8 not impact on accessibility of the service: i.e. it impacts the first two steps of the prevention  
9 cascade and not the final step(30). Well described barriers to uptake of HIV-testing and  
10 contraception in this area are internalized and externalized stigma, fear of judgement from  
11 health care workers and the social costs of accessing care in busy primary health care  
12 settings(31-33). Behaviour change intervention including mass communication campaigns  
13 can be constrained or facilitated by the context in which people live (17, 34). To optimise MTV  
14 Shuga's effect there may need to be parallel innovations in SRHR and HIV service delivery  
15 that makes the services easier to access. We aim to test this hypothesis by providing  
16 community-based delivery of HIV and SRHR services in the context of the MTV Shuga.  
17  
18  
19  
20  
21  
22  
23  
24

25 The behaviour change theory that underpins edu-drama as a vehicle for mass behaviour  
26 change communication (16) explicitly suggests that the audience, and especially the early  
27 adopters, need to be actively watching, rather than passively watching or listening (17, 18).  
28 TV watching in rural homesteads can be in the context of large, often grandparent-led  
29 households and competing chores and priorities. This coupled with the relatively late timing of  
30 the shows may explain why so few girls and young women were sufficiently engaged or  
31 immersed to be able to recall characters or story lines. Moreover, the timing of this analysis  
32 may have allowed insufficient time for early adopters to convey the message of the show.  
33  
34  
35  
36  
37  
38  
39

## 40 **Limitations**

41 The limitations of our study are that a meaningful exposure to MTV Shuga was low and so  
42 whilst the size of the relationship and direction of effect between exposure to MTV Shuga,  
43 condom use, and markers of unprotected sex (HSV-2 and pregnancy) suggested a possible  
44 effect, but we did not have the power to show a significant relationship between exposure to  
45 MTV Shuga and SRHR outcomes. We also do not have the power to see a difference by  
46 dose and immersion. Furthermore, as this is an observational study, we cannot exclude the  
47 possibility that those who are exposed to MTV Shuga are systematically different in ways that  
48 impact on the outcome of interest, for example more exposed to social media and sexual  
49 health promotion and innovative technologies to support sexual health than those who were  
50 not.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Conclusions and implications for the future

- Meaningful exposure to MTV Shuga was low across rural and urban settings in South Africa and so additional efforts need to be made to reach young people and increase their immersion in promising edu-drama if it is to have the desired effect, especially in rural and deprived settings.
- MTV Shuga was an effective vehicle to raise awareness and promote newer HIV prevention technologies such as HIV PrEP.
- There was some suggestion that MTV Shuga improved uptake of some HIV prevention and sexual health technologies (contraception and condoms)
- There was less evidence from this observational study that it improved SRHR and HIV outcomes

We highlight the importance of evaluating the real-world scale up of promising interventions to understand both the reach and population effect as well as inform interventions to increase impact and equity.

Efforts to increase exposure, which have been rolled out as part of MTV Shuga in SA, such as social media, school-based or community-based MTV Shuga film clubs will need to be evaluated, both to understand whether or not they increase exposure and coverage and improve SRH and HIV outcomes. However, to have a significant impact on the HIV and SRH prevention and treatment cascades, demand generation in AGYW needs to be delivered in parallel with accessible service delivery models that support adherence and retention (30).

## Contributorship

M.S., N.C., J.D., T.Z. N.K, G.H. and C.C. developed the study tools and performed the research. M.S., J.S. D.P., K.B., I.B., and S.F. designed the research study. T.S. and S.D. conducted the laboratory analysis. N.M. supported by K.B. conducted the statistical analysis and G.C. M.S wrote the first and final draft of the paper with input from N.C., N.M., G.H., J.S., I.B., G.C., K.B., C.C., T.S., T.Z, D.P and N.K. All the authors critically reviewed the manuscript. All authors have approved the final draft of the paper.

## Competing interests

All authors declare they have no conflict of interest

## Funding

The impact evaluation of DREAMS and MTV Shuga is funded by the Bill and Melinda Gates Foundation (OPP1136774 and OPP1171600, <http://www.gatesfoundation.org>). Foundation staff advised the study team, but did not substantively affect the study design, instruments, interpretation of data, or decision to publish. The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union's seventh Framework Programme FP7/2007-2013 under REA grant agreement n° 612216. MS National Institutes of Health 5R01MH114560-03 funding acknowledgement. This research was funded in whole, or in part, by the Africa Health Research Institute through the Wellcome [Strategic Core award: 201433/Z/16/A]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. N.C is supported by a training fellowship from the National Institute for Health Research (NIHR) (using the UK's Official Development Assistance (ODA) Funding) and Wellcome [grant reference number 224309/Z/21/Z] under the NIHR-Wellcome Partnership for Global Health Research. The views expressed are those of the authors and not necessarily those of Wellcome, the NIHR or the Department of Health and Social Care. GH is supported by a fellowship from the Royal Society and the Wellcome Trust [Grant number 210479/Z/18/Z]. MS work is also supported by a BMGF 3ie grant at AHRI. This research was funded in whole, or in part, by the Wellcome Trust [Grant number 210479/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

## Data sharing statement

Data are available on reasonable request.

## Ethics statement

The DREAMS Partnership impact evaluation protocol was reviewed and approved by the University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC) (BFC 339/16), the London School of Hygiene & Tropical Medicine Research Ethics Committee (Ref 11835) and the AHRI Somkhele Community Advisory Board, the Associate Director of Science of the Center for Global Health (CGH) at the United States Centers for Disease Control and Prevention (CDC) in Atlanta and the Department of Health, Province of KZN and Gauteng. Approval for the demographic surveillance and data collection in the clinics was granted by UKZN BREC. Participation in the study was voluntary. All participants provided separate informed consent to take part in data collection through the questionnaires and the HSV2 sero-

1  
2  
3 survey. Consent for follow-up interviews was provided separately. For participants aged <18  
4 years, written parental consent and participant assent were provided. All data were  
5 anonymised for analysis.  
6  
7  
8  
9

## 10 Acknowledgements

11 The authors are grateful to the communities of the Hlabisa sub-district, Ekurhuleni district,  
12 Thekwini district and City of Johannesburg who contributed their data to this study and to all  
13 the staff at Africa Health Research Institute and EpiCentre who collected the data. We  
14 acknowledge Eskindir Shambullo for his input in this manuscript.  
15  
16  
17  
18  
19

## 20 References

- 21 1. HSRC. The fifth South African National HIV prevalence, incidence, behaviour and  
22 communication survey [Report].  
23 [http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV\\_Impact\\_Assessment\\_Summary\\_ZA\\_ADS\\_cleared\\_PDFA4.pdf](http://www.hsrc.ac.za/uploads/pageContent/9234/SABSSMV_Impact_Assessment_Summary_ZA_ADS_cleared_PDFA4.pdf): South African Health Services Research  
24 Council 2017 [updated 01/11/2018].  
25
- 26 2. Chimbindi N, Mthiyane N, Birdthistle I, Floyd S, McGrath N, Pillay D, et al.  
27 Persistently high incidence of HIV and poor service uptake in adolescent girls and  
28 young women in rural KwaZulu-Natal, South Africa prior to DREAMS. PLoS One.  
29 2018;13(10):e0203193.  
30
- 31 3. Vandormael A, Akullian A, Siedner M, de Oliveira T, Bärnighausen T, Tanser F.  
32 Declines in HIV incidence among men and women in a South African population-  
33 based cohort. Nature Communications. 2019;10(1):5482.  
34
- 35 4. Birdthistle I, Kwaro D, Shahmanesh M, Baisley K, Khagayi S, Chimbindi N, et al.  
36 Evaluating the impact of DREAMS on HIV incidence among adolescent girls and  
37 young women: A population-based cohort study in Kenya and South Africa. PLoS  
38 medicine. 2021;18(10):e1003837.  
39
- 40 5. Department of Health RoSA. National Campaign for Young Women and Adolescent  
41 Girls. . 2016.  
42
- 43 6. Saul J, Bachman G, Allen S, Toiv NF, Cooney C, Beamon TA. The DREAMS core  
44 package of interventions: A comprehensive approach to preventing HIV among  
45 adolescent girls and young women. PLOS ONE. 2018;13(12):e0208167.  
46
- 47 7. PEPFAR. Preventing HIV in Adolescent Girls and Young Women: Guidance for  
48 PEPFAR Country Teams on the DREAMS Partnership 2015.  
49
- 50 8. PEPFAR. South Africa DREAMS overview  
51 <https://www.pepfar.gov/documents/organization/253958.pdf>: PEPFAR; 2017 [  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 9. Chang L, Serwadda D, Quinn T, Wawer M, Gray R, Reynolds S. Combination  
4 implementation for HIV prevention: moving from clinical trial evidence to population-  
5 level effects *The Lancet Infectious Diseases* 2013;13(1):65-76.
- 6  
7  
8 10. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al.  
9 Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-  
10 label, community cluster randomised trial. *Lancet HIV*. 2018;5(3):e116-e25.
- 11  
12 11. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation  
13 of the impact of immediate versus WHO recommendations-guided antiretroviral  
14 therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention)  
15 trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster  
16 randomised controlled trial. *Trials*. 2013;14:230.
- 17  
18 12. Birdthistle I, Schaffnit SB, Kwaro D, Shahmanesh M, Ziraba A, Kabiru CW, et al.  
19 Evaluating the impact of the DREAMS partnership to reduce HIV incidence among  
20 adolescent girls and young women in four settings: a study protocol. *BMC Public*  
21 *Health*. 2018;18(1):912.
- 22  
23 13. Shen F, Han J. Effectiveness of entertainment education in communicating health  
24 information: a systematic review. *Asian Journal of Communication*. 2014;24(6):605-  
25 16.
- 26  
27 14. Noar SM, Palmgreen P, Chabot M, Dobransky N, Zimmerman RS. A 10-year  
28 systematic review of HIV/AIDS mass communication campaigns: have we made  
29 progress? *Journal of Health Communication*. 2009;14(1):15-42.
- 30  
31 15. Kyegombe N, Zuma T, Hlongwane S, Nhlenyama M, Chimbindi N, Birdthistle I, et al.  
32 A qualitative exploration of the salience of MTV-Shuga, an edutainment programme,  
33 and adolescents' engagement with sexual and reproductive health information in  
34 rural KwaZulu-Natal, South Africa. *Sexual and Reproductive Health Matters*.  
35 2022;30(1):2083809.
- 36  
37 16. Barker K. Sex Soap and Social change- The Sabedo methodology  
38 <https://www.populationmedia.org/product/sabido-theory/>;  
39 <http://www.comminit.com/content/sabido-methodology> [  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 17. Baker V, Birdthistle I, Seeley J, Arnold G, Piot S, Hajiyanis H. How can a TV drama  
50 about Love, Sex and Growing up Increase Knowledge and Shape the Sexual Health  
51 Behaviours of Young People? . *AIDS Impact*; Cape Town, South Africa 2017.
- 52  
53 18. MTV Shuga Soap Opera Turns Edutainment into a Tool to Fight HIV and Gender-  
54 Based Violence [http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-  
55 soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-  
56 violence2017](http://www.worldbank.org/en/news/feature/2017/02/23/mtv-shuga-soap-opera-turns-edutainment-into-a-tool-to-fight-hiv-and-gender-based-violence2017) [  
57  
58  
59  
60

19. National Department of Health. The National Antenatal Sentinel HIV prevalence survey, South Africa, <http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-18-10/2015-04-30-08-21-56?download=2584:2015-national-antenatal-hiv-prevalence-survey-final-23oct17>, 2013 [
20. Herbst K, Law M, Geldsetzer P, Tanser F, Harling G, Barnighausen T. Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. *Current Opinion on HIV AIDS*. 2015;10(6):483-94.
21. Gareta D, Baisley K, Mngomezulu T, Smit T, Khoza T, Nxumalo S, et al. Cohort Profile Update: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *Int J Epidemiol*. 2021;50(1):33-4.
22. George G, Cawood C, Puren A, Khanyile D, Gerritsen A, Govender K, et al. Evaluating DREAMS HIV prevention interventions targeting adolescent girls and young women in high HIV prevalence districts in South Africa: protocol for a cross-sectional study. *BMC Women's Health*. 2020;20(1):7.
23. Filmer D, Pritchett LH. Estimating Wealth Effects Without Expenditure Data—Or Tears: An Application To Educational Enrollments In States Of India\*. *Demography*. 2001;38:115-32.
24. Arvin A, Prober C. Herpes Simplex Viruses. In: Murray P, Baron E, Pfaller M, Tenover F, Tenover F, Tenover R, editors. *Manual of Clinical Microbiology* 6th Ed Washington D.C.: ASM; 1995. p. 876-83.
25. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of Focus HerpeSelect ® and Kalon TM HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 (HSV-2) antibodies in a South African population. *Sexually Transmitted Infections*. 2009;86(1):46-50.
26. Ashley-Morrow R, Nolkamper J, Robinson N, Bishop N, Smith J. Performance of Focus ELISA test for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical Microbiology and Infection* 2004;10(6):530-6.
27. STROBE Statement. STROBE Checklists 2007 [Available from: <http://www.strobe-statement.org/index.php?id=available-checklists>].
28. Cuadros DF, Li J, Branscum AJ, Akullian A, Jia P, Mziray EN, et al. Mapping the spatial variability of HIV infection in Sub-Saharan Africa: Effective information for localized HIV prevention and control. *Scientific Reports*. 2017;7(1):9093.
29. Ngwenya N, Gumede D, Shahmanesh M, McGrath N, Grant A, Seeley J. Community perceptions of the socio-economic structural context influencing HIV and TB risk, prevention and treatment in a high prevalence area in the era of antiretroviral therapy. *African Journal of AIDS Research*. 2018;17(1):72-81.

- 1  
2  
3 30. Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S, Bhattacharjee  
4 P, et al. The HIV prevention cascade: integrating theories of epidemiological,  
5 behavioural, and social science into programme design and monitoring. *Lancet HIV*.  
6 2016;3(7):e318-22.  
7  
8  
9 31. Hargreaves JR, Krishnaratne S, Mathema H, Lileston PS, Sievwright K, Mandla N,  
10 et al. Individual and community-level risk factors for HIV stigma in 21 Zambian and  
11 South African communities: analysis of data from the HPTN071 (PopART) study.  
12 *AIDS*. 2018;32(6):783-93.  
13  
14  
15 32. Chimbindi N, Zuma T, Nakasone S, Birdthistle I, Mthiyane N, Dreyer J, et al.  
16 Platforms, Processes and Perceptions of PrEP Delivery Through DREAMS in a Rural  
17 Setting in KwaZulu-Natal, South Africa. . Research for Prevention 2018 (HIVR4P  
18 2018) Madrid, Spain 2018.  
19  
20  
21 33. Adeagbo O, Herbst C, Dlamini N, Mhlongo T, Luthuli M, Xulu S, et al. "If she tests  
22 negative, it means I am also negative": Men's construction of HIV testing in KwaZulu-  
23 Natal, South Africa. . HIV Research for Prevention (HIVR4P) 23 October 2018.;  
24 Madrid, Spain **2018**  
25  
26  
27 34. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for  
28 characterising and designing behaviour change interventions. *Implementation*  
29 *Science*. 2011;6(42).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure legends

Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

Figure 1: Conceptual framework for MTV Shuga impact on HIV prevention in uMkhanyakude




Figure 1 showing conceptual framework for MTV Shuga impact on HIV prevention on AGYW in uMkhanyakude

98x51mm (400 x 400 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2 Flowchart showing AGYW follow-up from nested cohorts 2017-2019

71x64mm (400 x 400 DPI)




Figure 3 Forest plots showing the association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the nested cohorts.

95x46mm (400 x 400 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4 Forest plots showing association between MTV Shuga exposure and HIV prevention and SRHR awareness and uptake in the cross-sectional surveys

101x54mm (400 x 400 DPI)

**Supplementary Table 1 Exposure to MTV Shuga and PrEP awareness in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		p-value
	OR	95%CI	OR	95%CI		OR	95%CI	
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	2.01	1.55 -2.62				2.06	1.57 -2.70	<0.001
<b>Age</b>	1.12	1.08-1.16	1.12	1.08-1.17	<0.001	1.11	1.06-1.17	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.47 -0.76	0.59	0.46 -0.75	<0.001	0.89	0.65 -1.23	0.488
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.99	0.71 -1.39	0.96	0.68 -1.35		1.01	0.71 -1.44	
High	1.13	0.81 -1.58	1.05	0.75 -1.47	0.744	1.11	0.78 -1.58	0.699
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.98	0.79 -1.22	0.93	0.75 -1.16	0.525	0.92	0.73 -1.15	0.459
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.89	0.73 -1.10	0.88	0.71 -1.08	0.212	0.99	0.79 -1.23	0.897

**Supplementary Table 2 Exposure to MTV Shuga and contraception uptake in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.92	1.37 -2.68				2.08	1.45-2.98	<0.001
<b>Age</b>	1.26	1.19-1.33	1.27	1.20-1.34	<0.001	1.32	1.24-1.42	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.6	0.44 -0.83	0.59	0.43-0.82	0.001	1.7	1.13-2.55	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.79	0.51 -1.22	0.76	0.49-1.19		0.8	0.51-1.28	
High	0.86	0.55 -1.34	0.8	0.51-1.24	0.489	0.83	0.52-1.32	0.646
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.91	0.68 -1.24	0.86	0.64-1.17	0.345	0.89	0.64-1.24	0.49
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.63 -1.11	0.83	0.62-1.10	0.191	1.04	0.76-1.42	0.813

**Supplementary Table 3 Exposure to MTV Shuga and consistent condom use in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		p-value
	OR	95%CI	OR	95%CI		OR	95%CI	
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	1.84	1.22-2.78				1.9	1.24-2.93	0.003
<b>Age</b>	0.94	0.86-1.01	0.94	0.87-1.02	0.157	1	0.91-1.10	0.984
<b>Currently in school</b>								
No	1		1			1		
Yes	1.76	1.22-2.53	1.73	1.20-2.49	0.003	1.78	1.15-2.76	0.01
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	1.01	0.60-1.70	0.97	0.58-1.63		0.98	0.58-1.67	
High	0.87	0.52-1.47	0.8	0.47-1.36	0.552	0.86	0.50-1.48	0.753
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.7	0.48-1.02	0.67	0.46-0.97	0.035	0.71	0.48-1.05	0.088
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	1.13	0.81-1.59	1.13	0.80-1.59	0.486	0.97	0.67-1.40	0.875

**Supplementary Table 4 Exposure to MTV Shuga and HIV testing in the nested cohort of AGYW aged 13-22 (n=2184)**

	Unadjusted		Shuga adjusted		p-value	Adjusted-All		
	OR	95%CI	OR	95%CI		OR	95%CI	p-value
<b>Ever watched MTV Shuga, 2018/19</b>								
No	1					1		
Yes	0.93	0.71-1.21				1.02	0.77-1.36	0.885
<b>Age</b>	1.3	1.25-1.35	1.3	1.24-1.35	<0.001	1.3	1.24-1.37	<0.001
<b>Currently in school</b>								
No	1		1			1		
Yes	0.37	0.28-0.48	0.37	0.28-0.48	0	1.07	0.74-1.53	0.726
<b>Socio-economic status, 2018</b>								
Low	1		1			1		
Middle	0.67	0.48-0.94	0.67	0.48-0.95		0.71	0.49-1.02	
High	0.58	0.41-0.81	0.58	0.41-0.81	0.007	0.6	0.41-0.86	0.018
<b>Urban or rural</b>								
Rural	1		1			1		
Peri-urban/urban	0.84	0.68-1.03	0.84	0.69-1.04	0.104	0.89	0.71-1.11	0.298
<b>Invited or received DREAMS, 2017/18</b>								
No	1		1			1		
Yes	0.84	0.69-1.02	0.84	0.69-1.02	0.081	0.98	0.79-1.23	0.89

**Supplementary Table 5: Exposure to MTV Shuga with HIV prevention and SRHR awareness and uptake in the cross-sectional analysis of AGYW aged 12-24 (n=4127)**

	aOR (95% Confidence Interval)	P-value
<b>District</b>		
City of Johannesburg	1	
Ekurhuleni	0.66 (0.47-0.91)	0.013
eThekweni	0.78 (0.54-1.13)	0.186
<b>Age group</b>		
12-14	1	
15-19	1.75 (0.35-8.84)	0.499
20-24	1.60 (0.32-8.07)	0.570
<b>Highest education level</b>		
Grade R to 7	1	
No schooling	3.84 (1.05-14.02)	0.041
Grade 8 to 12	3.17 (0.93-10.77)	0.065
Complete or incomplete tertiary	6.52 (1.90-22.33)	0.003
<b>Ever had sex with a boy/man</b>		
No	1	
Yes	0.67 (0.32-1.40)	0.286
<b>Away from home</b>		
No	1	
Yes	1.48 (0.93-2.37)	0.099
<b>PrEP awareness</b>		
No	1	
Yes	1.71 (1.20-2.43)	0.003
<b>Contraception use</b>		
No	1	
Yes	0.95 (0.74-1.23)	0.718
<b>Condom use at last sex</b>		
No	1	
Yes	1.19 (0.92-1.55)	0.183
<b>HIV test (self-report)</b>		
No	1	
Yes	0.88 (0.63-1.24)	0.471



Supplementary Table 6 Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group

Estimated causal effect of MTV Shuga on HSV-2 incidence, overall and by age group											
	% Outcome in total study population	Estimated % Outcome if no Shuga	95% CI	Estimated % Outcome if all get Shuga	95% CI	Risk Difference (%; PS adjusted)	95% CI	Prevalence Ratio (%; PS adjusted)	95% CI	Odds Ratio (%; PS adjusted)	95% CI
<b>PS adjustment: Primary results</b>											
Overall	17.3	17.2	14.71 - 19.67	18.0	14.51 - 22.32	0.80	-3.24 - 5.71	1.05	0.82 - 1.36	1.06	0.79 - 1.46
13-17 Years	13.2	12.4	9.85 - 15.16	15.7	11.63 - 20.26	3.34	-1.60 - 8.25	1.27	0.89 - 1.79	1.32	0.87 - 1.98
18-22 Years	24.3	25.8	21.01 - 30.74	22.0	15.19 - 30.17	-3.76	-11.92 - 5.68	0.85	0.59 - 1.24	0.81	0.51 - 1.34
<b>Sensitivity analyses</b>											
<u>Regression under counterfactual framework</u>											
Overall	17.3	17.2	14.74 - 19.66	17.8	14.50 - 22.08	0.65	-3.42 - 5.72	1.04	0.82 - 1.36	1.05	0.78 - 1.46
13-17 Years	13.2	12.42	9.86 - 15.21	15.9	11.85 - 20.49	3.47	-1.54 - 8.63	1.28	0.89 - 1.80	1.33	0.88 - 1.99
18-22 Years	24.3	25.7	20.78 - 30.63	21.3	14.88 - 28.28	-4.42	-12.28 - 4.95	0.83	0.57 - 1.22	0.78	0.48 - 1.31
<u>PS stratification</u>											
Overall	17.3	17.1	14.68 - 19.68	17.9	14.53 - 22.13	0.80	-3.21 - 5.52	1.09	0.84 - 1.40	1.11	0.82 - 1.51
<u>PS weighting</u>											

Overall	17.3	17.08	14.74 - 19.48	17.22	13.99 - 21.10	0.13	-3.76 - 4.63	1.01	0.79 - 1.30	1.01	0.76 - 1.37
---------	------	-------	------------------	-------	------------------	------	-----------------	------	----------------	------	----------------

For peer review only

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	10

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	12
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12- 16
		(b) Report category boundaries when continuous variables were categorized	12- 16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	17- 18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18- 19
Generalisability	21	Discuss the generalisability (external validity) of the study results	17- 19
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).